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Abstract 
Nature and extent of mental health problems among men with newly diagnosed 
prostate cancer and investigation of the association of mental health status with 
quality of decision making following diagnosis 
 
Telisa Marie Stewart 
Dr. Lisa Ulmer, Supervisor 
 
 
 
 
 There is a significant gap in the literature concerning men with newly 
diagnosed prostate cancer. Relatively little is known about the mental health 
status of men immediately following diagnosis. Currently, there is no consensus 
about the best treatment for newly diagnosed prostate cancer patients. 
Treatment protocols incorporate patients’ values into the complex decision 
making process.  
 
Mental health status may negatively influence decision making skills and it 
is paramount that newly diagnosed men weigh the different treatments and side 
effects to arrive at the best possible decision. It is critical to understand the 
nature and extent of mental health problems in newly diagnosed men, and to 
investigate the association of mental health status with decision making, in order 
to promote quality care in the immediate post-diagnosis period. 
 
 The author developed a system for electronically capturing newly diagnosed 
mental health status at the time of their pre-surgical consultation at the 
Dartmouth Hitchcock Medical Center in Lebanon, NH. A pilot was conducted with 
75 patients to ensure mental health status was identifiable prior to the clinical 
encounter. Analysis was drawn from a 484 patient sample. The results of the 
 
 
 
 
xi 
study indicate that there is clinically significant mental health needs. About one 
fourth of the population had at least 1 clinically significant unmet mental health 
need. There was impaired function with patients who had depression and post 
traumatic stress disorder. It appears that patients who have clinically significant 
mental health need were less sure about their treatment decision then patients 
who did not have mental health issues. In conclusion, there are unmet mental 
health needs in patients who are newly diagnosed with prostate cancer. Because 
of the complexities in the decision making process regarding treatment, it is 
imperative that the mental health issues be addressed, to ensure the best 
possible treatment decision is made. 
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1. Introduction 
 
1.1. Background of the Problem 
In 2005, 35 million people died from chronic diseases world wide. Chronic 
diseases or “Non-communicable diseases” such as heart disease, cancer, 
diabetes, respiratory disease and stroke are the leading cause of death (60%). 
Chronic disease deaths occur in almost half of people under the age of 70 (World 
Health Organization, 2009). 
 
The United States population is more likely to die of degenerative illnesses 
and chronic diseases then infectious diseases (Lang JE, 2005).The shift from 
infectious disease has lead the way to a emerging “diseases of civilization” (Keil, 
1993) that claims nearly one-third of all U.S. deaths in 2000 (Center for Disease 
Control (CDC) & DHHS, 2004). Chronic diseases are generally prolonged 
conditions (generally lifelong) that may impact quality of life for patients; and/or 
disabilities (CDC, DHHS, & Merck Institute of Aging and Health, 2004). Among 
adults aged 55 and older, the most prevalent chronic diseases attributed to death 
are - heart disease, cancers, stroke, chronic obstructive pulmonary diseases and 
diabetes (CDC, 2004);(Wan H, 2005). Although the mortality of chronic diseases 
has declined, the prevalence rates of the chronic conditions continue to grow 
(Federal Interagency Forum on Aging Related Statistics, 2006). 
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Chronic diseases take a considerable proportion of the U.S. health care 
spending. Of the population of older Americans, 80% have one chronic condition, 
with 50% of older Americans having at least two chronic conditions (Wan H, 
2005). Chronic conditions account for one third of the U.S. health care 
expenditures (CDC, 2006). Along with the financial burden of chronic diseases, 
patients also utilize resources from their social networks. 
 
The role of screening has been most useful at detecting certain chronic 
diseases at early stages for effective treatment and preventing premature death. 
Cancer screening for cervical, breast, prostate and colorectal cancer decrease 
pre-mature deaths by detecting cancer early in the disease progression (CDC, 
2008). Often chronic diseases can be prevented by physical activities, balanced 
diet, a low body mass index through out life (CDC, 2006);(Federal Interagency 
Forum on Aging Related Statistics, 2006). Healthy lifestyles are a major 
contributor for preserving health (CDC, 2007). Access to health care and 
preventative services help adults avoid chronic diseases during their lifespan 
(CDC, 2006).  
 
Cancer victims contribute by 13% to the overall chronic patient population 
(Agency for Healthcare Research and Quality, 2002) (WHO, 2009). In 2004, the 
number of deaths world wide attributable to cancer was estimated to be around 
7.4 million people. Cancer deaths predominately occur (70%) in low to middle 
income countries. It is estimated that 86% of all chronic disease occur in people  
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under the age of 70 and equally affect men and women (CDC 2006; CDC and 
DHHS, 2004; WHO, 2009). 
 
Screening protocols have proven to be a lifesaving tool for chronic 
diseases − cancers such as breast, cervical, and colon. Mammograms, pap 
smears and colonoscopies deliver results that are pathologically definitive. 
Disease progressions for these cancers are effectively managed with specific 
and direct treatment protocols for the highest degree of survival and quality of life 
(CDC 2006; CDC and DHHS, 2004; WHO, 2009).  
 
Unlike some cancer screenings, prostate cancer screening has been 
shown to reduce mortality by 20%, however, there is also over diagnosis of 
prostate cancer (Schroder, 2009). Prostate cancer screening does not 
conclusively associate early detection and followed earlier treatment to better 
outcomes (American Cancer Society, 2007, 2008a; Harris & Lohr, 2002). Due to 
the medical uncertainty regarding prostate cancer, screening does not always 
lead to active treatment. PSA and/or DRE for prostate cancer screening are 
unable to differentiate between prostate cancer that may be fatal, cancer that 
may infringe on an individual’s quality of life, and/or prostate cancer that would 
never cause clinical problems (American Cancer Society, 2009; Litwin, Pasta, & 
Yu, 2000; Steineck, Helgesen, & Adolfsson, 2002). Survival rates for most 
prostate cancer patients do not change with active treatment; causing many men 
to make their treatment choice based on personal values and preferences of 
treatment side effects (ACS, 2007, 2008a, 2009; Smith, Cokkinides, Brooks, 
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Saslow, & Brawley, 2010; Wolf, et al., 2010). The medical uncertainty regarding 
prostate cancer treatment creates a challenging paradigm for men as they 
struggle to make their treatment decisions (Steginga, Turner, & Donovan, 2008). 
 
1.2. Statement of the Problem 
Currently, the benefits of early diagnosis and treatment are clear for many 
cancer patients. The medical community has clear clinical guidelines that 
recommend treatment protocols for the optimal survival rates and quality of life. 
For a few cancers, there is medical uncertainty regarding survival rates, and the 
best treatment choice is not definitive. Prostate cancer is unique in that a positive 
diagnosis for prostate cancer may not always result in treatment. Disease 
progression and the impact on quality of life are unclear. Regardless of 
treatment, the five-year survival rate for prostate cancer is 100% and the ten-year 
survival rate is 91% for prostate cancer patients (ACS, 2007, 2008a; National 
Cancer Institute, 2008b; Smith, et al., 2010). Because survival rates for most 
patients are above ten years, prostate cancer has become a chronic disease in 
the last decade (CDC, 2006, 2009; CDC & DHHS, 2004).  
1.3. Purpose of the Study 
The purpose of this research is to effectively assist men with distress and 
other psychological barriers as they make a decision regarding their cancer 
treatment. The objectives of this study are to:  
1) assess unmet mental needs of newly diagnosed prostate cancer   
    patients  
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2) gain a better understanding of the relationship between mental health  
    and decision making  
3) provide policy and medical practice organizational service  
    recommendations. 
 
1.4. Specific Aim 
The goal of this research is to develop a system for detecting the unmet 
needs of newly diagnosed prostate cancer patients and refining the organization 
of medical services to address these needs. The research questions include:  
1) What are the unmet mental health needs of newly diagnosed prostate  
    cancer patients? 
2) How does mental health relate to treatment decision making? 
 
1.5. Importance of the Study 
Distress, anxiety, depression and impairment of function have negative 
impact on the newly diagnosed prostate cancer patients. Research has 
substantially supported that psychological distress often occurs after a cancer 
diagnosis (Derogatis, et al., 1983; Hopwood P., 1991).  
 
However, very little research has focused on newly diagnosed prostate 
cancer patients (Bisson, et al., 2002). Psychological issues (anxiety, distress, 
PTSD, depression) can cause considerable difficulty in absorbing medical 
information and making a treatment decision (Steginga, et al., 2008). It is 
important to develop methods to detect men with mental health difficulties in 
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hopes of managing psychological difficulties that may impede their 
comprehension, impede their decision making on prostate cancer treatment, 
and/or develop further psychological issues (Baider Lea, Peretz, Hadani, & Koch, 
2001). 
 
It is critical for the medical community to understand the needs of newly 
diagnosed prostate cancer patients. Psychological distress issues can have 
significant negative implications for understanding medial information on prostate 
cancer, making a decision about prostate cancer treatment, and recovery and 
survival rates of prostate cancer (Vitek, Rosenzweig, & Stollings, 2007). Current 
research needs to focus on detecting psychological and distress issues in newly 
diagnosed prostate cancer patients at the onset of their cancer treatment and 
management. The medical community needs to know if electronic methods for 
data collection are effective at capturing psychological and distress issues. H-
Quest currently uses validated psychological and distress tools (GAD 7, distress 
thermometer, PTSD, PHQ, etc.) to determine the prevalence rates within the 
newly diagnosed prostate cancer population. It is critical to assess the role of 
psychological and distress issues in medical information absorption and decision 
making. 
 
1.6. Scope of the Study 
This study will explore the nature and extent of mental health issues of 
newly diagnosed prostate cancer patients and will explore the link between the 
mental health status and quality of decision making following a diagnosis.  
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1.7. Definition of Terms 
“Chronic diseases are non-communicable illnesses that are prolonged in 
duration, do not resolve spontaneously, and are rarely cured completely”(CDC, 
2009).  
Chronic Disease: 
 
The national cancer institute defines ‘symptom’ as “an indication that a 
person has a condition or disease”(National Cancer Institute, 2008a). Within 
research, the word ‘symptom’ has not been used consistently (Hsiao, Loescher, 
& Moore, 2007). Psychology has defined ‘symptom’ as “A participative indication 
of a disorder reported by an afflicted person rather than being observed by an 
examiner”(Colman, 2006). Many researchers in nursing have defined ‘symptom’ 
as a disease feature that is used to diagnose a patient that most often includes 
the patients’ perception and physical manifestation (Goodell TT, 2005; Hsiao, et 
al., 2007; Rhodes VA, 1987). Nursing research has also identified the definition 
of a ‘symptom’ to include a person’s experience and their perception of their 
experience, which is completely participative and can only be verified by the 
individual (Fu M, 2004; Hsiao, et al., 2007). Within this research, ‘symptom’ will 
be referred to a patient’s “participative indication” of a problem that is associated 
with prostate cancer either by a patient’s perception or by the physical 
manifestation of prostate cancer (Oxford, 2008). 
Symptom: 
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The National Cancer Institute defines distress as an “Extreme mental or 
physical pain or suffering” (National Cancer Institute, 2008a).“ Distress is derived 
from the word stress; psychology defines ‘stress’ as “Psychological and physical 
strain or tension generated by physical, emotional, social, economic, or 
occupational circumstances, events, or experiences that are difficult to manage 
or endure” (Colman, 2006).This dissertation focuses on cancer related distress. 
Cancer related distress will be defined as “psychological (cognitive, behavioral, 
emotional), social, and/or spiritual nature that may interfere with the ability to 
cope effectively with cancer, its physical symptoms, and its treatment” (National 
Comprehensive Cancer Network, 2007).  
Stress-Distress: 
 
Within this research, Post-Traumatic Stress Disorder (PTSD) is viewed as 
an “anxiety disorder arising as a delayed or a prostrated response after 
experiencing” a traumatic event (example: diagnosis of prostate cancer/ 
threatened death). PTSD is “characterized by intense fear, helplessness, or 
horror lasting more than four weeks, the traumatic event being persistently re-
experienced in the form of distressing recollections, recurrent dreams, and 
sensations of reliving the experience” (Colman, 2006). 
Post Traumatic Stress Disorder: 
 
PTSD may include “intense distress and physiological reactions” in 
response to a diagnosis of prostate cancer (a traumatic event) in which 
“persistent avoidance of stimuli associated with the trauma, a numbing of 
responsiveness, and heightened arousal manifested as insomnia, irritability, 
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difficulty concentrating, hyper vigilance, or exaggerated startle response” 
(Colman, 2006). 
 
Depression in newly diagnosed prostate cancer patients will be defined 
as, “a state of sadness, gloom, and pessimistic ideation, with loss of interest or 
pleasure in normally enjoyable activities, accompanied in severe cases by 
anorexia and consequent weight loss, insomnia (especially middle or terminal 
insomnia) or feelings of worthlessness or guilt, diminished ability to think or 
concentrate, or recurrent thoughts of death or suicide. It appears as a symptom 
of many mental disorders” (Colman, 2006). 
Depression: 
 
Anxiety in this research is defined as, “A state of uneasiness, 
accompanied by dysphoria and somatic signs and symptoms of tension, focused 
on apprehension of possible failure, misfortune, or danger“ (Colman, 2006). 
Anxiety: 
 
Cancer is defined as “any malignant tumor” that “arises from the abnormal 
and uncontrolled division of cells that then invade and destroy the surrounding 
tissues.” “Treatment of cancer depends on the type of tumor, the site of the 
primary tumor, and the extent of spread” (ACS, 2008b; NCI, 2008a; Oxford). 
Cancer: 
 
Prostate cancer is being defined as “a malignant tumor (carcinoma) of the 
prostate gland”. In this research, we are specifically looking at localized prostate 
cancer, also referred to as early stage prostate cancer. Localized prostate cancer 
Prostate Cancer: 
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is defined as cancer of the prostate that has not extended beyond the prostate 
gland(ACS, 2008b; NCI, 2008a).   
1.8. Limitations 
The limitations of the study are that there is no long term patient follow-up 
analysis. Decision regret and other decision quality markers may be better 
represented post-treatment (Davison & Goldenberg, 2003; Talcott, 2006). The 
decision quality is participative and based on patient’s perceptions. Although 
decision quality may be high with newly diagnosed prostate cancer patients, the 
medical communities’ interpretations about the quality of the medical decision are 
not incorporated in this study.  
 
This study only uses patient-reported information. No data is verified 
against medical records, or reviewed by a provider. 
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2. Review of the Literature 
 
2.1. Definition of the Problem 
The prostate is a small gland the size of a walnut that sits in front of the 
rectum and under the bladder (NCI, 2008a). It is reported that 95% of all prostate 
cancers are adenocarcinoma, which will define the future discussion of prostate 
cancer patients within the scope of this thesis (ACS, 2009; NCI, 2008b). 
“Prostate cancer is a malignant tumor that begins growing in the prostate gland”. 
Prostate cancer, if left untreated, is generally not deadly; localized prostate 
cancer if confined to the prostate shows no potential health risks. However, it can 
spread to the bones, lymph nodes and other organs (Carroll, 2001). Prostate 
cancer that metastasizes outside of the prostate can be fatal (NCI, 2008b). 
2.2. Clinical Information 
Following positive indicators from PSA and/or DREs, prostate biopsies are 
generally performed. Prostate carcinoma can only be confirmed by a prostate 
biopsy. A Biopty gun, which is ultrasound guided, is generally used to perform 
the biopsy (ACS, 2009). Transperineal (inserted between the anus and the 
scrotum) or transrectal (an ultrasound guided needle inserted into the rectum) 
approaches are the techniques used in administering a “fine-needle aspiration of 
the prostate”, or “core needle biopsy” where several specimens of the prostate 
are taken(ACS, 2009; NCI, 2008b).  
 
12 
 
 
 
2.2.1. Gleason Score 
 
In 1966, collaboration between the Veterans Administration Cooperative 
Research Group and Dr. Donald F. Gleason created the first grading system for 
prostatic carcinoma. The World Health Organization (WHO) recognized the 
Gleason grading system in 1993 and increased its importance at the WHO 
Consensus conference. Since the conference, the Gleason grading system for 
prostatic cancer has become the most commonly used grading system world 
wide. Studies confirm that the Gleason grading system is powerful in that it can 
predict the risk of recurrence after prostate cancer treatment (radiotherapy or 
prostatectomy) and thus the natural history of his prostate cancer. 
 
The Gleason grading scale has two components. First, histological 
patterns are grouped by their architectural design. The histological patterns are 
grouped into five different categories; the lower the grade, the less severe the 
cancer. The histology grading system (Gleason) averages the histological 
patterns, lending two Gleason grades. The two assigned grades are added 
together, forming the Gleason Score ranging from two to ten. Based on the 
Gleason score, the provider predicts the prognosis of the patient.  
 
There have been several controversies within the Gleason grading 
system. The first issue with the Gleason grading system is the over-diagnosis of 
Gleason grade two through four. Several different growth patterns and cellular 
differentiation may be visible in one field (Algaba F, Epstein JI, & Aldape HC, 
1996), however, pathologist must select the highest level stage in the cancer 
13 
 
 
 
specimen (thus “ignoring” lower levels of cancer) (Montie, 1995).  Similarly, 
pathologists must objectively determine the most prevalent patterns within the 
prostate specimen in order to obtain the Gleason grade (Gleason DF, 1977; 
Gleason DF & Mellinger GT, 1974; John Hopkins University, 2004).  
 
Another controversy focuses on the technique of obtaining the biopsies. 
Biopsies select several samples of the prostate. If the samples do not capture the 
carcinogenic cells, the diagnosis may be a false-negative which ultimately does 
not yield a diagnosis. 
2.2.2. Cancer Staging 
 
The digital rectal exam provides a clinical stage. Prostate cancer staging 
creates debate on the ability to properly establish the cancer stage. There is a 
concern that providers assessing the prostate cancer stage are not consistently 
objective in their assessments.  The inconsistencies that arise from one providers 
assessment to another provider’s assessment raise concerns with cancer 
staging.   
 
The American Joint Committee on Cancer (AJCC) and the International 
Union Against Cancer established the most widely used cancer staging system in 
1997. The system consists of three main categories: Tumors, nodes, and 
metastasis (TNM). The pathologic “T” (T for tumor) staging system refers to the 
seminal vesicles, the prostate and any extension of cancer off the prostate and 
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looks at the total prostatoseminalvesiculectomy, which includes the regional node 
specimen.  
 
The American Joint Committee on cancer provides guidelines for the 
clinical pathological staging of prostate cancer. Broad “T” categories 
subcategorize patients according to histological findings and are clinically useful 
in the discussion of treatment choices and survival (American Joint Commitee on 
Cancer, 2009). Providers rely on a histology staging system, which categorizes 
the prostate sample to assist them in their discussion of treatment, or lack there 
of.  
 
The “N” and “M” staging processes are not done during a biopsy. Instead, 
the staging of nodes, or “N”, is determined by a computed tomography scan (CT 
scan) or by Magnetic Resonance Imaging (MRI). There are three types of node 
staging. Positive node diagnosis confirms that cancer has spread outside the 
prostate. Similarly, cancer or metastases outside the prostate or nodes are 
labeled as the “M” stage. A bone scan generally determines if metastases have 
been found into the bone and/or other organs. It should be noted that positive 
staging for “N” and “M” decrease survival rates.  
 
Histopathologic grade (G) is determined by the Gleason score. Where G1  
(well differentiated) is a Gleason score from 2 to 4, G2 (moderately differentiated) 
is a Gleason score of 5 or 6, and G3-4 (poorly differentiated or undifferentiated) 
is a Gleason score of 7 through to 10. 
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The TNM stages are grouped together to form stage I, Stage II, Stage III, 
Stage IV. The AJCC grouping system is:  
• Stage I-T1a, N0, M0, G1;  
• Stage II- T1a, N0, M0, G2-4, T1b, N0, M0, any G, T1c, N0, M0, any 
G, T1, N0, M0, any G, T2, N0, M0, any G;  
• Stage III-T3, N0, M0, any G; Stage IV- T4, N0, M0, any G, Any T, 
N1, M0, any G, Any T, any N, M1, any G.  
  
The standard treatment for Stage I indicates:  
1) Careful observation (Watchful Waiting) (Cantrell BB, 1981; T. R.   
Chodak GW, Gerber GS,, 1994; Epstein JI, 1986; Graversen PH, 
1990a)  
2) Radical prostatectomy with lymphadenectomy and a nerve sparing  
technique if possible (B. J. Catalona WJ, 1993; B. S. Catalona WJ, 
1990; Zincke H, 1994) 
3) Brachytherapy or interstitial implantation of radiosotopes as treatment  
    Options (D'Amico AV & Coleman CN, 1996; Ragde H, Blasko JC, & 
Grimm PD, 1997; Wallner K & Roy J, 1996).The standard treatment for 
Stage II indicates:  
 1) Watchful Waiting,(T. R. Chodak GW, Gerber GS,  , 1994; Graversen 
PH, 1990b) 
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2) Radical prostatectomy,(B. S. Catalona WJ, 1990; Eastham JA & 
Scardino PT, 2002; Paulson DF, Lin GH, & Hinshaw W, 1982; Zincke H, 
1994) 
3) External beam radiation therapy (EBRT)(Amdur RJ, Parsons JT, & 
Fitzgerald LT, 1990; Bagshaw MA, 1980; Forman JD, Zinreich E, & Lee 
DJ, 1985; Perez CA, Garcia D, & Simpson JR, 1989; Pilepich MV, 
Bagshaw MA, & Asbell SO, 1990; Ploysongsang S, Aron BS, & 
Shehata WM, 1986) 
4) EBRT with androgen-suppression therapy(Ragde H, et al., 1997) and  
5) Brachytherapy or interstitial implantation of radiosotopes as treatment 
options(D'Amico AV & Coleman CN, 1996; Ragde H, et al., 1997; 
Wallner K & Roy J, 1996). 
2.2.3. The Partin Tables 
 
The Partin Tables have been incorporated into clinicians’ practices for 
counseling newly diagnosed prostate cancer patients. The tables stipulated that 
three components are known about a man’s prostate cancer: PSA, Gleason 
Score, and Clinical Stage. The Partin Tables help predict the surgical 
pathological stage (determined after a prostatectomy by a pathologist). Predicting 
the surgical pathological stage helps providers counsel patients on their best 
treatment options (since prostate cancer that has moved outside the prostate can 
not be cured by surgery). The nomograms calculate the probability of four areas: 
Extraprostatic Extension, Organ Confined disease, Lymph Node Invasion, and 
Seminal Vesicle Invasion. The probabilities from the Partin Tables aid patients 
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and providers in the discussion regarding therapy, individual risks and the 
potential outcomes (Partin Alan, 2007). 
 
2.2.4. Choices of Treatment 
Initial Oncology approaches were historically geared towards conventional 
surgery for treatment. More recently, however, the diagnosis and treatment of 
prostate cancer have escalated in their sophistication and complexity. In 2000, 
the Center for Disease Control (CDC) published research on the frequency of 
treatment modalities: radical prostatectomy (58%), external beam radiation 
(36%), medical castration with luteinizing hormone-releasing hormone agonists 
(20 to 30%), hormonal ablation by orchiectomy (12%), and Brachytherapy (6%), 
watchful waiting with surveillance (9%), and cryotherapy (4%), (CDC & DHHS, 
2004). In 1991, Prostatectomies were the second most common operation for 
Untied States Medicare-aged men with 311,000 cases performed (Wan H, 2005). 
The 2004 reports in the treatment modalities listed radical prostatectomy and 
radiation therapy as the two most widely used modalities (NCI, 2008b).  
 
2.2.4.1. Radiation Therapy for Prostate Cancer 
Radiation is used in a variety of ways to treat localized prostate cancer. 
Radiation Therapy, also known as Radiotherapy, is a general term describing 
different types of radiation treatment that may include placement of radioactive 
seeds into the prostate, injections of radioactive substances, and high powered 
radio active beams. Prostate cancer patients may choose from a vide variety of 
radiation therapies. The most commonly used radiation therapy is External Beam 
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Radiation Therapy (EBRT), which emerged in the 1950’s as a treatment for 
prostate cancer. Linear accelerators (high powered X-ray machines) produced 
deep penetrating, powerful X-rays; prostate cancer cells are destroyed by the 
radioactive X-rays that damage the cells DNA. Patients treated by EBRT are 
exposed to radiation that typically lasts for several minutes. Once treatment is 
over, there is no radiation left in the patients’ body. EBRT is non-invasive (except 
with Image Guided Radiation Therapy (IGRT) where gold seeds are placed 
under transrectal ultrasound guidance) and patients experience no discomfort 
during treatment. Generally, localized prostate cancer requires patients to 
receive eight weeks of treatment − once per day, five days per week (American 
Urological Association, 2002). 
 
Another form of radiation treatment is Brachytherapy or also known as 
“seed implants”. Brachytherapy can be performed in a Low Dose Rate (LDR) or 
High-dose rate (HDR) (various isotopes decay at different rates and the rate is 
dependent upon the isotope). During a LDR Brachytherapy treatment, radioactive 
material is inserted into the prostate. The radioactive material or seeds are about 
the size of a small grain of rice. During the procedure, the patient is sedated and 
small pre loaded needles are passed through the skin between the scrotum and 
the anus. The pre loaded needles inject the seeds directly into the prostate 
gland. Ultrasounds, CT Scans or MRI may be used to provide information for a 
computer to determine the most optimal position and number of seeds. During 
the procedure, the physician watches the seed placement on a monitor to ensure 
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they are placed in their predetermined position. Once the seeds have been 
inserted, the needles are withdrawn. 
 
The insertion of radioactive material into the prostate can be dated back to 
early in the 20th century. However, at the time, physicians were unable to 
accurately place the radioactive material in desired locations, limiting the use of 
Brachytherapy. In the early 1980, more sophisticated ultrasound devices enabled 
new, more reliable, techniques for placing tiny radioactive “seeds” into the 
prostate (American Urological Association, 2002). In Brachytherapy, radioactive 
“seeds” are permanently placed in the prostate. The seeds gradually give off the 
radiation over several months, in which prostate cancer cells are destroyed. 
Brachytherapy and EBRT may be administered simultaneously when treating 
prostate cancer (American Urological Association, 2002). 
 
HDR Brachytherapy refers to temporary implants of radioactive material. 
HDR Brachytherapy (which is similar to LDR) requires catheters to be placed in 
the prostate. The catheters allow for high doses of radioactive material to be 
administered over several days. The catheters have a pre-determined location 
along with a calculated period of time that the catheters must administer the 
radiation. Upon completion of the treatment, the catheters and the radioactive 
material are removed (American Urological Association, 2002). 
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2.2.4.2. Prostatectomy 
 
Surgery has remained the most widely used prostate cancer treatment. 
Prostatectomies have been performed since the 1920s (Harris Harry, 1928). 
Traditionally, Prostatectomy was an invasive surgery that required a lengthy 
recovery period. There are two types of open radical prostatectomy approaches: 
retropublic and perineal approach. The retropublic technique remains the most 
widely used laparoscopic technique. This approach is a surgical incision below 
the umbilicus and allows for access to the pelvic lymph nodes and prostate. This 
technique allows for preservation of the neurovascular bundles (that help 
maintain erectile function). The perineal approach requires a small semi-lunar 
incision in the perineum. This approach avoids the pelvic vein (which can lead to 
significant bleeding) and allows for a re-attachment of the urethra to the bladder) 
and allows for nerve preservation. 
 
More recently, laparoscopic surgical techniques have vastly cut down on 
the recovery time, pain, infection and scaring from treatment. There are two 
types of minimally invasive surgical techniques: Laparoscopic Prostatectomy, 
and Robotic Assisted Laparoscopic Radical Prostatectomy (da Vinci) (Cleveland 
Clinic Health System, 2005). Laparoscopic Radical Prostatectomies are known 
as minimally invasive surgeries in which many small surgical incisions are made 
in the patient’s abdomen. Under anesthesia, the patient’s entire prostate gland 
(including the seminal vesicles and vas deferens and often the pelvic nodes) is 
removed intact through one of the incisions that is appropriately enlarged 
(American Urological Association, 2002).  
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The da Vinci or Robotic Assisted Laparoscopic Radical Prostatectomy 
was introduced in 2001. This minimally invasive surgery utilizes computer 
technology and a surgical robotic system to remove the prostate. It employs four 
interactive robotic arms equipped with surgical instruments and cameras. A 
surgeon controls the miniaturized instruments by a remote console that transmits 
the surgeon’s movements within the patient’s body. The da Vinci precision and 
robotic movements have shown to be less damaging to surrounding nerves and 
tissues (American Urological Association, 2002). 
 
2.2.4.3. Hormonal Deprivation Therapy 
 
There are several other techniques used to treat prostate cancer. 
Luteinizing Hormone-Releasing Hormone (LHRH) prevents male hormones from 
being produced by the testicles. Since testosterone (male hormone) stimulates 
the prostate cells, depleting the body of testosterone may slow down the growth 
of prostate cancer cells. Other types of hormonal deprivation therapy consist of 
an Orchiectomy (surgical castration consist-removal of the testicles), receptor 
androgen blockade (flutamide and bicalutamide), estrogens (female hormone) to 
stop male hormones in the body or a combination of these (National Cancer 
Institute, 2008b). 
 
2.2.4.4. Other Techniques 
 
Cryotherapy is a prostate cancer treatment that destroys the prostate by 
freezing the gland. Similar to Brachytherapy, cryoprobes (special needles) are 
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inserted into the prostate transperineally guided by ultrasound. The special 
needles administer Argon gas that creates an “ice ball” and instantly kills the cells 
in the predefined area. Hormonal Deprivation Therapy, Cryotherapy, and other 
less popular techniques have limited roles with newly diagnosed prostate cancer 
patients (American Urological Association, 2002; National Cancer Institute, 
2008b). 
2.2.4.5. Active Surveillance 
 
Despite popular belief, active surveillance (passive treatment) is a 
“treatment option” for newly diagnosed prostate cancer patients. Men with 
serious health problems may opt for active surveillance instead of active 
treatment. Similarly, the growth of prostate cancer is extremely slow, and some 
men may never require treatment. Closely monitoring prostate cancer with 
continued screening may be a reasonable option. Men with a low Gleason, low 
PSA, and/or no prostatic symptoms, may feel that side affects of treatment may 
out weigh the benefits. Active surveillance does not mean decrease in medical 
care, it is careful Urologic/Oncology monitoring instead (ACS, 2009; American 
Urological Association, 2002; NCI, 2008b). 
 
2.2.5. Treatment Side Effects 
The active treatment risks and side effects may outweigh the possible 
benefits. Although Watchful Waiting is a passive treatment, providers have no 
way of distinguishing a slow growing cancer from a fast growing. Watchful 
Waiting carries the risks when the cancer may spread to outside organs if no 
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intervention is chosen. Active treatment may yield a plethora of side effects that 
may be long term and may affect the patient’s quality of life.  
 
Treatment side effects of EBRT for prostate cancer include: urinary 
problems, bowel irritability, mild irritation of the skin around the rectum, lower 
blood counts and fatigue” (American Urological Association, 2002). Medication 
and life style modifications may help manage EBRT symptoms. Generally within 
a few months of completing the EBRT, patients’ symptoms generally disappear. 
A small percentage of men (20%) do experience long term bowel irritability. 
Erectile Dysfunction (ED) following EBRT is extremely variable and presently 
cannot be estimated for risk.” 
 
Brachytherapy side effects are similar to EBRT with urinary irritability. It 
carries higher rates of obstructive symptoms with urination (prostate usually 
swells with the insertion of seeds), 5-15% of men experience complete urinary 
obstruction for several weeks (catheters are usually required). Short term side 
effects include irritable bowel symptoms and possible Erectile Dysfunction 
(ED)(ACS, 2009; American Urological Association, 2002; NCI, 2008b). 
 
Surgery side effects include, but are not limited to, incontinence, 
impotence; sterility; pain, bladder problems, bowel problems (very infrequent) 
(ACS, 2009). The da Vinci procedure appears to cause less erectile dysfunction 
and urinary incontinence compared to Open Radical prostatectomy. Patients 
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treated laparoscopically generally leave the hospital within 24 hours (ACS, 2009; 
American Urological Association, 2002; NCI, 2008b). 
 
Treatment side effects that include “Erectile Dysfunction (ED), bowel 
problems, and/or urinary incontinence” can have long term mental heath 
implications that would include affecting a man’s body image, sense of self worth, 
relationships (physical and emotional) and cultivate feelings of embarrassment 
(Hyacinth Joseph, Thibault G., & Ruttle-King J., 2006; Kornblith AB, 1994). 
2.3. Incidence, Prevalence, and Variation in Prevalence 
In 2004, the Center for Disease Control (CDC) reported that prostate 
cancer is the leading most common non-skin cancer among all men1 in America. 
Prostate cancer is the second leading cause of cancer-related deaths among 
men2
 
 in the United States (U.S. Cancer Statistics Working Group, 2007). In 2008, 
the American Cancer Society approximated that 186,320 men will be diagnosed 
with prostate cancer leading to estimated 28,660 deaths (ACS, 2008a). 
The SEER Cancer Statistics Review from 2001 to 2005 reports that the 
median age at diagnosis for prostate cancer is 68, with a median age at death for 
prostate cancer at 80 years old. The review reports that there has been a steady 
decrease of prostate cancer related deaths from 1992 to 2005. Overall, there is a 
98.9% five-year survival rate for all races for prostate cancer patients. Based on 
the 2003-2005 statistics, 15.7% of men at some point in their lifetime would be 
                                            
 
1 Prostate Cancer  (161.2), Lung Cancer  (86.4), Colorectal Cancer  (61.3) 
2 White  (25.8), black  (63.0), Hispanic  (22.0) men 
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diagnosed with prostate cancer (Ries L, 2005). The extent of the prostatic 
carcinoma predominately determines the survival rates of men. Prostatic 
carcinomas confined to the prostate gland have expected median survival of 
more then five years. Advance prostate cancers that have metastasized outside 
the prostate have predicted survival of one to three years. However, patients 
categorized with advanced prostate cancer have been documented to have 
prolonged survival past three years (NCI, 2008b; Ries L, 2005). 
 
Currently, the benefits of early diagnosis and treatment of prostate cancer 
remain debatable, and men with low grade confined prostate cancer may gain 
little benefit from current aggressive interventions (Parker C, 2006). Generally, 
most men with localized prostate cancer face a complex decision regarding 
treatment (Garnick M. B., 1994). Treatment choices include surgery, radiation 
and hormone therapy, which have devastating side effects that include bowel, 
urinary and sexual dysfunction (Bryan & Pamela, 2005). Men with prostate 
cancer have to make irreversible decisions regarding treatment causing an 
increased sense of anxiety about making “the right choice” (Montie J. E., 1994). 
 
The psychological distress, denial and anxiety that often follow a prostate 
cancer diagnosis (Kronenwetter C, 2005; Kunkel EJ & LG., 2000) can have a 
negative effect on patient’s comprehension of their cancer and their ability to 
make treatment decision (Mc Vea KLSP, 2001; S. K. Steginga, Ferguson, 
Clutton, Gardiner, & Nicol, 2007). Suicide rates are 4.24 times higher for men 
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diagnosed with prostate cancer than cancer free men at the same age (Llorente 
MD, 2005). 
2.4. Health, Social, and Economic Consequence if Not Treated 
The shock and anxiety of a cancer diagnosis can skew positive health 
outcomes towards socially confident and intellectual patients. More then half of 
the population are unable to understand, absorb and be “truly informed” about 
their choices (Jenkins V., 2001; Manning, 2006). Patient education plays a vital 
role in the decision making process of treatment for prostate cancer (Kane C., 
Lubeck D., & Knight S, 2003). Patient education levels have a direct influence on 
their ability to understand medical information (Kim S, Knight S, & Tomori C, 
2001) and influence their choices in treatment (Kane C., et al., 2003).The 
psychological distress, denial, and anxiety that often follow a prostate cancer 
diagnosis (Kronenwetter C, 2005; Kunkel EJ & LG., 2000) can have a negative 
effect on patient’s comprehension of their cancer and their ability to make 
treatment decision (Mc Vea KLSP, 2001; S. K. Steginga, et al., 2007). 
 
2.5. Key Determinants of the Problem 
Research shows that men are consistently less likely than women to 
provide, receive and seek social support, despite a positive association between 
emotional support and adaptation to the diagnosis of cancer (Ashton WA & A., 
1993). As stated earlier, more then half of the population are unable to 
understand and absorb their choices, and 90% of patients diagnosed with cancer 
would like to know more about their disease (Jenkins V., 2001; Manning, 2006). 
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Many patients seek more information from sources other than their 
provider; not understanding that some sources may not always be reliable or 
have complete literature information (Balmer C., 2005; Manning, 2006). 
Numerous patients benefit from information available on the internet; however, 
often patients with the greatest needs lack confidence to use the internet 
(Manning, 2006; Ziebland S., 2004) and/or lack internet access (Manning, 2006; 
Oftel Residential Survey, 2003). 
 
Patients with poor literacy not only struggle to comprehend and 
conceptualize information presented during the appointment, but the appointment 
time constraints may further exacerbate their low absorption and comprehension 
(Ley P. & Llewelyn S., 1992, Manning, 2006). During the consultation time, 
patients can only be expected to absorb a limited amount of clinical information. 
Despite the fact that practitioners take the time to explain pertinent heath 
information about a patient’s condition, patients receive, retain and understand 
less than 20% of the information(Agre, 2006; Mayer & Villaire, 2004; Schillinger 
D, 2004). 
 
 Due to appointment time constraints, communication during a 
consultation may not always present an opportunity for informing the patient, as it 
is usually rushed. In this age of information technology, where internet-based 
health information and education has become readily available to patients, it is 
essential for patients to be given a physician’s interpretation of appropriate 
28 
 
 
 
treatment options before searching the web for prostate cancer treatment 
information (London, 2000). 
2.5.1. Empirical Framework 
Figure 1: Empirical Framework 
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2.6. Intervention Strategies 
The National Comprehensive Cancer Network supports intervention for 
distress by integrating the Distress Thermometer in clinics. Research conducted 
by Mary Vachon focused a distress intervention that was developed around the 
provider initiating the conversation that would highlight distress if present. As part 
of the intervention with cancer survivors, the clinicians were instructed to ask 
“How can I help you today?” and/or “What are the two most troubling problems 
for you today?” along with administering the Distress Thermometer. Vachon 
found that further investigation was needed to create a stronger intervention 
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(American Cancer Society and National Comprehensive Cancer Network, 2008; 
National Comprehensive Cancer Network, 2007; Natlonal Comprehensive 
Cancer Network, 2003; Patrick-Miller, 2004; Vachon, 2006).  
 
2.7. Critical Issues in Moving to the Next Stage of Research 
2.7.1. Psychological Issues Associated with Cancer 
 
Research has substantially supported the view that psychological distress 
often occurs after a cancer diagnosis (Derogatis, et al., 1983; Hopwood P., 
1991). However, very little research has focused on newly diagnosed prostate 
cancer patients (Bisson, et al., 2002). Psychological and psychiatric problems 
among cancer patients have a “higher prevalence immediately after initial 
diagnosis” (Roth A. J., 1998). Anxiety, sadness and anger often follow a cancer 
diagnosis, as patients struggle to understand the diagnosis and are forced to 
make multiple decisions during their cancer journey. Psychosocial distress 
maybe be elicited from having to quickly decide on a treatment after a cancer 
diagnosis; or general overwhelming experience may result in anxiety (Gobel, 
1987 ; Stephenson Pamela, 2006). Research shows that 44% of patients 
diagnosed with cancer experience anxiety at one point in their lifetime (National 
Cancer Institute, 2006; Stephenson Pamela, 2006). Distress can have negative 
impact on cancer outcomes including: non treatment compliance (Kennard BD, 
2004), life quality issues (Skarstein J, 2000), and poor satisfaction (Von Essen L, 
2002).  
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According to 2006 research, a third of cancer patients experience distress 
and would benefit from some type of psychological intervention (Vachon, 2006). 
Studies have found that the risk for distress in cancer patients increases for: 
patients that are over 70 (Aass N, 1997; Zabora J, 2001), patients who have 
problems with their emotions, patients who have family issues (practical and/or 
physical problems) (Jacobsen PB, 2005), patients with a history of distress and 
other motional difficulties (Aass N, 1997; Stommel M, 2004.), and those with low 
socioeconomic status (Carlson LE, 2004; Stommel M, 2004.).  
 
Depression has also been explored after an oncology diagnosis. Distress 
over treatment, survival, disruption of family and social relationships can 
significantly attribute to depressive symptoms (Kurtz ME, 2001). Sellick and 
Crooks found that 25% of cancer patients had depressive moods, adjustment 
disorders and/or major depressive disorders (Sellick SM and Crooks DL, 1999). 
Other studies have reported depressive symptoms in as many as 58% of the 
cancer patients, with 38% of the patients having major depression (Massie MJ, 
2004).  
 
2.7.2. Psychological Issues Associated with Cancer have Negative 
Impact on Patients 
 
In a cancer trajectory, patients may experience anxiety as new information 
is presented; however, at any point in cancer treatment and management anxiety 
may become evident (Stephenson Pamela, 2006). Mild anxiety can stimulate 
awareness and attention to the problem along with increasing concentration 
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(Smith-Alnimer, 1996; Stephenson Pamela, 2006). However, moderate to severe 
anxiety can interfere with patient’s ability to understand and concentrate on 
information (Bush K, 1998; Stephenson Pamela, 2006).The psychological 
distress, denial and anxiety that often follows a prostate cancer diagnosis 
(Kronenwetter C, 2005; Kunkel EJ & LG., 2000) can have a negative effect on 
patient’s comprehension of their cancer and their ability to make treatment 
decision (Mc Vea KLSP, 2001; S. K. Steginga, et al., 2007). Distress in cancer 
patients can be detrimental to their ability to make a decision, comply with 
treatment, and can affect their treatment outcomes (Patrick-Miller, 2004).  
 
Links between quality of life (QOL) and psychiatric issues have been 
found in the general cancer population. Several studies have linked mental 
health issues to low quality of life (QOL). The American cancer society and the 
National comprehensive Cancer network report that distress associated with 
cancer can have a significant effect on the quality of life (QOL) of patients 
(American Cancer Society and National Comprehensive Cancer Network, 2005, 
2008).  
 
QOL of cancer patients with mental health issues post-treatment have 
been explored. Schag, Ganzs, Wing and associates conducted QOL research in 
adult survivors of lung, colon, and prostate cancer. Their findings suggest that 
patients with either past or present psychiatric issues (including depression) was 
associated with worse QOL then their counterparts with no psychiatric issues 
(Schag CA, 1994). Distress symptoms have also been documented to have a 
32 
 
 
 
negative influence on patients QOL post-intervention (Heiney SP, 2003; Vega 
BR, 2002; Vos PJ, 2004). Research on depressive symptoms has significantly 
predicted low QOL of prostate cancer survivors after a radical prostectomy 
(Rondolf-Klym, 2003).  
 
Mental health issues have also been linked to decreased survival rates 
and treatment outcomes. Longitudinal studies predicated that depression 
predicts greater morbidity and mortality (even after adjusting for age) in cancer 
patients (Buccheri G, 1998; Faller H, 2002; Goodwin JS, 2004; Herjl K, 2003; 
Herrmann C, 1998; Pirl, Siegel, Goode, & Smith, 2002). Poor treatment 
outcomes have also been explored. Research suggests that depression affects 
treatment outcomes, leading researchers to believe that the main reason for poor 
treatment outcomes is mainly associated with mental health issues  (particularly 
depression) (McDaniel JS, 1997). Similarly, distress has been significantly 
associated with poor cancer recovery, poor treatment outcomes and decreased 
long term survival (Alferi SM, 2001; Helgeson VS, 2004; Manne S, 2003; 
Maunsell E, 1995; Osborne RH, 2003; Owen JE, 2004; Weihs KL, 2000). 
 
Mental health issues have been shown to be detrimental to the biological 
equilibrium in the body. Depression, for example, has been shown to impair the 
immune response. Patients with significant depression are associated with 
immune response suppression (Andersen BL, 1998; Newport Dj, 1998; Reiche 
EMV, 2004). 
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2.7.3. Magnitude of Psychological Issues in Cancer 
 
 According to a 2006 research, a third of cancer patients experience 
distress and would benefit from some type of psychological intervention (Vachon, 
2006). However, cancer professionals fail to recognize and diagnose distress in 
the cancer population (Passik, 1998; Taylor, 1996; Zhao, 2003).  
 
 Prevalence estimates for psychological problems have a large variability, 
estimating psychological problems in at 25-50% patients diagnosis with cancer 
and patients treated for cancer (Derogatis, et al., 1983; Hopwood P and 
Stephens RJ, 2000; Maguire GP, 1978; Massie MJ and Holland JC, 1990). As 
stated earlier, Sellick and Crooks found that 25% of cancer patients had 
depressed moods, adjustment disorders and/or major depressive disorders 
(Sellick SM and Crooks DL, 1999) and that  44% of patient diagnose with cancer 
illicit anxiety at one point in their lifetime (Carter RM, 2001; Namiki, et al., 2007; 
Stephenson Pamela, 2006; Wittchen HU, 1994). 
 
Men with newly diagnosed prostate cancer face an extremely high level of 
medical uncertainty since most prostate cancers do not develop into a fatal 
disease with or without treatment (Eddy DM., 1992; Kassirer JP., 1994). For most 
prostate cancer patients there is no “best” choice of treatment. Health decisions 
for prostate cancer treatment are complicated by placing weight on individual 
values and personal preference on various treatment and treatment outcomes. 
As there is uncertainty in science about the pros and cons of each treatment 
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choice, clinical guidelines have incorporated personal preferences into treatment 
recommendation (Eddy DM., 1992; Smith, et al., 2010; Wolf, et al., 2010). 
 
Prostate cancer treatment decisions are complex due to the lack of 
evidence regarding long term outcomes. Furthermore, treatments have “different 
risk-benefit profiles” to each individual patient (Eddy DM., 1992; Kassirer JP., 
1994). Providers, for example, may use a patients age, Gleason score and/or 
general health as factors for recommending a treatment option (American Joint 
Commitee on Cancer, 2009; Carroll, 2001). Patients must then choose between 
a plethora of treatment options and their side-effects. The level of medical 
uncertainty in patients’ experience, their need to manage their own feelings, 
values and preferences, and the need to understand the cancer they are making 
a medical decision about, can be overwhelming. The overwhelming feelings can 
create a cascade of distress and psychological issues that follow (American 
Cancer Society, 2009; S. K. Steginga, et al., 2007).  
 
2.7.4. Intervention Strategies 
 
There is currently no research that focuses intervention strategies for all 
psychological needs of cancer patients, or more specifically prostate cancer 
patients (before treatment). Intervention strategies generally target a few 
psychological issues after treatment and/or quality of life after treatment. 
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2.8. Conceptual-Empirical Model 
Figure 2: Conceptual Empirical Model 
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2.9. Significance of the Proposed Research 
 The proposed research will focus on the nature and extent of mental health 
problems in prostate cancer patients along with the association between mental 
health and decision making. Since prostate cancer patients need to make 
treatment decisions, mental health issues could impede this decision making 
process, and consequently impact the final outcome. 
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3. Research Methods 
 
3.1. Context, Approach, and Preliminary Work 
Development and collaboration for the research took place at Dartmouth 
Hitchcock Medical Center (DHMC) located in Lebanon, New Hampshire.  DHMC 
mission is to advance health through education, outreach, clinical practices and 
research. The medical center is made up of five main institutions: Dartmouth 
Hitchcock Clinic (DH-Clinic), Norris Cotton Cancer Center (NCCC), Mary 
Hitchcock Hospital, Dartmouth College, and Borwell Research Center. Each 
institution operates as a separate entity with different financial obligations, 
physical locations, overall missions and personnel. However, the institutions are 
also heavily intertwined (often inseparable from each other) and function as one 
large facility with shared recourses, no physical institutional boundaries and 
shared personnel.  
3.1.1. Quantitative Research 
 
 Quantitative Research provides a scientific approach to the analysis of the 
relationship between mental health and decision making. Quantitative research 
was chosen because the outcome variables were measurable scores; several 
validated tools were available to look at mental health status. The outcome 
variables can be associated with the mental health status variables making the 
qualitative research the most suitable approach for this study. 
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3.1.2. Developing Collaborations to Support the Research and 
Obtain Sanctions 
 
Before the research could begin, collaboration needed to be established in 
a multi institutional setting in multidimensional levels. Collaboration was initiated 
for the purpose of developing the Health Questionnaire with Dynamic Clinical 
Systems (DCS), the integration of the health questionnaire with newly diagnosed 
prostate cancer patients with Urology and Radiation Oncology, and the 
standardization of the health information (prostate cancer packet) and shared 
decision making for each clinic.  
 
Extensive systematic changes were made to accommodate and 
incorporate the health questionnaire as part of the standard process of care. 
Support staff, automated notification and institutional accommodations were all 
modified to integrate into the health questionnaire, which was also incorporated 
into pre-existing patient support programs. The health questionnaire took a 
multifaceted approach to gain provider and system support as the standard 
process of care (see appendix collaboration). 
 
3.1.3. Pilot Study Results-Feasibility of Methods 
 
A pilot study was conducted as a first step in evaluating distress, 
psychiatric syndromes and impairment of function in newly diagnosed prostate 
cancer patients. The objectives of the pilot were to evaluate:  1.  proper 
implementation of the H-Quest into the standard care of each provider 2.  the 
proper integration of SDM and the prostate cancer packet 3.  equipment  4.   
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provider and administrative staff training  5. patient flow  6.  patient compliance 7.  
length of health questionnaire 8.  and explore H-Quest in capturing distress, 
psychiatric syndromes and impairment of function in newly diagnosed prostate 
cancer patients. 
 
The pilot was implemented in phases, each phase was the incorporation 
of the H-Quest into the normal process of a care provider.  
 
The pilot was firstly implemented in Urology (Phase 1 and 2), and 
Radiation Oncology (Phase 3) (See Appendix “Implementation Process for the 
Pilot Study” and Appendix “Graphical Display of Pilot Implementation”). 
Enrollment criteria were based on a diagnosis of prostate cancer, a visit type pre-
determined by the scheduling secretary and location of the visit (see Appendix 
“Eligibility and Enrollment”). Careful consideration and accommodations were 
integrated to support patients that filled out a health questionnaire and were “red 
flagged” with high depression, anxiety, PTSD, etc. (see Appendix “Monitoring 
and Management”). Issues arising during the course of the pilot process were 
reviewed by the corresponding provider and adjusted to fit within the entire 
process of care for a newly diagnosed prostate cancer patient (See Appendix 
“Trouble-Shooting”). 
3.1.3.1. Study Results 
Table 1: Pilot Results* 
Patient Characteristics  (N=75 ) 
Characteristic    No.  (%) 
Mean age:    63.71y; SD 8.38y 
Marital status 
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Married       59  (78.7%) 
Single       3  (4.0%) 
Divorced or separated    10  (13.3%) 
Widowed       2  (2.7%)  
Employment 
Full time      43  (57.3%) 
Part time       8  (10.7%) 
Retired      20  (26.7%)  
Race, ethnicity 
White, Non-Hispanic    72  (96.0%) 
White, Hispanic     0 
Asian/Oriental/Pacific Islander  0 
Other       3  (4.0%) 
Education 
Some high school or less    0 
High school or GED    16  (21.3%) 
Some college     15  (20.0%) 
College or graduate degree   42 (56.0%) 
 
Screening for Emotional Distress and Psychiatric Disorders  (N= 75) 
 
Measures                  No.  (%) 
Distress screening, scale: 0–10 
Mean  (SD) distress,   2.85  (2.62) 
Distress thermometer >5   12  (16.0) 
 
Psychiatric screening 
Major depression  (PHQ-9 >10)   3  (4.0)  
Moderate  (11–14)               2  (2.7) 
Moderate to severe  (15–19)   1  (1.3)  
Severe  (≥20)     0  (0) 
PC-PTSD  (≥3)     3  (4.0) 
Generalized anxiety disorder  (≥8) 3  (4.0)   
 
*Note all participants answered all the questions. 
3.2. Design 
3.2.1. Design Description 
 
 At DHMC, we primarily see 2 groups of patients with newly diagnosed 
prostate cancer. The first group are patients who undergo biopsy at DHMC and 
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are newly diagnosed with prostate cancer. The second group of patients are 
diagnosed with prostate cancer outside of DHMC. These patients come to 
Urology-Oncology and/or Radiation Oncology for their first Oncology 
appointment, or to get a second opinion regarding disease management.  
 
Group 1: The standard of practice for the Urology section has been to call 
patients who are diagnosed (biopsied) with prostate cancer at DHMC with the 
results of prostate biopsy. The patients are briefly counseled by telephone by the 
practitioner. The secretary calls the patients and schedules them for a newly 
diagnosed prostate cancer diagnosis and discusses the health questionnaire  
(why its important, completion prior to appointment and locations to complete the 
H-Quest). Following the phone call, the patients are mailed:  
1) A letter greeting them to DHMC, information about their appointment, a 
written outlining about their cancer stage and grade  
2) A folder of information on prostate cancer (NCCN patient guideline, 
book list, website list, support group information) 
 3) The SDM DVD/video.  
The patients then return one to two weeks later for a consultation with an 
Urologist and/or Radiation Oncologist. 
 
Group 2: The second group of patients were diagnosed with prostate 
cancer outside of Dartmouth Hitchcock. The patients or their provider calls 
Urology and/or Radiation Oncology for a second opinion about treatment or for 
an initial consultation about disease management. The secretary schedules them 
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for a newly diagnosed prostate cancer diagnosis and discusses the health 
questionnaire (why its important, completion prior to appointment and locations to 
complete the H-Quest). Following the scheduled appointment by phone, the 
patients are mailed the same material as group 1 *except for the customized 
letter about their diagnosis3
1) A letter greeting the patient to DHMC and information about their 
provider and appointment.  
):  
2) A folder of information on prostate cancer (NCCN patient guideline, 
book list, website list, support group information)  
3) The SDM DVD/video.  
The patients then return one to two weeks later for a consultation with both 
Urologist and/or Radiation Oncologist. 
 
Secretaries in each department are responsible for making appropriate 
appointments. The contacted secretary is fully responsible for coordinating and 
scheduling all necessary appointments and for requesting office notes, biopsy 
slides and reports, radiology films (CT, MRI, Bone scans) and blood lab reports.  
3.2.1.1. Locations for H-Quest 
The study was conducted in the out-patient Norris Cotton Cancer Center  
(NCCC) at DHMC where Urology/Radiation Oncology patients are seen. Patients 
from both departments either complete their health questionnaire: a) online prior 
                                            
3 Because the provider has not seen the newly diagnosed prostate cancer patients’ pathology report, the 
provider can not make a customized letter about the cancer diagnosis. Only patients that are diagnosed at 
DHMC and have their pathology reviewed by the Urologist can have a customized letter about their 
diagnosis.  
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to their appointment either at their preferred internet connection or at DHMC 
Health Education Center (HEC) b) at their scheduled appointment one hour 
earlier. 
 
HEC Location: If patients choose to do their H-Quest at 4H/Health 
Education Center (HEC), a reception secretary greets them at the registration 
desk. The HEC is equipped with two full time staff to educate and “log” the 
patient into the survey system. The secretary enters the Medical Record Number  
(MRN) that is pre-assigned. The patients’ MRN triggers the appropriate 
questionnaire that is then displayed. The secretary leaves the patient to complete 
the health questionnaire. The HEC is equipped with desktop computers and 
relaxed office furniture. The space provides patients with a quiet atmosphere for 
filling out surveys, along with privacy away from the waiting room. Upon the 
questionnaire completion, the patients leave the HEC and may continue with 
their normally scheduled appointment or return on a later date for their 
appointment.  
 
Patient Preferred Internet Location (at Home): Patients log into the Patient 
Online System. The health questionnaire is electronically self-administered. 
Patients may call Patient Online Services with any technical questions (any 
health specific questions are answered by Telisa Stewart-Project Specialist in 
Urology). Upon completion of the H-Quest, patients may come to their normally 
scheduled prostate cancer appointment. 
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Clinic Location One Hour Prior: The patients arrive in the clinic one hour 
prior to the normally scheduled appointment. The secretary takes all necessary 
insurance information for patient registration, which includes: insurance 
information, billing information, and verification of information already received 
(address, phone number, next of kin, etc.) The secretary then activates an 
electronic touch pad computer by entering the Medical Record Number (MRN) 
that is already assigned by the appointment scheduling process. The patients’ 
MRN triggers the appropriate questionnaire that is then displayed; secretary 
provides the patients with an electronic touch pad computer and instructs the 
patient (see Appendix D). The patients conduct the H-Quest either in an exam 
room or in the waiting area of the clinic by putting the touch pad on their lap and 
completing the health questionnaires. Upon completion of the survey, patients 
return the pad to the staff (see Appendix D and Appendix E). The secretary asks 
the patients to either wait in the waiting area or in the clinic space so that their 
scheduled appointment can continue.  
 
Regardless of where the H-Quest is completed, the completed H-Quest is 
uploaded into the patients’ medical chart in about four seconds. A summary 
report is displayed in a patient-entered data folder that is accessible to providers. 
Providers have been trained to look for “red flag” patients that reached a high 
score category (high levels of mental health distress for example). A “red flag” is 
separately displayed in the summary report that notifies the providers of mental 
health distress and/or a positive screen for psychiatric disorder(s). Providers 
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review the patients’ medical record chart prior to the appointment. Depending on 
the severity of the “red flag” 4
 
 the provider addresses the psychiatric concern.  
The encounter with the patient starts in the exam room. The patient is 
called into an exam room by a nurse who takes body counts (blood pressure, 
temperature, weight and heart rate). Dr. Seigne, Dr. Hartford and Dr. Zaki start 
their standard one-hour consultation. Dr. Heaney’s appointment includes seeing 
an Advanced Nurse Practitioner for 30 minutes. The Nurse Practitioner 
consultation usually includes reviewing demographics and general information 
collected and discussed; followed by a 60 minute consultation by Dr Heaney. The 
provider enters the exam room with two copies of the graphical electronic 
questionnaire interpretation. The provider does a clinical exam; reviews 
treatment options and/or makes interdisciplinary referrals. The provider also 
discusses and reviews the different components evaluated in the graphical 
electronic questionnaire interpretation.  
 
The H-Quest data is stored in a secured DCS database where it is 
extracted for the purpose of this study.  
 
 
 
 
                                            
4 Severity and intervention is the responsibility of the provider. The provider determines the intervention 
whether it is by a phone call to follow up, make a referral, asking the patient to come to the clinic to meet 
with a masters of social work  (MSW), or addressing as part of the normal process of care.  
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3.2.2. Graphically Portray Design 
Figure 3:  Retrospective Cross-Sectional Study 
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3.2.3. Rationale-Strength in Ruling Out Alternative Explanation 
 
It is possible that distress and psychiatric syndromes existed prior to the 
diagnosis of prostate cancer. In order to rule out this plausible explanation, the 
MSAS specifically asks the patients to recall information about the last two 
weeks. Seasonal variability could account for psychiatric syndromes; however, 
data has been collected for over a year to account for any seasonal variations.  
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3.3. Sampling Methods 
3.3.1. Population-Implications for Generalization 
 
The sample population in this study only captures patients that utilize 
DHMC for newly diagnosed prostate cancer care. The sample represents rural 
communities and rural health. The population consists only of males, given that 
prostate cancer is gender specific. The sample population is generally 
Caucasian; not ethnically and/or racially representative of the general public. 
There is an estimated age of 65 and over with the majority of patients who speak 
English. Generalizing this population to urban areas, public/private hospitals, and 
ethnic or racially diverse population would be difficult.  
 
3.3.2. Sampling Plan 
 
There is no active recruitment for this study. All patients who are newly 
diagnosed with prostate cancer are selected for the sample. All patients are 
selected from the Urology Oncology and Radiation Oncology patient population. 
Four providers support, treat and diagnose prostate cancer patients within these 
two clinics: Dr. John Heaney, Dr. John Seigne, Dr. Alan Hartford, Dr. Bassem 
Zaki. Patients are identified first by the providers’ secretary and secondly by the 
scheduling code on each providers’ schedule. 
 Patients are only recruited from selective criteria:  
1) Patients are only selected from “SPC -special prostate cancer clinic” 
and “IVT” Radiation Oncology clinic at DHMC;  
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2) Patients must have original pathology report confirming a positive 
diagnosis of prostate cancer;  
3) Patients must be within one year of the original diagnosis;  
4) Patients must have “untreated” localized prostate cancer (early stage 
prostate cancer), and  
5) Patients must be over the age of 40. 
Employees of DHMC may seek out DHMC for care. By default this population will 
be included in the study; there will be no active recruitment for this population nor 
will they be singled out in any way: They are included in the standard process of 
care.  
3.3.3. Graphically Portray Sampling Plan 
Figure 4: Sampling Plan 
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3.3.4. Power Analysis 
 
 A statistical power analysis was conducted on a sample size of 320 
participants for a 95% confidence interval. 
 
3.3.5. Rationale-Strength in Minimizing Sampling Bias 
 
 This study is part of the standard process of care, which greatly reduces 
and minimizes any sampling bias. All newly diagnosed prostate cancer patients 
at DHMC fill out the health questionnaire as part of the standard process of care. 
By selecting “Yes, I consent to the study” in the beginning of the health 
questionnaire, patients health questionnaires results are copied to a separate 
dataset that only includes consented patients (it does not contain health 
information for patients that selected “No, I do not consent.” Regardless of the 
practitioner or the department at DHCM, the patient is asked to complete the 
electronic questionnaire. As patients are identified by diagnosis,  
discrepancies within the sample population entering through Urology, and/or 
Radiation Oncology, or by provider are limited.  
 
3.4. Measurement Methods 
3.4.1. Measurement Matrix  
Table 2:  Measurement Matrix 
Mental Health 
 
Post Traumatic Stress Disorder (PTSD) 
General Anxiety Disorder  (GAD 7) 
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Patient Health Questionnaire (PHQ9)  
Social Functioning: Mental Health Composite Score  
(SF-12: MCS) 
 
Distress Thermometer 
 
3.4.2. Measuring Variables 
 
 The core demographic questions (living situation, marital status, working 
and employment information, level of education, race/ethnicity, height, weight, 
smoking, core conditions, family history, core review of symptoms) were taken 
directly from the DHMC patient registration form.  
 
3.4.2.1. Core Condition 
A portion of the core conditions is used in this study. The form was 
developed by a set of providers during a focus group. No documentation was 
collected during the focus group. The core condition questions have not been 
validated for validity and/or reliability; no research on the core demographic 
questions has been conducted. The core condition questions are used for the 
normal process of care for all patients. The core condition questions that are 
used are:  
• Have you ever been diagnosed with or treated for health conditions in the 
following areas?  
Decision Making 
 
Treatment leaning toward 
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• Which of the following mental, emotional, or psychiatric conditions have 
you been diagnosed with or treated for?  
• Of the health conditions you selected, which ones are you currently 
experiencing or being treated for?  
• Of the conditions you selected, for which ones were you hospitalized? 
• How many times have you been hospitalized for mental, emotional, or 
psychiatric conditions? 
• Of the conditions you selected, for which ones were you given surgery?  
• Have you recently experienced any of the following mental or emotional 
symptoms? 
3.4.2.2. Audit 
 “The Alcohol Use Disorders Identification Test” (AUDIT) was constructed 
in 1992 by World Health Organization (WHO) investigators. AUDIT was 
developed as a screening tool to identify individuals at risk of alcohol-related 
issues and those with current alcohol problems(Babor TF, 1992). AUDIT was 
designed as a ten-item scale that assessed alcohol intake, dependence, and 
adverse consequences (Reinert Duane F., 2002). AUDIT is usually completed in 
approximately two minutes. After the completion of AUDIT, a score is generated. 
A score ranges from 0-40, with a potential alcohol problem score of eight or 
higher (Babor Thomas, 2001).  
  
AUDIT was developed as a primary care screening tool but subsequently 
moved to other settings (Babor Thomas, 2001; Saunders JB, 1993). It has been 
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used in  (but not limited to): epidemiological studies(Fleming J, 1996; Ivis FJ, 
2000; Reinert Duane F., 2002), work force screenings, and psychiatric 
screenings (Hulse GK, 2000; Reinert Duane F., 2002). Standard paper versions 
may work similarly to computerized version (Chan-Pensley E, 1999; Rathbun J, 
1993). Reinert and Allen found no evidence to suggest that a computer version 
would yield more information from patients (Reinert Duane F., 2002). 
 
 Several screening methods have been developed to assess alcohol 
problems (C. M. e. Allen JP, 1995). A review by Allen et. al. (A. R. Allen JP, 
2001) evaluated and contrasted the specificity and sensitivity of AUDIT against 
alternative measures. The performance of AUDIT often exceeded the 
performance of the other measures (Reinert Duane F., 2002). Reinert and others 
looked at the integration of AUDIT within a larger screening questionnaire. 
AUDIT as a “stand alone” scale performed consistently regarding the test-retest 
reliability, internal consistency and accuracy, as it was integrated into a larger 
screening tool. Integration of AUDIT into other health measures did not 
compromise its validity (Daeppen J, 2000).   
  
The English version of AUDIT had relatively good specificity and 
sensitivity in many different samples and settings (Reinert Duane F., 2002). 
Reinert and Allen found that the lowest sensitivities were among elderly 
respondents. Several studies reported sensitivities in the upper 50s(Bradley KA, 
1998; Bush K, 1998; Morton JL, 1996; Powell JE, 1994; Reinert Duane F., 2002). 
Research has yet to account for the low accuracy rates, suggesting more 
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analysis is needed and may warrant lowering the 8-point cutoff point for the 
elderly (Reinert Duane F., 2002). 
 
The reliability of AUDIT has shown consistencies in a wide variety of 
research. AUDIT’s reported the Cronbach’s alpha to be within .80s to .90s. 
(Reinert Duane F., 2002). A test-retest study with 126 primary care patients 
showed a reliability in .81 cases(Daeppen J, 2000). An alcohol treatment 
intervention over a 2 week period showed a .64 Pearson correlation in 260 
patients (Maisto SA, 2000). Research using AUDIT’s has documented short to 
intermediate stability (Reinert Duane F., 2002).  
 
3.4.2.3. SF-12v2 
The short form health survey version 2 (SF-12v2) is a 12 question 
multipurpose health questionnaire developed by QualityMetric Incorporated. 
SF12-v2 is a generic measure that looks at health status and health outcomes. 
SF12-v2 measures eight domains of health that are categorized into mental and 
physical health scores(Ware J., 2005). 
 
SF-12v2 was originally derived from a short form 36 question (SF-36) 
multipurpose health questionnaire that was developed in 1994(Ware J., 2005; J. 
E. Ware, Jr., Kosinski, & Keller, 1996). From the original SF-36, a shorter version 
was developed (SF-12), to be completed in 2 minutes or less with a single 
questionnaire page (J. E. Ware, Jr., et al., 1996). 
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 From the SF-12, a second version was developed (SF-12v2) and 
incorporated changes such as: improvement in instructions, simplification in 
questionnaire items to be less ambiguous, improved layout, better cultural 
adaptation, greater comparability with translations, dichotomous response 
choices changed to five level response choices, and five level response 
categories from the original six-level (J. Ware, Kosinski M., Turner Bowker, 
Diane, Gandek, Barbara, 2005).  
  
SF12-v2 looks at two components of health: Physical component of health 
and the Mental component of health. In each component of health (Physical and 
Mental), four domains are measured. The physical health domains look at 
Physical Functioning (PF), Role Physical (RP), Bodily Pain (BP) and General 
Health (GH); the mental health domains look at Vitality (VT), Social Functioning 
(SF), Role Emotional (RE), and Mental Health (MH). 
  
After completion of the health survey, Physical Component Score (PCS) 
and the Mental Component Score (MCS) are generated from each of their 
respective domains. PCS and MCS are based on a 0-100 scoring scale. 
  
Scoring for the SF-12v2 is based on Norm-Based Scoring (NBS). NBS is 
based on the 1998 general U.S. population where each question in the SF-12v2 
has a linear z-score transformation for all questions and summary measures. A 
mean of 50 and a standard deviation of 10 is used from the NBS. Each question 
score is transformed for a meaningful interpretation. 
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1. Firstly, each questions raw scale score is calculated. To calculate the 
raw scale score, each question response is pre-coded and a final item 
value is selected. The patient’s selection from the final item value 
generate the raw score (J. Ware, Kosinski M., Turner Bowker, Diane, 
Gandek, Barbara, 2005) (see Appendix R). 
  
2. Secondly, each question raw score is then transformed to a 0-100 
scale score (See Appendix S). 
  
3. Next, after each score is transformed to the 0-100 scale score, the 
scores are transformed into a Norm-base score. (Norm-base scoring 
allows for a meaningful comparison between SF12v1 and SF12v2 a 
long with comparisons with the U.S. population) (see Appendix S). 
  
4. Finally, after standardization of each scale using the z-score, the 
Norm-base transformation of the SF-12v2 is standardized. To 
transform the scores into the NBS, each z-score is multiplied by the 
standard deviation (10) and the standard mean (50) from the 1998 
general U.S. population mean (See Appendix T). 
  
Summary scores for the Physical component scores (PCS) (consisting of 
PF, RP, BP and GH) and Mental Component Scores (MCS) (consisting of VT, 
SF, RE and MH) are calculated. Firstly, PCS and the MCS scores are 
standardized. The z-scores are calculated for each scale (see above). The 
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scores are then computed with each respective factor score coefficient form the 
1998 General U.S. population (see Appendix U). 
  
After the aggregate scores have been calculated, the t-score 
transformation is conducted. The Transformation involves standardizing the 
score to the NBS with the (SD of 10 and a mean of 50). 
 
Transformed (PCS) = 50 + (AGG_PCS*10) 
Transformed (MCS) = 50 + (AGG_MCS*10) 
  
Reliability was calculated for each individuals scale and for the PCS and 
MCS. Reliability for the SF12v2 was estimated using the 2000 sample of general 
U.S. population that contained the original SF 36 questionnaire. The reliability 
was significant for all scales (PF .78, RP .86, BP .73, GH .75, VT .74, SF.75, RE 
.74, MH .87) and for the PCS (.89) and MCS (.86). The reliability for subgroups 
was also estimated and found to be significant. The sample subgroups within this 
research study include an age sample of 45-64 and 65+. All individual scales 
were above .71 with a PCS and MCS above .82 respectively. A gender sample 
subgroup was calculated with a reliability of .88 for PCS and .84 for MCS. Eight 
Scales in the SF12v2 were above .71 for the all the reliability estimates in each 
category. The internal consistency reliability for the SF12v2 MCS and the PCS 
ranged from .80 to .90(J. Ware, Kosinski M., Turner Bowker, Diane, Gandek, 
Barbara, 2005). 
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Empirical validation studies for the SF12v2 were performed using SF12v1. 
Unpublished studies of the SF12v2 found it to be more statistically significant 
than SF12v1 in 14 of the 22 comparisons of the F-statistic. Furthermore, 
unpublished studies have shown that SF12v2 has greater discriminate validity 
than the SF12v1(J. Ware, Kosinski M., Turner Bowker, Diane, Gandek, Barbara, 
2005); (Utah Health Status Survey, 2001).  
 
3.4.2.4. MSAS 
 The memorial symptom assessment scale short form (MSAS-SF) is a 90 
question short form measure derived from the Memorial Symptom Assessment 
Scale (MSAS). MSAS-SF measures a diverse group of 32 physical and 
psychological symptoms with their corresponding severity and frequency. In each 
symptom characteristic, the MSAS-SF measures the distress associated with 
each symptom. Symptom subscales are calculated for physical (Phys), 
psychological symptoms (PSYCH) and a global distress index is calculated 
(Portenoy RK, 1994; Victor T. Chang, 2000).  
  
MSAS-SF is a validated and reliable tool. The MSAS-SF Cronbach alpha 
coefficients range from .76 to .87. The Physical and psychological score 
subscales have convergent validity with extent of disease, performance and 
inpatient status. The subscales showed convergent validity when compared to 
the FACT subscales (Functional Assessment Cancer Therapies). The PHYS and 
FACT-G showed a correlation coefficient of 20.74 (P.001); PSYCH and FACT 
subscale of emotional wellbeing showed a correlation coefficient of 20.68 (P, 
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.001). The correlation coefficients for the Global Index score and the FACT 
summary of quality of life subscale was 20.70 (P, .001). Spearman correlation 
coefficients were used to test the MSAS-SF subscales. Results ranged from .86 
to .94 for one day and .40 and .84 for the group at one week for the test- retest 
correlation coefficients. Reliability for the MSAS subscales has a Cronbach alpha 
range from .76 to .87. (Cella DF & al, 1993; Victor T. Chang, 2000). 
 
3.4.2.5. Karnofsky 
 The self reported Karnofsky scale is a one-to-one point ordinal scale that 
assesses the patients physical functioning. The scale particularly looks at how 
treatment and the patient’s illness affect physical functioning. The self reported 
Karnofsky scale is based on the Karnofsky performance scale. The self reported 
Karnofsky scale shows significant correlation between patient and provider 
scoring. The scale ranges from 0 to 100 in 10 point increments, where 0 is no 
functioning  (dead) with 100 being “normal; no complaints”(Baker, 1991; 
Karnofsky, 1948; Karnofsky DA, 1949).  
 
3.4.2.6. PHQ-9  
 The Patient Health Questionnaire  (PHQ) is an instrument used to 
diagnose depression and other mental disorders.  The PHQ is a nine-item 
depression scale that was developed by incorporating criteria used in diagnosis 
of depression (DSM-IV). PHQ-9 was originally tested with 3,000 primary care 
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patients and with 3,000 gynecology patients(Kroenke K, 2001; Spitzer RL. 
Kroenke K, 1999; Spitzer RL., 2000).  
  
Each of the nine items can be scored on the scale form zero to three, with 
an overall PHQ-9 score between in the range 0 - 27. Interpretation of the overall 
PHQ-9 score is broken down into categories of depression: Minimal (0-4), Mild 
(5-9), Moderate (10-14), Moderately Severe (15-19), and Severe Depression (20-
27) 
  
The PHQ-9 showed a Cronbach’s α of .89 revealing an excellent internal 
reliability in the primary care setting and a .86 in OB-Gyn patients. PHQ-9 also 
had excellent test-retest reliability. The ROC analysis (.95) showed that PHQ-9 is 
able to properly identify people with and without depression. Internal validity and 
external validity were both achieved. Specificity and Sensitivity were achieved by 
having a patient re-interviewed; PHQ-9 scores ten and over had a sensitivity and 
specificity of 88%(Kroenke K, 2001).  
 
3.4.2.7. GAD-7 
 A seven-item anxiety scale (GAD-7) is used to diagnose and measure 
symptoms of generalized anxiety disorder. Items selected for GAD-7 were 
derived from the symptom criteria for anxiety using the Diagnostic and Statistical 
Manual for Mental Disorders (Forth Edition). The self-reported scale identified 
probable cases of GAD by asking “how often in the last 2 weeks” were they 
affected by a problem. Each of the seven questions is scored on a range from 
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zero to three, allowing the GAD-7 scores to range in 0-21. Scores on the GAD-7 
greater than or equal to ten reasonably indicate general anxiety disorder (Robert 
L. Spitzer, 2006).  
 
 GAD-7 internal consistency was excellent with a Cronbach α =.92 and 
results were acceptable in terms of the Test-retest reliability (intraclass 
correlation=.83). Sensitivity and specificity exceeded .80 at a cutoff point of ten or 
greater (Robert L. Spitzer, 2006). GAD-7 demonstrated good convergent validity 
with its correlations the Beck Anxiety Inventory (r = .72) and Symptom Checklist-
90 anxiety subscale (r.074)(Carter RM, 2001; Robert L. Spitzer, 2006; Wittchen 
HU, 1994).  
3.4.2.8. PTSD 
 The four-item Primary Care Post Traumatic Stress Disorder (PTSD) 
screening tool is used to assess PTSD. The four-item scale has a yes/no (binary) 
responses. The questions consist of: In your life, have you ever had 
any experience that was so frightening, horrible, or upsetting that, in the past 
month, you: 
a) Had nightmares about it or thought about it when you did not want to? 
b) Tried hard not to think about it or went out of your way to avoid situations that 
reminded you of it?  
c) Were constantly on guard, watchful, or easily startled?  
d) Felt numb or detached from others, activities, or your surroundings? 
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A score is calculated by adding up yes responses. A score of three or higher 
indicates PTSD (Prins A, 2004). 
 
 Alter et. al. find that cancer survivors have higher rates of PTSD then 
general population. Their research found that PTSD in cancer survivors was 
similar to PTSD found in other members of society that had experienced 
traumatic events(Alter CL, 1996).  
3.4.2.9. Distress Thermometer  
 The Distress Thermometer was created by the National Comprehensive 
Cancer Network (NCCN) to identify distress in patients. The distress 
thermometer is a patient-administered screening tool for cancer patients. The 
patients view a temperature thermometer on which a scale of 0 - 10 is labeled. 
Patients are asked to rate their distress using the scale(Roth Andrew J., 1998) 
(Zero equaling “no distress” and Ten equaling “Extreme distress”). As the 
distress rises, so does the thermometer (mirroring a temperature thermometer). 
The distress thermometer scoring is categorized based on the face value of the 
thermometer score. A thermometer score of 5 or less is considered to be mild 
distress and a score of 6 or more is considered to be moderate to severe 
distress. 
 
 The “problem checklist” that follows the distress thermometer is a 35 
problem checklist that asks binary questions (yes, no). The checklist looks at 
factors that contribute to distress in the patient including: practical problems  
(insurance, child care, housing, transportation, work/school), family problems 
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(children and partner issues) and physical problems (appearance, hygiene and 
physical health). This check list is not scored but aids in the discussion of the 
score for the distress thermometer (Vitek, et al., 2007). 
 
3.4.2.10. FIMDM 
 The Foundation for Informed Medical Decision Making (FIMDM) created a 
patient decision form. The form has not been tested for validity or reliability. The 
24-question form is directed at newly diagnosed prostate cancer patients who 
have watched the FIMDM Shared Decision Making Video on prostate cancer 
treatment. The form consists of asking questions about prostate cancer 
knowledge, patient values, making a choice about prostate cancer treatment and 
video feed back (see Appendix F). 
3.4.3. Graphical Portray of Data Collection Timeline 
Figure 5: Data Collection Timeline 
 
 
 
Collection Timeline
Start of Pilot
Collection
July 2007
cross-sectional 
Study Start
February, 2008
End of Pilot
Collection
December 2007
cross-sectional 
Study Start
October, 2008
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3.4.4. Rationale-Strength in Minimizing Measurement Bias 
 
There are two types of populations of patients being evaluated that would 
create measurement bias: patients diagnosed at DHMC that have a two to three 
week window between the time of diagnosis and first clinical encounter, and 
newly diagnosed patients outside DHMC that have varied windows between the 
time of diagnosis and the first clinical encounter. The first group has limited recall 
basis as the window of analysis is two to three weeks retrospectively from their 
encounter. As patients are able to access the H-Quest via the internet, patients 
often complete their health questionnaire well within the two to three week 
window. Recall bias is minimized with the ability to complete the health questions 
prior to their appointment.  
 
Measurement bias may exist with the uncontrolled length between the 
time of diagnosis and the first clinical encounter for patients that are newly 
diagnosed prostate cancer patients outside DHMC. To minimize the 
measurement bias, several different validated health questionnaires are 
reviewed; each validated health questionnaire looks at different snapshots of 
time (e.g. 2 weeks, 4 weeks, have you ever, etc). Analysis of these validated 
health questionnaires in comparison to the health questionnaire as a whole helps 
to minimize any measurement bias.  
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3.4.5. Training and Supervision of Data Collectors 
 
Training and supervision was minimal because data is strictly collected 
through an electronic system. Training was directed towards support staff issuing 
electronic pads to patients. Training consisted of providing and reviewing 
information about the pads, how to turn them on/off, how to access the system 
(since the health questionnaire is wi-fi based), how to use the stylus, and H-
Quest launching. Basic troubleshooting was reviewed for electronic pad 
functions. Staff issuing the H-Quest quickly reviewed with the patient how to use 
the stylus, demonstrated by tapping the screen with the stylus selecting the 
answer, demonstrating that after each question H-Quest is saved (thus no 
information is ever lost, patients will always be able to return to the last question 
that was answered), and asked the patient to read each question and answer the 
questions to the best of their ability (making it clear that if the patient is unable to 
answer question, then the patient is to select the “next” button (which skips the 
question). 
3.5. Data Management and Analysis Methods 
3.5.1. Data Storage and Security 
 
All users of ISS are assigned unique account numbers and each user 
maintains his/her own password. The ISS application uses Role-based (e.g. front 
desk vs. clinician) security to prevent users from accessing functions they do not 
have appropriate permissions for. ISS also uses Context-based (Urology vs. 
Radiation) security to restrict users to only see the data for which they have been 
given permission. ISS maintains a complete HIPAA audit of all activity 
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surrounding a particular patient; including time of activity, the responsible user 
and the action taken. ISS also maintains full system audits to detail all changes 
made by a given user. All sessions on the ISS web server are secured using 
128-bit HTTPS encryption. 
 
3.5.2. Entering, Verifying and Documenting Data 
 
 Patients can enter the data for this study by using a touch pad located in the 
clinic space, from a desk top wireless computer located in the health education 
center at DHMC, or at patient’s designated internet location. The information 
provided through the electronic health questionnaire is patient-reported 
information. No information is verified. The data is electronically captured by the 
dynamic clinical systems and subsequently stored. A customized and 
summarized report is electronically added to the patient’s medical record.  
 
3.5.3. Analytic Issues 
 
 The dependant variable “Sure of treatment” will be recoded from five 
categorical questions and summarized into a binary variable. The specific 
treatment choice the patient is most likely to accept is not captured by the binary 
variable. However, it later becomes clearer which patients are leaning towards a 
particular treatment choice and which patients are unsure which treatment option 
to choose. 
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 Missing data is analyzed and its impact on the data set is assessed. 
Statistical methods for generating missing data may be used.   
3.5.4. Analysis Plan for Each Specific Objective 
Table 3:  Analysis Plan 
 
Variables Descriptive Stats Bivariate Stats 
Logistic 
Regression 
PTSD  (Post Traumatic 
Stress Disorder) Histogram 
Independent Sample 
T-Test 
Independent 
Variable 
GAD 7  (Anxiety) Histogram Independent Sample T-Test 
Independent 
Variable 
Distres Thermometer Histogram Independent Sample T-Test 
Independent 
Variable 
SF 12  (Mental Health 
Composite Score) Histogram 
Independent Sample 
T-Test 
Independent 
Variable 
PHQ 9  (Depression) Histogram Independent Sample 
T-Test 
Independent 
Variable 
Treatment Leaning 
toward 
Bar Chart Independent Sample 
T-Test 
Dependant 
Variable 
 
3.6. Ethical Issues 
3.6.1. Risks and Benefits 
 
The participants involved in this study were not exposed to any immediate 
or long-term risks from completing the health questionnaire. There were no 
physical, legal or social implications arising from participation in this study. 
However, it is recognized that patients may experience minimal psychological 
stress by being asked to answer multiple choice questions. To alleviate and/or 
minimize any potential stress associated with the educational questions, the 
questions are designed with an “I am not sure” response for patients who do not 
feel comfortable answering the question.  
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3.6.2. Informed Consent 
 
H-Quest is integrated into the standard process of care in Urology and 
Radiation Oncology. Part of the clinical encounter includes utilizing the results 
from the health questionnaire. Regardless of where the patient takes the health 
questionnaire, consent is required. Before beginning the standard process of 
care, i.e. H-Quest for newly diagnosed prostate cancer patients; the initial survey 
question is a HIPPA regulation and consent form (which is in compliance with 
Dartmouth protection of human rights). As patients can opt to take the health 
questionnaire outside of DHMC/NCCC, the patient self-consents to allow 
research to be conducted on the health information collected. The patient 
consents to the HIPPA and Consent form by checking ‘Yes’ (see Appendix A). 
Regardless of where the patient consents to use of their information for research 
purposes, the patient is still required to complete the health questionnaire for 
standard process of care. By consenting to having their health information be 
used for research, a separate survey is generated (a copy) for the research data 
collection. Patients are instructed to contact Urology if interested in a copy of the 
consent.  
3.6.3. Confidentiality 
 
There is a minimal confidentiality risk. The ISS system maintains unique 
identifiers indefinitely, as it requires these identifiers to support interfaces 
between the DHMC IDX and CIS systems. However, once the data is extracted, 
individual patient’s name is removed; whilst the medical record number remains 
in the system, allowing the information from the medical record to be extracted. 
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Once the information has been gathered, the MRN is discarded and anonymous 
identifiers are subsequently used. Security measures have been implemented; 
including − but not limited to − passwords, encryption codes and tracking 
mechanisms for each user. 
3.6.4. Level of Review 
 
 The IRB level of review is expedited. The collection of data was conducted 
used non-invasive procedures and posed no health risk to patients. 
3.6.5. IRB Plans 
 
 Drexel University IRB department was contacted as the first step in starting 
the IRB process. Henceforth the following steps were carried out: 
• Drexel IRB requested that an IRB of the proposed project first be reviewed 
by Dartmouth College IRB.  
• An IRB was submitted to Dartmouth College.  
• Dartmouth College reviewed and approved the research.  
• Drexel University was contacted after the IRB was approved at Dartmouth 
College.  
• Drexel was then mailed the approved Dartmouth College IRB along with 
Dartmouth College IRB contact information.  
• Drexel then contacted Dartmouth College IRB and an alliance between the 
two Universities was established.  
• Drexel defaults to the Dartmouth College IRB.  
• The IRB at both Dartmouth College and Drexel University is on file.  
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3.7. Research Plan 
3.7.1. Task Timeline 
 
 
Figure 6: Research Timeline 
 
 
Collection Timeline
Start of Pilot
Collection
July 2007
Retrospective 
data Pulled 
June 1, 2009
End of Pilot
Collection
December 2007
cross-sectional 
Study Start
June 12, 2009
 
3.7.2. Potential barriers to conducting research and strategies for 
minimizing barriers 
  
As stated above, there are two types of populations of patients being 
evaluated that would create measurement bias: patients diagnosed at DHMC 
that have a two to three week window between the time of diagnosis and first 
clinical encounter; and newly diagnosed prostate cancer patients outside DHMC 
that have varied windows between the time of diagnosis and the first clinical 
encounter. The first group has limited recall basis as the window of analysis is 
two to three weeks retrospectively from their encounter. Because patients are 
able to access the H-Quest via the internet, patients often complete their health 
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questionnaire well within the two to three week window. Recall bias is minimized 
with the ability to complete the health questions prior to their appointment.  
 
To minimize measurement bias, several different validated health 
questionnaires will be reviewed; each validated health questionnaire looks at 
different snaps shots of time (e.g. 2 weeks, 4 weeks, have you ever, etc.). 
Analysis of these validated health questionnaires in comparison to the health 
questionnaire as a whole will help to minimize any measurement bias.  
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4. Results 
 
4.1. Description of Sample 
The data set extracted for the final analysis revealed 603 participants who 
fully completed the health questionnaire. Of the 603 participants, 44 
participants were removed, as they did not meet the inclusion criteria. 
Participants who participated in the pilot (75 participants) were also removed 
from the dataset. 
4.1.1. Sample Size 
A total of 484 participants were analyzed for this study. 
4.1.2. Demographic Characteristics  
The SEER data from 2000-2006 has the median age of a newly diagnosed 
prostate cancer patient at 68 years old (Surveillance Epidemiology and End 
Result (SEER), 2003-2007). The national estimate for a newly diagnosed 
prostate cancer patient by age distributions is: ages 35-44 −0.6%, ages 45-54 
−8.7%, ages 55-64 −29.0%, ages 65-74 −35.6%, ages 75-84 −21.4%, and for 
ages 85+ is 4.7%. The median age of the newly diagnosed sample is slightly 
younger than the national average at 63 with standard deviation of 7.785. The 
sample age distribution is: age 35-44 at .8% (4), ages 45-54 at 13% (62), ages 
55-64 at 41% (200), ages 65-74 at 38% (186), ages 75-84 at 6% (30) and ages 
85+ years at .4% (2). 
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New Hampshire and Vermont are states that are largely homogeneous. NH 
population is 94.9% Caucasian with a 5% racial/ethnic minority (U.S. Census 
Bureau, 2006-2008 Data); Vermont population is 96.1% Caucasian with a 4% 
racial/ethnic minority group (U.S. Census Bureau, 2006-2008). The “age” 
variable originally had five categories. The categories were grouped together in 
order to better represent the sample. Of the 462 participants, 456 participants 
identified themselves as Caucasian (98.7%) (see Appendix V) with only 6 (1.3%) 
participants identifying themselves as other then Caucasian.  
 
The “education” variable had six categories. The categories were collapsed 
to 4 categories. The majority of the participants were educated (54%, 258); 
further 21% (102) participants had some college or technical schools; 20% (94) 
of participants graduated from high school; whilst 5% (24) of participants did not 
complete their high school education (see Table 4). The majority of New 
Hampshire residents aged 25 years and older have a high school diploma 
30.3%, 18.4% of residents have attended at least a part of a college curriculum, 
and 41.7% graduated with an associates degree or higher. Only 9.6% of New 
Hampshire residents did not complete a GED or receive their high school 
diploma. Furthermore, 32.5% of Vermont residents aged 25 years and older have 
a high school diploma, 16.3% of residents have attended at least a part of a 
college curriculum, and 41.5% of participants graduated college with at least an 
associate’s degree. Only 9.6% of Vermont residents did not complete a GED or 
receive their high school diploma (U.S. Census Bureau, 2006-2008, 2006-2008 
Data). 
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The “relationship” variable was first represented with fourteen categories 
identified. They were subsequently collapsed into four categories, in order to 
better represent the data set using: marriage/civil union, living with someone, 
divorced alone and widow, single. The collapsed categories better represent 
participant’s personal social support levels. The majority of participants were 
married or had a civil union partnership (81%, 374); further 11% (50 participants) 
were widowed, divorced or legally separated; 4% of participants were single and  
5% of participants lived with a significant other (see Table 4). The New 
Hampshire distribution of “relationships” were: 69% of males aged 65 and over 
were married or had a civil union; 23.2% were widowed, separated, or divorced; 
and 4.6% never married (single). Vermont residents reported that 71.2% of 
males aged 65 and over were married or had a civil union; 23% were widowed, 
separated, or divorced; and 5.9% never married (single) (U.S. Census Bureau, 
2006-2008, 2006-2008 Data). 
 
The “employment status” variable was first analyzed with fourteen categories 
identified. Categories were collapsed into five categories (working, retired, 
unemployed, other, disabled). The majority of participants were working (55%) or 
retired (35%). A few of the participants (3%) selected ‘other’ as their status, whilst 
3% of the patients were unemployed and 5% of the patients were disabled (see 
Table 4). The New Hampshire state statistics estimate that residents aged 65-74, 
27.2% are working and 3.0% are unemployed. The Vermont state statistics 
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estimate that 28.7% are working and 4.3% are unemployed (U.S. Census 
Bureau, 2006-2008, 2006-2008 Data).  
 
Substance abuse regarding smoking and alcohol in New Hampshire is 
prevalent. It is estimated that 62.4% of New Hampshire residents (aged 45 years 
and older) smoke (NH Department of Health and Human Services, 2005) and 
56% of Vermont residents smoke (Vermont Department of Health, 1998-2008). 
At present, 11% of this sample smoke. The sample indicated that 7.9% of the 
participants had an alcohol abuse issue (Audit score). 
 
In summary, the participants were generally well educated and were 
employed. Participants were more likely to be married and Caucasian. In 
general, participants were similar to the state of Vermont and New Hampshire 
demographic population. Participants were slightly more educated then both the 
state of Vermont and New Hampshire populations.  
Table 4:  Demographics 
Variable 
United 
States 
Population 
N.H. 
Population 
Vermont 
Population 
Research 
Participants 
Race     
White  94.9% 96.1% 95.3% 
Other minorities  4% 4% 4% 
Median age of diagnosis 68 - - 63 
Age of prostate cancer 
2000-2006  (SEER)     
Aged 35-44 .6% - -  
Aged 45-54 8.7% - -  
Aged 55-64 29% - -  
Aged 65-74 35.6% - -  
Aged 75-84 21.4% - -  
Aged 85+ 4.7% - -  
     
Age of Vermonters at     
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Diagnosis of cancer 2008  
(BRFSS) 
Aged 35-44 - - .4%  
Aged 45-54 - - .06%  
Aged 55-64 - - 3.4%  
Aged 65+ - - 11.8%  
     
Age of New Hampshire at 
Diagnosis of cancer 2006  
(NH Cancer Registry) 
   2010 sample 
Aged 35-44  - - .8% 
Aged 45-54  10.4% - 13% 
Aged 55-64   - 41% 
Aged 65-74   - 38% 
Aged 75-84    6% 
Aged 85+    .4% 
     
Education     
Less than high school - 9.6% 9.6% 5% 
High School - 30.3% 32.5% 20% 
Some college - 18.4% 16.3% 21% 
Graduated from college - 41.7% 41.5% 54% 
     
Employment status: 65-74  65-74 ages 65-74 age All sample 
Working  27.2% 28.7% 55% 
Retired  NA NA 35% 
Unemployed  3.0% 4.3% 3% 
Disabled  NA NA 5% 
Other  NA NA 3% 
     
Relationship     
Marriage/civil union - 69% 71.2% 81% 
Divorced/separated/widowed - 23.2% 23% 11% 
Single  (never married) - 4.6% 5.9% 4% 
Living with significant other - NA NA 5% 
     
Smoking 45+  62.4% 56% 11% 
Alcohol use    7.9% 
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4.2. Nature and Extent of Mental Health Problems 
The results from the health questionnaire for newly diagnosed prostate 
cancer patients (prior to a surgical and radiation consultation) revealed unmet 
mental health needs. Overall, about a quarter of newly diagnosed prostate 
cancer patients had at least one mental health issue or distress symptom 
(distress, PTSD, depression, anxiety, low MCS). The analysis reveals that 12.6% 
(61) of the sample that completed the PHQ-9 had met the depression threshold. 
The majority of patients had mild depressive symptoms with less then 16 patients 
who had clinically significant depressive symptoms. Overall, less then 3% of 
patients had clinically meaningful posttraumatic stress levels. Anxiety seems to 
be slightly more detected then distress levels, with about 14% of patients 
meeting the GAD-7 threshold for anxiety then 11.4% of patients scoring greater 
then five on the distress thermometer (indicating clinically meaningful distress 
levels). Participants with anxiety more often reported mild anxiety (11%) then 
severe anxiety (1%). 
 
The mental health component score (MCS) mean was similar to the 
national average with a slightly less variation in the standard deviation. MCS 
revealed that 6% of the participants were below the national average for mental 
health functioning (see Table 5). Overall, there are clinically significant mental 
health problems.  
Table 5: Mental Health Screening 
 
Measure No.  (%) 
At least 1 mental health/distress threshold 26%  (124) 
Distress screening, scale 0-10  
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Mean  (SD) distress 2.15 
Distress Thermometer >5 51 (11.4%) 
SF-12 Mental Component Score <40 29  (6%) 
Psychiatric Screening  
Major Depression  (PHQ-9 >10) 15  (3.1%) 
Mild depressive symptoms  (6-10) 46  (9.6%) 
Moderate  (11-14) 11  (2.3%) 
Moderate to severe  (15-19) 4  (.8) 
Severe  (>20) 0 
Post Traumatic Stress Disorder  (>3) 10  (2.1%) 
Generalized anxiety disorder  (>10) 69  (14.2%) 
Mild 52  (11%) 
Moderate 11  (2.3%) 
Severe                6 (1%) 
 
4.3. Investigating Association of Mental Health Status with Quality of 
Decision Making 
 
4.3.1. Quality of Decision Making 
 
Participants who screened negative for depression where clinically higher 
on the mental component score than patients who screened positive (mean 
score, 53.5 vs. 34.3, P < 0.01). Similarly, participants who had a negative 
screening for depression were almost three-fold less likely to score below 40 on 
the MCS then participants who screened positive for depression (15% and 4.8% 
respectively). Participants who screened negative for PTSD where clinically 
higher on the mental component score then patients who screened positive 
(mean score, 53.2 vs. 41.6, P < 0.01). Similarly, participants who had a negative 
screening for PTSD were almost ten-fold less likely to score below 40 on the 
MCS then participants who screen positive for PTSD (40% and 5.4% 
respectively) (Hegel, et al., 2006) (see Table 6). Overall patients with PTSD and 
depression have clinically significant lower mental health functioning.  
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Table 6:  SF-12 Mental Component Score (MCS) for patients meeting 
threshold criteria for major depression or PTSD and percentage achieving 
clinical significance by falling below a score of 40 on each scale. 
 
 
Condition Screen  (-) Screen  (+) T P 
Depression 416 61   
MCS mean  (SD) 53.5  (7.22) 34.3 (13.02) 9.49 < 0.001 
MCS<40 4.8%  (N=20) 14.8%  (N=9) 3.232 0.003 
     
PTSD 459 10   
MCS mean  (SD) 53.216  (7.8) 41.64  (11.86) 4.53 < 0.001 
MCS<40 5.4%  (N=25) 40%  (N=4) 0.616 0.54 
  
 
 
 
4.3.2. Bivariate Results 
 
Categorical variables were collapsed to better represent the data and 
were categorized into binary variables. The variables were represented by either 
meeting the threshold for clinical significance of a mental health disorder or not 
meeting the threshold.  MCS was normally distributed and was not collapsed into 
a categorical variable.  The distress variable was not normally distributed and 
was normalized using the log function.  The log distress variable remained 
continuous.   
 
An independent sample T-Test was performed on the continuous 
variables. The SF-12 mental health component score was not statically 
significant with a P value of 0.460. The logged distress thermometer variable was 
statistically significant with a P value of 0.001.  
Independent sample T-test 
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Cross-tabulation 
Cross-tabulation was performed with variables: PTSD, GAD7 and PHQ9. 
Participants with PTSD were more likely to be sure about their choice (1.8%, 6) 
than not sure about their choice (2.9%, 4). Participants with no PTSD were more 
likely to be sure about their treatment choice (98%, 320) and than not sure (97%, 
135). The P value is 0.480. Participants who demonstrated least clinical 
symptoms of depression (PHQ) were slightly more sure about their choice 
(33.7%, 112) then not sure about their choice (30.7%, 43). Participants who did 
not have clinical symptoms of depression were more likely to be sure about their 
choice (66.3%, 220) then not sure (69.3%, 97). P value is 0.523. Participants with 
clinical symptoms of anxiety (GAD7) are generally more sure about their 
treatment choice (12.9%, 18) then not sure about their treatment choice (12.9%, 
18). Participants with clinical symptoms of anxiety are generally more sure about 
their treatment choice (84.9%, 281) then not sure about their treatment choice 
(87.1%, 122). P value of .526 (see Appendix V). In summary, PTSD, SF-12 MCS, 
GAD 7 and PHQ 9 variables were not statistically significant and the distress 
thermometer was statistically significant. 
 
4.3.3. Logistic Regression 
 
 A logistic regression was used to explore the probability that mental health 
issues affect whether a participant is sure or unsure about their treatment 
decision.  Several variables were considered when exploring the logistic 
regression. The age variable was considered. The age variable was manipulated 
to account for several different stages in aging. The marriage variable was 
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adjusted and categorized into two different dimensions. The Karnofsky variable 
was also explored. Lastly, the biopsy location (out-house or in-house) was also 
included in a logistic regression model. None of the age, marriage, Karnofsky or 
biopsy location variables enhanced the logistic regression model and were not 
kept in the final regression. 
 
 Several variables were explored but did not have a large enough sample 
size for the logistic regression.  Two questions from the “core conditions” of the 
health questionnaire were considered.  The first question which asked “Which of 
the following Mental, Emotional, or Psychiatric conditions have you been 
diagnosed with or treated for?” and “Of the health conditions you selected, which 
ones are you currently experiencing or being treated for?”  Only 161 participants 
answered the question and therefore a decision was made not to include the 
variable.  Similarly, only 8 subjects answered the question, “How would you 
describe your tobacco habits?”  Because of the low number of participants who 
answered the question this question was not included in the logistic regression.   
 
 The SF-12 (including the physical functioning score) was also reviewed for 
inclusion in the logistic regression.  Final SF-12 scores for most patients were not 
generated because participants skip one or more of the SF-12 questions.  A 
decision was made to not include the SF-12 because a null score was generated.  
The MSAS variable had less then 200 and 350 subjects in each of the MSAS 
questions who responded. A decision was made to not include the MSAS 
because of the low number of respondents. Lastly, the Foundation for Informed 
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Medial Decision Making questionnaire was reviewed.  The questionnaire was not 
validated and the questions within the questionnaire were not individually 
explored because none of the questions:  a. were not supported in the literatures 
or b. add to the validated tools that were being used.  A decision was made to 
not use the questionnaire.  Unfortunately, the variables described above were not 
explored in the logistic regression model.   
 
 The regression model included: clinical cancer stage, educational level, 
MCS, PTSD, PHQ9, GAD7, and distress.  Clinical cancer stage, MCS, PTSD, 
PHQ9, and GAD7 were not statistically significant and were removed from the 
final model. 
 
 The final regression model included “education” level and “log distress” 
variables.  The “education” and the “log distress” variables were statistically 
significant (p=.011, p=.016).  The final regression model revealed that there is a 
correlation between being sure/not sure about the treatment choice and 
education level and distress.  The odds ratios suggests that having a unit 
increase in distress on the log scale makes it 1.6 time more likely to be sure 
about the treatment choice.  Similarly, men with “some college” are more likely to 
be unsure about their treatment choice.   The model fit trended in a good 
direction respectfully (see Table 8). 
 
 Even though some of the independent variables were removed from the 
final logistic regression (GAD, PTSD, PHQ9, MCS), the sample size may not 
have been large enough to show an association with the binary variables. The 
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original dependant variable had 5 categories (Question: Which treatment choice 
are you leaning toward? Brachytherapy, External beam radiation, Active 
Surveillance, Surgery, or Unsure) before it was collapsed into a binary dependant 
variable for the logistic regression.  Descriptive statistics were re-run looking at 
the independent variables and which treatment choice a subject was leaning 
toward.  Subjects who had distress and anxiety, were more likely to lean toward 
active treatment (radiation or surgery) then passive treatment (active 
surveillance) (see table 9).   
 
 It is unclear whether mental health is the only factor impeding on the 
decision making process. Therefore, further exploration into other factors that 
may hinder the decision making process is warranted. In conclusion, mental 
health status has an impact on the decision making regarding prostate cancer 
treatment.  
Table 7:  Final Logistic Regression Model 
 
Beta Significance 
Odds 
Ratio 
Log 
Likelihood 
Cox & 
Snell  
Nagelkerke 
Log 
Distress 
.451 .016 1.57 503.983 .012 .017 
School-
Some 
college 
-.832 .011 .435 492.792 .038 .054 
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Table 8: Mean of Treatment Leaning Toward 
 Mean Brachytherapy External 
Beam 
Radiation  
Not 
Sure 
Surgery Active 
Surveillance 
Logdistress .5106 .1540 .0502 .0100 .1712 .0291 
MCS <40 - 29.23 33.17 33.17 31.98 30.84 
GAD .333 .1277 .125 .124 .1804 .0851 
PHQ .400 .2708 .3429 .307 .350 .347 
PTSD - - - .029 .031 - 
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5. Conclusion 
5.1.  
 The demographics of the population were similar to the pilot. Patients at the 
time of diagnosis were generally younger (then the national average), were more 
educated, and more likely to be married. The demographic information of the 
sample was not surprising, given the general demographics of the local 
community.  
 
 A significant amount (26%) of newly diagnosed patients were identified with 
having at least one mental health issue or distress. More specifically, patients 
suffering distress, depression, PTSD and anxiety can have symptoms that 
impede on their ability to make a decision (Patrick-Miller, 2004).  
 
 The concern arises when clinical symptoms from mental health disorders 
and distress impede on participant’s ability to make a decision. We can conclude 
with fair certainty (from the use of validated questionnaires) that at least 26% of 
the population struggles to retain the medial information presented (essential in 
making an informed decision), along with struggling to comprehend and use the 
information and knowledge necessary to make a treatment decision. For patients 
with no mental health issues or clinical distress levels, patients struggle with 
making a treatment decision especially weighing the pro/cons of treatment, along 
with incorporating their own morals and values into the decision-making process.  
 
 It is uncertain how the negative ramification of having a mental health issue 
impacts their ability to make an informed choice.  
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 When looking at depression and the relationship with the MCS, it is clear 
that participants who screen positive for depression were almost three-fold more 
likely, then patients who screened negative for depression, to have a clinically 
significant MCS score. Even more revealing is the PTSD score for participants 
who were eight-fold more likely to have clinically significant MCS scores then 
patients without PTSD. For both samples (patients with PTSD and depression), a 
low MHC corresponds to vitality, social function, emotional health and mental 
health. This research may suggest that increased social support services may be 
essential to this population (despite low utilization levels) to address the mental 
health unmet needs. 
 
 The logistic regression reveals that there is a correlation between patients 
with clinically significant distress and educational level, and patient’s certainty 
about treatment choice. It is clear that further investigation into other factors that 
may impede on the decision making process need to be explored.  
5.2. Limitations 
 There were several limitations to the study. The first limitation is that it was 
unclear how many patients had a previous diagnosis of a mental health disorder  
prior to the diagnosis of prostate cancer. Similarly, it was unclear which patients 
were currently seeking treatment for the mental health disorders.  
 
 
 Secondly, a significant portion of patients were diagnosed with prostate 
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cancer off-campus (not at DHMC). Some patients sought out DHMC for a 2nd 
opinion regarding their new diagnosis, whilst others were diagnosed at DHMC. 
The analytical approach to both patient groups was the same. The initial 
consultation about diagnosis of prostate cancer prior to coming to DHMC needs 
further exploration. For patients who were diagnosed off-campus, the level of 
counseling, medical educational resources, and the urologist’s medical opinion 
regarding treatment for prostate cancer are unknown (and vary with each 
provider). Its is also unclear whether there was any impact on patient uncertainty 
about treatment and/or whether these factors had any effect on level of distress 
and/or other mental health factors.  
 
 The third limitation is concerning the specificity and sensitivity of patient-
reported information. Patient-reported information was self-reported from 
different locations including, but not limited to: self selected locations within the 
patient’s home or community, at the health education center on the DHMC 
campus, or in the waiting area prior to the appointment. It is unclear whether 
there was any impact into the quality of information received from the patient.  
 
 The fourth limitation was the questionnaire in its entirety. The questionnaire 
was a series of validated and non-validated questionnaires. It is unclear whether 
the sequence of the questionnaires had any impact on the results. Initial 
validated tools that are asking participants to recall in the “last 4 weeks”, followed 
by  validated tools asking participants to recall “in the last 2 weeks”. This 
sequence may or may not affect the quality of the data.  
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 The logistic regression percentage correct did not increase with additional 
variables. This suggests that the independent variable may not have accounted 
for all of the uncertainty with the prostate cancer treatment decision making 
process. Personal coping style may have influenced the level of “unsure about 
choice” as well as other unknown factors that may have contributed to being 
“unsure” about their treatment choice.  
 
 Lastly, the study was limited regarding the time of diagnosis to decision of 
treatment. Understanding the final treatment decision and when the treatment 
decision was made for newly diagnosed prostate cancer patients may yield 
further understanding about the impact of clinically significant distress and mental 
health issues. 
 
 These limitations influenced the conclusion, since mental health status was 
not solely the predictor for being unsure regarding prostate cancer treatment.  
 
5.3. Recommendations 
 The mental uncertainty and the weight of personal morals and values into 
the treatment decision process, makes newly diagnosed prostate cancer patients 
a unique and vulnerable population. For this reason alone, DHMC institutional 
policies should focus on initiatives that support the decision making process and 
provide mental heath support to men diagnosed with prostate cancer. Policies 
and standards should be at least similar, if not more robust, in nature to the 
support offered to women (quality and quantity) diagnosed with breast cancer; 
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because of the uncertainties men are facing in the decision making process. 
 
Currently, the standard process of care could be adjusted to incorporate 
appropriate referrals to mental health services from the validating tools currently 
being utilized. Small alterations into the standard of practice could support a 
referral process to clinics already established within the institution. Physicians in 
both Radiation oncology and Urology could increase referrals to mental health 
support services. To increase mental health referrals, urologist and oncologist 
need to:  
a. be engaged in looking for and making referrals during their clinical 
encounter  
b. have automatic referrals that identify “red flags” to mental health support 
services responsible for following up with patients (below),  
c. have adequate support services to accommodate newly diagnosed 
prostate cancer patients in a timely fashion and  
d. have support services that are evidence-based and have gender specific 
training and knowledge about the controversies of prostate cancer.  
 
 Institutionally, a more robust process of care for newly diagnosed cancer 
patients and patient support services should be developed. Integration of an 
additional provider that can address the psychological and distress needs of this 
population, as part of the routine care, is essential. An integration of master of 
social work (MSW) into the normal process of care could be assigned to all 
patients who meet the threshold for the mental health. This process should be 
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facilitated by use of:  
• Validated questionnaires on the newly diagnosed prostate cancer patients,  
• Questionnaires and/or referrals form providers that feel need additional 
support through the process − but who have not been “flagged” through the 
validated tools.  
The majority of process could be automated through the online paging and email 
system currently set up for breast cancer patients.  
5.4. Further Research 
Further research should focus on developing a set of validated tools to 
assess distress and other mental health disorders that may impede on the 
decision making process of newly diagnosed prostate cancer patients. 
Furthermore, research should find innovative ways to track the mental health 
trends (in particular their transition towards positive mental health) of patients 
through life-altering decisions, to ensure patients are at the optimum mental 
health during the decision making process.    
 
 There is an opportunity for research to further understand how coping and 
learning styles affect mental health and the decision making process. Certainly 
essential medial information pertinent to the decision making process may be 
more effective, if tailoring information toward specific learning styles. This 
information tailoring process may play a role in minimizing distress in patients.  
This research warrants a longitudinal study that looks at the decision making 
process along with decision regret. It is currently unclear whether patients who 
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were sure about their treatment choice and patients who were unsure about their 
treatment choice had any long term regrets following their chosen treatment. 
Exploring whether patients had decision regret one year from their treatment 
decision, may yield more precise areas for aggressive intervention; as it may be 
that decision regret has a stronger correlation with mental health status.  
 
Lastly, when comparing this research to Mark Hegel’s work, men yield 
significantly lower mental health prevalence rates then women diagnosed with 
breast cancer (Hegel, 2006). Future research should explore whether newly 
diagnosed prostate cancer patients need to have a lower threshold on the 
validated tools for depression, anxiety, PTSD and distress; or that other validated 
tools need to be developed to better identify men with mental health needs.  
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Appendix A: Consent 
 
 
 
 
Dr. John Heaney CPHS#20769 
HIPPA and Consent Form 
 
Introduction: 
 
As part of your appointment with a prostate cancer specialist at DHMC, you are 
being asked to complete a Health Questionnaire. The questions help provide 
your provider with demographic, general health, and urology-specific health 
information. This information helps your provider understand your unique case.  
 
The information collected will be used to assist in your care at DHMC. The 
information may also be used to help with clinical improvement activities at 
DHMC.  
 
Combining your information with information from other men with similar 
problems may help future patients. 
 
Your medical care at DHMC: 
 
You are being asked to complete the Health Status Questionnaire because you 
are receiving care from the Dartmouth-Hitchcock Medical Center (DHMC) for 
prostate cancer. Your provider is asking that you complete the questionnaire 
before you meet. The questionnaire takes 30-40 minutes to complete. You also 
may be asked to complete follow-up questionnaires related to your oncology 
problem in the future. 
 
It is most useful for your provider if you complete the entire health questionnaire, 
but you need not respond to any question you do not wish to answer. Your 
survey responses are maintained in your DHMC medical record as part of your 
current and on-going medical care and are available to all DHMC clinicians. 
 
Research activities: 
 
Dr. John Heaney is asking that information from your medical record and your 
responses from the Health Questionnaire by used for research. 
 
You are being asked to participate in a research study. The name of 
the study is called, “The impact of prostate cancer education on 
knowledge, attitudes, and shared decision making among newly 
diagnosed prostate cancer patients.” Your participation is 
 
voluntary. 
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Your decision whether or not to participate will have no effect on the 
quality of your medical care you receive at DHMC. Regardless of your 
decision, your provider would still like you to complete the Health 
Questionnaire. Please ask questions if there is anything you do not 
understand. 
 
The purpose of the study is examine how success DHMC is at educating 
patients about prostate cancer and prostate cancer treatment options. We 
want to understand how much patients are able to apply the prostate 
cancer education to their unique case. We hope to understand how a 
patient’s knowledge impacts their ability to choose a treatment and their 
ability to cope with cancer.  
What is the purpose of this study ? 
 
This study involves looking at the responses from the health questionnaire 
and comparing them with the patient’s medical records. There is NO 
experiment in this study. There is no testing and no special procedures for 
this study. 
What does this study involve ? 
 
There will be no immediate benefits to you should you decide to 
participate in this study. Your participation will help future prostate cancer 
patients at DHMC.  
Are there any benefits from participating in this study ? 
 
If you do not participate in this study, you will still be asked to fill out the 
30-40 minute health questionnaire for your provider.  
How is this different from what will happen if you do not participate 
in this study ? 
 
There is a possibility that a patient may experience a small amount of 
psychological stress from answering questions about their health. Every 
effort has been made to decrease the number of questioned asked; each 
question has been carefully reviewed for importance. 
What are the risks involved with being enrolled in this study ?  
 
 
Other important items you should know:  
• Withdrawal from the study: You may choose to stop your participation 
in this study at any time. Your decision to stop your participation will have 
no effect on the quality of medical care at DHMC.  
 
• Number of participants: We expect  (300) prostate cancer participants 
to enroll in this study here.  
 
• Funding: There is no outside funding for this research project. 
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How will your privacy be protected? 
The information collected as data for this study includes:  
Information about your general health, your health history, key information 
about yourself  (age, race, etc.), your mental health, health behaviors, 
your knowledge about prostate cancer, values about treatment, and 
information about your prostate cancer treatment decision.  
 
Data collected for this study will be maintained indefinitely.  
 
Efforts will be made to protect the identities of the participants in this 
study. The research from the study will only be presented as group 
information.  
Only authorized researchers will be allowed to look at the information. 
Each researcher uses special passwords, encryptions and coding to keep 
the health information confidential. Confidentiality procedures will strictly 
follow HIPAA Privacy Rules.  
 The study will include personal health information about the 
participants. This information is the crux to the research by allowing us to 
know if the patient understands their own diagnosis. Once the research is 
conducted, participant’s names and medical record numbers will be 
removed. 
 
The information collected for this study will be used only for the purpose of 
conducting this study. 
 
By signing this form, you are allowing the research team to use and 
disclose to others information from your medical records. The research 
team includes the researcher and other people at DHMC and elsewhere. 
Your permission to use medical record information for this study will not 
end until the all study activities by the research team are completed. 
 
In the course of this study, information that identifies you may be 
disclosed to organizations that do not have a legal duty to protect it. 
These organizations may disclose it for other purposes. 
 
During this study, participants may not have access to the study data. 
You may request study data once the study activities have been 
completed. 
 
If you do not allow use of information from your medical record for this 
study, you may not participate in this study. 
 
If you choose to stop taking part in this study, you may cancel permission 
for the use of information from your medical record. You should let the 
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researcher know in writing that you are cancelling your permission. 
Information collected for the study before your permission is cancelled will 
continue to be used in the research. 
 
Dynamic Clinical Solutions  (the group who created and supports the 
electronic questionnaires) will electronically receive the data from the 
health surveys. Your provider will also be able to review your results. 
Research data may be shared with officials of DHMC and others involved 
in the oversight of this study as permitted by law. There is no guarantee 
that research data cannot be obtained by a court order or other legal 
process. 
 
There are No additional costs to you.  
 What about the costs of this study?  
 
There is no stipend for participating in the study. 
Will you be paid to participate in this study? 
 
Questions about this study or concerns about a research related injury 
may be directed to the researcher in charge of this study: 
Whom should you call with questions about this study? 
Dr. John Heaney at  (603) 650-5091.  
 
If you have questions, concerns, or suggestions about human research at 
Dartmouth, you may call the Office of the Committee for the Protection of 
Human Subjects at Dartmouth College  (603) 646-3053 during normal 
business hours. 
 
 
CONSENT 
I have read the above information about “The impact of prostate cancer 
education on knowledge, attitudes, and shared decision making among 
newly diagnosed prostate cancer patients.” and have been given an 
opportunity to ask questions.  
 
I agree to allow my medical record information and responses to the Health 
Status Questionnaire to be used for research purposes. 
 
[   ] YES   [   ] NO 
 
I request a copy of the information about allowing my medical record information 
and responses to the Health Status Questionnaire to be used for research 
purposes. 
[   ] YES   [   ] NO 
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Appendix B: Keep in Mind 
 
 
 
 
Dear Patient: 
 
Please keep in mind that every patient is different. We strive to give you 
individualized care. We have also done our best to give you current and well 
rounded information. Please review the prostate packet and the video about 
prostate cancer before your appointment. Please complete the electronic health 
questionnaire prior to your appointment by accessing Patient Online at 
.DHMC.org (you may have the option to do your health questionnaire at DHMC 1 
hour prior to your appointment.) 
 
Keep in Mind 
 
 
1. Health Questionnaire: 
The health questionnaire  (H-Quest) is part of your normal process of 
care. Your provider uses the health information gathered in the H-Quest to 
give you individualized care. The H-Quest also allows your provider to 
monitor your health over time. 
  
2.  Prostate Cancer Packet:  
The information is to cover GENERAL information about prostate 
cancer. Some information may not
 
 apply to you.  
 
3. Video 
The video is to help you understand prostate cancer treatments and 
side effects. Some treatments may not
 
 be right for you. 
 
4. Internet Sites/Books 
Please use CAUTION with the internet. Internet sites and books may 
not be up to date. Internet sites and books may not have correct 
information. Some information may not
 
 apply to you.  
 
Thank you 
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Appendix C: Internet Suggestions 
 
 
 
 
Suggested Internet Sites 
 
 
 
 
►American Cancer Society 
.cancer.org 
 
►Prostate cancer Foundation 
 
www.prostatecancerfoundation.org 
►American Foundation for Urologic Disease 
.auafoundation.org 
 
►National Cancer Institute 
.cancer.gov 
 
Prostate Cancer Support 
 
 
►Us TOO  
.ustoo.com 
►Man-to-Man  (Currently available at DHMC) 
 
www.cancer.org
 
Suggested books about Prostate Cancer 
 
 
 
►  “100 Questions and Answers about Prostate Cancer.” by Pamela    
   Ellsworth, John A. Heaney, Oliver Gill 
 
► “Prostate Cancer: A Family guide to Diagnosis, Treatment and   
  Survival.” by Sheldon Marks 
 
► “Complete Guide to Prostate Cancer.” by American Cancer Society 
 
► “A Primer on Prostate Cancer: The Empowered Patient’s guide.” by 
Stephen Strum, and Donna Pogliano 
 
►  “Guide to Surviving Prostate Cancer.” by Patrick Walsh  
 
►  ”Surviving Prostate Cancer: What You Need to Know to Make  
     Informed Decisions.” by E. Fuller Torrey and Carlton Stoiber
  
 
Appendix D: Staff Protocols 
 
 
 
 
ISS Health Questionnaires 
In the world of transforming medicine this is yet another opportunity for individual 
providers as well as the Medical Center to better provide care for our patients. 
Therefore, displaying a positive attitude about the entire DCS ISS Health 
Questionnaire process is a must for all users at all times. When problems or 
issues arise it is vital that you relay these on to those responsible supervisors in 
General Ambulatory Services. 
• Registration areas presently included in the ISS Tablet project 
• Access/Training 
• Morning Prep 
• Logging on DCS process 
• Arriving Patient – Initiate Tablet 
• Tablet Communication Script 
• Survey Close out process 
• Print Patient Report process 
• Tablet failure process 
• Accountability of Tablets 
• Tablet Inventory 
Registration Area 
 3A  Orthopedics 
 3C  Orthopedics 
 3D  Spine Center 
   Pain  
 3M  GIM 
 4L  SMA (Shared Medical Appt)  
 4M  Plastic Surgery 
 5B  Urology 
 2  Radiation Oncology 
 5L  Urogyn 
 NCCC  Breast Program  
 
ACCESS/TRAINING 
Supervisory Responsibility: 
 
• Overall Clinical supervisory responsibility lies with Mary E., Director of 
General Ambulatory Services.  
 
Access: 
 
  
 
• Access to ISS should be handled in accordance with standing DHMC 
computer services account requests. Scheduling access is packaged 
in with ongoing GE Web Based scheduling training. Access for 
registration/reception personnel is obtained by completion of the 
DHMC Computer Services Account Request Form, which is faxed or 
forwarded to General Ambulatory Services Trainers at Evergreen 1.  
 
Training 
 
• General Information about the ISS Health Questionnaire will be 
included in both the HOOP’s  (general two week training session for all 
new support staff) and MOST (Medical Secretary Training) classes. 
 
• Scheduling training will be incorporated into the GE Web Based 
Scheduling application and taught by the General Ambulatory Services 
Training Group. 
 
• Registration training will be the responsibility of General Ambulatory 
Services and will be conducted as an OJT model. Receptionist will be 
trained as needed. 
 
Early AM prep 
 
• Encounter labels will indicate patients who are scheduled to take 
questionnaire as well as the time when the questionnaire is scheduled:  
 
SAMPLE TOP PORTION OF ENCOUNTER LABEL 
 
V13492974*      00000000 – 0 
PATIENT, ISS      10/10/1900 
JONES MD, JAMES  (12345)     3A 
11/23/2006 11:00      RV4 
REF: SELF 
 
: RES- ORTHO QUESTIONNAIRE / 10:15 / R 
 
PCP: DOE, JOHN A 
FSC:  AM 
 
• Easy identification a must. Until such time as DCS has a real time 
crossover to DH1 it will be necessary for the Registration Staff to check 
DCS registration lists to ensure that all patients scheduled for a 
questionnaire are identified. This can be accomplished by toggling 
back and forth. 
 
 
  
 
• Collect tablets from secure storage location or unlock if stored in 
reception area 
 
 
• If you are using a mobile cabinet/cart ensure that once in the reception 
area you plug in to A/C to ensure ongoing battery charging 
 
• Check to make sure that all tablets are fully charged and ready for use 
 
• Each time tablets are returned to the reception area they must be 
plugged back into the battery charger. 
 
   LOGGING ON TO DCS 
     
On desktop computer, log into: dhmc.dynamicclinical.com 
Accomplished by opening Internet Explorer 
 or my DH page Secretarial portal and then DCS  (preferred 
method) 
 
SAMPLE OF DCS LOG ON  
 
 
 
 
 
Desktop login ID and password – Note* receptionist should 
  only need to log in once daily – can minimize and toggle between 
ISS and other systems using Alt-Tab. Access/Password will be 
provided to you by Alicen H.  (5-XXXX) or Julie A.  (5-XXXX) 
  
 
  
• Once you have DCS homepage open, you need to select, from the 
drop down box, the appropriate Clinical Area that you are working. 
 
• Following is an example of the DCS basic screen that you will see 
once you have signed on. 
 
 
 
 
• DCS Reception List  
 
From the DCS menu bar go to “Work” and the drop down box. 
  
 
 
 
Reception list :  
Broken down to Clinical Specialty ( i.e. GIM, Pain, Plastic Surg. 
Etc.) Provides a list of all patients scheduled for questionnaire 
today along with present status: 
 
 
 
 
 
PATIENT ARRIVAL AT RECEPTION AREA 
 
 Upon patient arrival, complete normal appointment arrival process 
 Toggle to ISS receptionist list to see status of patients’ questionnaire 
 Normal options in the Patient Survey column are: 
 
   Pending  - Patient has not started the questionnaire yet 
   In Progress  - Patient is presently working on survey 
   View Results  - Survey completed – awaiting printing  
   Closed   - Survey not needed, cancelled 
 
SAMPLE PATIENT SURVEY COLUMN 
 
  
 
 
 
If still pending then the registration/reception staff need to: 
 
  Retrieve a tablet from the storage bin 
Launch the Patient Survey from the Tablet  
 
This is accomplished by Logging into the Tablet, Use your Tablet 
username and password (* note – this is different than you desktop 
username) This username and password will be assigned to you by 
General Ambulatory Services. 
Select the appropriate Clinical area (only if you have access to multiple 
clinical areas) 
 Click on “TAKE SURVEY” next to the desired patient 
 In the pop-up window, enter the patients MRN# and click “Start” 
The system will automatically log you off and log the patient on to take the 
survey. 
 
  
 
Note: The occasion may arise where the patient arrives and no questionnaire has 
been scheduled. At the present time without the real time cross over feature 
between DCS and DH1 there is no way for last minute/real time appointments to 
be scheduled by secretaries. Because of this and the fact that registration 
personnel will not have the necessary information to correctly schedule the right 
questionnaire for all patients that we will need to work case by case and area by 
area. More information will be forthcoming. 
 
 
TABLET COMMUNICATIONS SCRIPT 
 
 It is important that you communicate well with the patient to ensure that 
they understand the importance of completing the questionnaire and that 
they also know how to operate the tablet. You can determine if they have 
completed the questionnaire prior to coming in by reviewing the status on 
DCS registration screen.  
 Depending of the situation you may want to announce to the patient that 
their visit today includes the completion of a health questionnaire. This 
would be followed up with the question as to whether they are familiar with 
the tablet and how it works. 
 If they have taken previous questionnaires they will only need to be given 
a brief reminder to tap gently and to return the tablet to your drop off area 
when completed, followed by “If you have questions please feel free to ask 
me.” 
 If they are not familiar then you need to demonstrate the most efficient 
way to respond to questions. This would include: 
•  “Tapping very lightly” 
•  “In-between screens, hold off tapping until a “Please Wait” sign 
disappears” 
•  “If screen does not change within a minute, see receptionist.’ 
•  “Carefully read instructions located under questions” 
•  “Choose a close answer rather than skip it.” 
•  Please answer every question.” 
•  “Some questions are repeated – we greatly appreciate your patience”  
•  As you hand the tablet to the patient, state: “At the beginning of the  
questionnaire, please read the Informed Consent and select either 
“Yes” or “No”.  
• “Once you have finished the questionnaire please return it to (area 
designated in your specific work space)”  
 
    SURVEY CLOSE OUT 
 
It is the responsibility of the registration/reception area to close out  (update the 
status) of pending visits in DCS by the end of each day. This is done by: 
 
Going into the DCS (Dynamic Clinical Systems) 
  
 
 
 My D H Page 
 Under Secretarial Portlet select DCS 
 Sign on to DCS 
  Username: 
  Password: 
 Under View: select the appropriate Survey 
   FRP 
   GIM 
   Hand 
   Hip & Knee 
   Pain RF 
   Spine Clinic 
   Uro/Gyn 
 
  A list of patients scheduled for that date will appear 
 
 
 
 Select appropriate “patient name” 
 
 Go to the last column on right and click on appropriate Survey # 
  
This will bring up Patient Screen: 
 
  
 
 
  
 
Lower left box – Patient Survey 
 
Click on “CHANGE” 
 
 A drop down list of no survey reasons will appear: 
 
   Cancelled 
   Computer Problem 
   Unavailable 
   Insufficient time 
   No Consent 
   Not needed 
   Patient Incapable 
   Refused 
   Too young 
   Unknown 
• Choose the reason applicable to this visit 
• Double click anywhere on desired reason row to change the No Survey 
Reason 
• While the close out process can be carried on through out the day as 
applicable 
  
 
• A final review is needed at the end of the day to ensure that all pending 
survey’s have a “no survey reason” included.  
 
PRINT PATIENT REPORT: 
 
Although report printing is not normally the responsibility of the 
registration/reception staff there may very well be situational times when at the 
request of the provider or nurse a single report may need to be printed. For that 
time follow the directions listed below. 
 
Go to DCS site 
Scroll over to the “View” menu 
Click on “Receptionist List” 
Under “Clinical Area” use the drop down box to select the appropriate area 
Under the “Report” column, click “view results” for desired patient 
  (Note: if the report column for the patient says “Pending” or “In Progress” then 
the report is not ready to be printed) 
 
 
 
 
Click the “Print” button in the upper right corner 
Click “Close” 
(note: once the report has printed the patient will no longer appear in the 
receptionist list 
Upon returning to the receptionist list click “Refresh” the patients name will 
disappear 
 
TABLET FAILURE 
 
• From time to time you may find a tablet that fails. Probably the most 
common reason is that its battery will not hold a charge. If you have 
spare batteries change the battery. If this doesn’t solve the problem 
  
 
then activate another tablet so that the patient can complete the 
questionnaire without delay.  
• When time permits go back to the inoperative tablet and complete a 
quick evaluation of the tablet. The following is a list of sometime quick 
fixes: 
 
o If the touch pad is not acquiring the signal you can plug the red 
cord from a computer into it and shut it down and restart it. This 
will reconfigure it. 
o If the touch pad goes to sleep while a patient is using it, just 
quickly tap the on/off switch and it will come to life. 
 
*If you have tried the above suggestions and are still not successful it’s time to 
complete the template for “ISS Tablet work order”. This is done by going to: 
 \\DH306\Clinic Administrative Services\Tablets\Admin and bringing up the 
work order template. 
 
Complete the template with all information requested and forward via e mail to 
General Ambulatory Service attention: Lisa (Glavickas) Bailey . To ensure rapid 
response please use the email address of:  
   “Clinic Admin”.  
 
   SAMPLE ISS TABLET WORK ORDER 
 
 
ISS Tablet Work Order 
Date:Time:Reception Area:
 
    
Tablet Type M1400 orLE1600   ISS Asset #     
 
 
Problem:      
 
Completed by:   Ext:      
 
 
Delivered to USER SUPPORT by:     Date/Time:     /
Ready for pick up: Date/Time: 
      
     ,      
 
 
Picked up by:     
 
and returned to reception area 
  Date: Time:     
 
 
 
 
Upon receipt of the work order – General Ambulatory Services will 
a. pick up the down tablet as soon as possible –  
b. complete the work order 
  
 
c. print the work order 
d. deliver the down tablet along with the copy of the work order to User 
Support 
e. This should all be accomplished as soon as possible but no later than 
the end of the business day 
 
Once User Support has completed repairs they will contact General Ambulatory 
Services 
Notifying them that the tablet is ready to be returned to service. 
 
General Ambulatory Services will collect the tablet, return it to the appropriate 
reception area, then complete and file the work order 
 
By retaining a file of completed tablet work orders it will be possible to track and 
identify tablets with higher failure rates as well as reasons for failures. 
 
TABLET INVENTORY 
Maintaining an ongoing inventory of available tablets is very important. As more 
and more sections or specialties come onboard there is a potential that tablet 
sharing between reception areas may become necessary. General Ambulatory 
Services will maintain a master inventory list. However, to assist them it would be 
wise if each area has knowledge of tablets signed out to them.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Appendix E: Layout of Patient Education Center 
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Appendix F: FIMDM Prostate Cancer Survey 
 
 
 
 
PROSTATE CANCER: 
Personal Decision Form 
 
There are several different ways to treat prostate cancer. Each has possible 
benefits and risks. This form and video, together with your healthcare team, will 
help you make the decision that is best for you.  
Please return this form with the video.                       Your answers will tell us 
three important things:  
 Knowledge 
 How well we are doing our job of giving you information? 
 Values 
 
 What matters most to you? 
 Making Choices 
 
How far along you are in decision making and what else you may 
need?  
 
 
BEFORE WATCHING THE VIDEO,  
PLEASE ANSWER QUESTION 1 – 2 
    
1. Have you talked with a healthcare provider about this decision? 
 Yes 
 No 
    
2. At this time, which treatment option are you leaning toward?  
 Watchful waiting 
 Brachytherapy (radiation seeds) 
 External beam radiation  
 Surgery 
 Unsure            
 
  
 
Knowledge 
NOW, PLEASE WATCH THE VIDEO 
 
 
  
 
    
AFTER WATCHING THE VIDEO, 
please check  one answer for each question. 
3.  Without treatment, about how many men diagnosed with early prostate 
cancer will eventually die of prostate cancer? 
 Most will die of prostate cancer 
 About half will die of prostate cancer 
 Most will die of something else. 
 I am not sure 
 
4.  About how many men diagnosed with early prostate cancer will eventually 
have their cancer come back after treatment with surgery or radiation? 
 Almost none 
 Less than half  
 More than half 
 I am not sure 
 
5.  Which of the following possible harms from treatment for early prostate 
cancer is more common five years after surgery than five years after 
radiation? 
 Sexual problems 
 Dripping or leaking urine  
 Both are equally common 
 I am not sure 
 
6. There is good evidence that some men with early prostate cancer can 
slightly increase their chance of still being alive ten years later with which of 
the following treatments? 
 Surgery 
 Radiation 
 Both surgery and radiation 
 I am not sure 
 
7.  Which of the following are good reasons for a man with early prostate 
cancer to consider not having active treatment (surgery or radiation) right 
away? 
 To avoid or delay the possible harms of active treatment 
 To make sure active treatment is really needed 
 Both to avoid or delay possible harms and to make sure active 
treatment is really needed 
 I am not sure 
  
 
 
 
 
 
On a scale from 1 to 10, where 
    1 is not at all important and 10 is very important: 
 
       Not at all               Very 
  How important is it to you . . .          not important        
important 
8.  to try to do everything possible as soon as 
   you can to avoid dying of prostate cancer? 
 
9.  to avoid radiation?  
 
10.  to avoid surgery? 
 
11.  to avoid problems with dripping or leaking urine? 
 
12. to avoid sexual problems? 
 
 
 
 
13. At this time, which treatment option are you leaning toward?  
 Watchful waiting 
 Brachytherapy (radiation seeds) 
 External beam radiation  
 Surgery 
 Unsure            
             Yes  No 
14. Do you feel sure about the best choice for you?     
15. Do you know the benefits and risks of each option?    
16. Are you clear which benefits and risks matter most to you   
17. Do you have enough support and advice to make a choice 
 
18. What do you plan to do next? 
  Get the treatment I chose  
 Get more information 
 Talk now with a member of my healthcare team 
 At my next visit, talk with my healthcare provider  
 Other _______________________________________ 
Making Choices 
Values 
  
 
 
 
19.  Age: ________ years old 
 
20. Education level: 
 
 8th grade or less                           
 Some high school 
 Graduated high school or GED 
 Some college or technical school  
 Graduated from college 
 Postgraduate school or degree  
 
 
 
21. How would you rate the length of the video? 
  Should be much shorter 
  Should be a little shorter 
  About right 
  Could be a little longer 
  Could be much longer 
 
22. Did the video present one treatment as the most important for prostate 
cancer?  
 Yes, watchful waiting 
 Yes, radiation 
 Yes, surgery 
 No, all presented as equal            
 
 
23. Overall, how would you rate the video? 
 Poor 
 Fair 
 Good 
 Very good 
 Excellent 
 
24. Please write comments about the video or booklet here: 
______________________________________________________ 
______________________________________________________ 
______________________________________________________ 
 
Tell us about yourself 
Video Feedback 
  
 
 
Appendix G: Prostate Cancer Packet Protocol 
 
 
 
 
Prostate Cancer Packets 
 
What goes into the prostate cancer packet? 
 
Brochures: 
1. Where to Turn: Support through your cancer journey 
2. Prostate cancer support group (Green heading) 
3. Rest Easy (Red Heading) 
4. Man to Man: Prostate Cancer Education and Support Program 
5. Shared Decision making: Helping with Making Your healthcare decision 
6. Treatment choices for men with early stage prostate cancer (NCI-Blue 
book) 
7. Cancer Resource Guide  (Purple) 
8. Prostate Cancer: Treatment Guidelines for Patients (green and white) 
9. H-Quest brochure 
10. Patient On-line brochure 
DHMC Color Paper Letters: 
11. Provider letter: Dear Patient: Dartmouth-Hitchcock Medical Center offers 
comprehensive care for individuals who have been diagnosed with 
prostate cancer. Etc. 
12.  Suggested internet sites, Prostate cancer support, Suggested books 
about prostate cancer 
13. Keep in Mind: Please keep in mind that every patient is different 
14. Before you arrive check list 
 
How do I order for the prostate cancer packet? 
 
1. American Cancer Society Brochures: 
a. Call the American Cancer Society for brochures. Order 75 
brochures of each at a time (if you order more then 75 we will 
have to pay shipping and handling). Provide ACS with order 
number and DHMC address.  
 
  Phone number: 1-800-ACS-2345 
5-7 Day window to receiving brochures. 
b. Where to Turn: Support through your cancer journey 
i. Number: 3031.00 order 75 brochures 
c. Man to Man: Prostate Cancer Education and Support Program  
i. Number: 4533.03 order 75 brochures 
  
 
d. Prostate Cancer: Treatment Guidelines for Patients (green and 
white) 
i. Number: 9404.02 order 75 brochures 
 
2. Center for Shared Decision Making brochure 
a. Share Decision Making services Brochure 
b. Stop in the Shared Decision Making Center (either North Mall or 
in 4H) 
c. Pick Up Shared Decision Making Service Brochures 
 
3. DHMC brochures 
a. Email- Amity Johnson or call 5-6439. Patient Education sends 
requests to print.  
b. Prostate cancer support group (Green heading) 
2 week window for receiving brochures. 
i. Order 150 (information changes every 6 months) 
c. Rest Easy (Red heading) 
i. Order 50 (information changes often) 
ii. *can also pick up brochures at rotunda 
d. Cancer Resource Guide (Purple) 
i. Order 150 (Information changes every year) 
 
4. National Cancer Institute Brochures 
a. Treatment Choices for Men with early-Stage Prostate Cancer 
(National Cancer Institute-Blue book) 
 
b. Support Services for the NCCC will be ordering the booklets 
2-3 Week Window for receiving brochures. 
c. Call Cheryl Flemming at 5-7703 or Deb Steele they will be 
automatically ordering on a monthly basis and will distribute or 
schedule a pick up. 
 
5. Admit Services 
a. Patient Online brochure and H-Quest brochure 
b. Call 653-3800 to get more distributed 
 
6. Color Paper Letters and green folders: 
a. Color paper is ordered through Sandee Shipley for Urology and 
Stacey Wilk for Radiation 
i. Order through office Max 
1. Color Paper 
a. Canary/Yellow YB24P1MP-2201-CY 
i. For “Dear patient” introduction letter 
b. Green        YB24P1MP-2201-GN 
i. For Please keep in Mind letter 
c. Blue         YB24P1MP-2201-BE 
i. For Suggested internet sites 
  
 
d. *stalk paper Canary/Yellow P1MP-2651-CY 
i.  Before you arrive check list 
 
b. Provider letter: Dear Patient: Dartmouth-Hitchcock Medical Center 
offers comprehensive care for individuals who have been 
diagnosed with prostate cancer. Etc. 
i. Original in word document labeled: (Providers have 
separate letters) 
1. Dr. John Heaney- HeaneyCFSDMLetter 
2. Dr. Seigne- SeigneCFSDMLetter 
3. Dr. Hartford-Hartfordcfsdmletter 
c. Suggested internet sites, Prostate cancer support, Suggested 
books about prostate cancer 
i. Original in word document labeled: “prostate cancer packet 
suggestions” 
d. Keep in Mind: Please keep in mind that every patient is different 
i. Original in word document labeled: “Please keep in mind” 
e. Before you arrive check list 
i. Original in word document labeled: 
1. For John Heaney: “before you arrive check 
listheaney” 
2. For John Seigne: “before you arrive check 
listseigne” 
f. Green Dartmouth Hitchcock Folders will be ordered through the 
8th floor of the NCCC.  
  
i. Andrea Gilbert 3-6018 will order the folders 50 at a time 
2-3 Week Window for receiving green folders 
 
 
How does it all fit together in the prostate cancer packet? 
 
In the left pouch from front to back (or top to bottom) 
1. Yellow sheet “ Dear Patient” provider specific 
2. Green sheet- Keep in mind green 
3. Blue sheet- suggested internet sites 
 
In the right pouch from front to back (or top to bottom) 
1. Patient Online brochure 
2. H-Quest brochure 
3. Where to turn, ACS 
4. Man to Man, ACS 
5. Prostate Cancer Support Group, ACS/DHMC 
6. Shared Decision Making Services 
7. Rest Easy 
8. Treatment Choices for men with early state prostate cancer, NCI 
9. Cancer Resource Guide, NCCC and DHMC purple 
  
 
10. Prostate Cancer-Treatment Guidelines for Patients, ACS, NCCN green 
and white 
11. *stalk card Yellow- Before you arrive check list. 
 
Scheduling with the prostate cancer packet? 
1. Patients/referrals will call the office for a New Patient Appointment with 
Radiation/Onc/Urology  
2. Secretary schedules as usual 
3. Secretary gives information about H-Quest 
3.1.  Offers H-Quest through patient online or 1 hour prior to appointment 
4. Secretary inquires about: 
4.1. Does the patients have localized or metastasizes cancer? Only localized 
prostate cancer patients will receive packet 
4.2. Has the patient already had radiation and/or surgery? (Seeds, external 
beam, prostatectomy, prostate surgery). Only patients that have NOT had 
radiation/surgery will receive the packet. Patient has not had an 
intervention.  
5. Request the New Patient Letter to the department, NOT to be sent directly to 
the patient. 
6. Place new patient letter on top of the prostate cancer packet and DIMO label 
for mailing 
7. Inter-Office new patient letter and the prostate cancer packet to Center for 
Shared Decision Making. 
8.  (Center for Shared Decision Making will include video and mail packet and 
new patient letter to patient prior to appointment). 
 
KEEP IN MIND: 
No provider card should be stapled or added to the packet. The packet is 
supposed to represent the treatment choices available to localized newly 
diagnosed prostate cancer patients. Placing a provider business card may sway 
a patient into a particular treatment choice (even though they are seeing a 
particular provider).  
 
  
 
 
 
Appendix H: Before You Arrive 
 
 
 
 
 
BEFORE YOU ARRIVE CHECK LIST 
 
 
What is required BEFORE
   All office notes from provider(s) involved in your care  (that are 
 your appointment? 
NOT
   All lab results: Labs, PSA blood Tests, or Urine cultures (
 
  DHMC providers). Please Fax to Dr. John Heaney at  (603)650-4985 
NOT
   All biopsy glass slides and report (pathology sides and pathology report 
Please mail (FED X, UPS, etc) to: DHMC, 1 Medical Center Dr., 
Lebanon, N.H. 03756. 
 done at  
  DHMC). Please Fax to Dr. John Heaney at  (603)650-4985 
   All Films: CT, Bone Scan, MRI, Dexa Scan (NOT
Please mail them to: DHMC Film Library, Attn: Dr. John Heaney,  
 done at DHMC) 
1 Medical Center Drive, Lebanon, N.H. 03756 or HAND CARRY to 
your appointment 
 
PLEASE CALL THE UROLOGY DEPARTMENT at (603) 650-5091 
TO MAKE SURE ALL YOUR INFORMATION HAS ARRIVED. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Appendix I: New Heaney Patient Letter 
 
 
 
 
 
Dear Patient: 
 
Dartmouth-Hitchcock Medical Center offers comprehensive care for individuals 
who have been diagnosed with prostate cancer. The Genitourinary Oncology 
Group (Urology/Oncology) and the Center for Shared Decision Making are 
working together to give you information about prostate cancer treatments. An 
appointment has been made for you with Dr. John Heaney in the Norris Cotton 
Cancer Center. We are sending with this letter a prostate cancer packet about 
prostate cancer and a video about prostate cancer for you to watch before your 
appointment. 
 
This video: 
• gives general
• describes some treatments and side effects 
 information about early stage prostate cancer 
• is not
 
 meant to provide specific recommendations for you 
At your appointment, you will meet with Laura Stempkowski, an advanced nurse 
practitioner, and/or Dr. John Heaney for at least 45 minutes. The providers will 
explain the treatment options that apply to you and go over your specific case. 
Because of the nature of the visit, there are many question and concerns that 
arise. Often the appointments may last longer then expected as providers strive 
to address ALL the needs of their patients. We ask for your patience in the event 
the clinic is behind schedule.  
 
You may wish to watch the video again after you have met with your Urologist. 
When you are ready to return the video, you may drop it off at the Center for 
Shared Decision Making or send it back in the enclosed mailing envelope. 
Please return the enclosed questionnaire and consent with the video. 
 
If you do not have a DVD player, please call us at 603-650-5578 to request a 
VHS version. You can also set up a time to watch the video at the Center for 
Shared Decision Making.  
 
 
Thank You 
 
_____________________________________________ 
  
 
Dear Patient: 
 
You have been scheduled to see Dr. John Heaney in the Norris Cotton Cancer 
Center at Dartmouth Hitchcock Medical Center (DHMC). The purpose of the visit 
is to provide you with a comprehensive and prompt assessment. The 
Genitourinary Oncology Group offers comprehensive multi-disciplinary 
genitourinary oncology care throughout the cancer continuum from prevention to 
end-of-life care. We are pleased to be able to offer a multi-disciplinary clinic 
(Radiation Oncology, Genitourinary Oncology Group and Medical Oncology) to 
help you make the next step in your care. 
 
There is considerable controversy about the best management of prostate 
cancer. Enclosed with this letter is a “prostate cancer packet” of information 
about the various treatment options and a video about prostate cancer from the 
Center for Shared Decision Making.  
Please read through the material and watch the video prior to your 
appointment.  
 
We strive to coordinate the Radiation Oncologist and Urologist Oncology upon 
request. If you have not already scheduled a Radiation Oncology appointment 
but wish to see a Radiation Oncologist, please call the Urology Department at  
(603) 650-5091. 
 
To prepare for your visit, please carefully read the material below. Call the 
Urology Department at (603)650-5091 if you have any questions regarding your 
appointment. 
 
What is required BEFORE
   1) Any and 
 your appointment? 
all office notes from providers (s) that are involved in your care 
(that are not
 
 at DHMC), please have your test results faxed to Dr. John 
Heaney at  (603)650-4985. 
   2) If you have had prior Labs, PSA blood Tests, or Urine cultures (not
 
 done 
at DHMC), please have your test results faxed to Dr. John Heaney at  
(603)650-4985. 
  3) If you have had prior biopsies (not
 
 done at DHMC), please have the 
pathology slides  (glass slides) and pathology report express mailed (FED X, 
UPS, etc.) to: DHMC, 1 Medical Center Dr., Lebanon, N.H. 03756. 
  4) If you have had prior CT (computer tomography), Bone Scans, MRI  
(Magnetic Resonance Imaging) or any other radiology test (not done at 
DHMC), please mail them to: DHMC Film Library, Attn: Dr. John Heaney, 1  
  
 
Medical Center Drive, Lebanon, N.H. 03756. 
 
 
 
 
 
 
 
 
 
 
What should you bring to the visit? 
All your health information should arrive prior to your visit. 
Please provide insurance information. 
 
Where am I going to be seen? 
The multi-disciplinary clinic sees patients in the Hematology Oncology clinic. The 
clinic is located on the 3rd Floor in the East Mall (Near the parking garage 
elevators). 
Directions from thee parking garage to the hematology oncology clinic: 
From the 4th floor of the parking garage, take the elevators to the 3rd 
floor. On the 3rd floor take a sharp left as you come out of the 
elevators and follow the East Mall Corridor. Directly after the first 
set of stairs on the left hand side, you will see the entrance for the 
Hematology Oncology Clinic. Please check in at the front desk. 
 
Directions from the Main Entrance to hematology Oncology clinic: 
From the Main Entrance on Level 3. Continue straight past the 
information desk toward the East Mall. Turn right at the East Mall 
corridor toward the Cancer Center and parking garage entrance. 
On the right hand side you will see the entrance for the 
Hematology Oncology clinic. Please check in at the front desk. 
 
What will happen at the visit? 
1) Laura Stempkowski, a Registered Advanced Nurse Practitioner-
Specializing in Urology Oncology, will meet with you, review all your 
material and provide discussion. 
 
2) Dr. John Heaney will evaluate and discuss your clinical situation; he may 
recommend further tests and will review treatment options. 
 
How long will the visit take? 
The office visit will take about 1 hour (30 minutes with Laura Stempkowski and 
30 minutes with Dr. John Heaney). Providers give each patient individualized 
attention. Because of the nature of the visit, there are many questions and 
concerns that arise. Often the appointment may last longer then expected as we 
 
 
Please call the Urology Department at  (603) 650-5091to ensure 
that ALL your information has arrived. 
 
 
 
 
 
 
 
 
 
Prior to your appointment 
Prior to your appointment 
  
 
strive to address ALL the needs of our patients. Thus, we ask for your patience 
in the event our clinic is behind schedule. 
 
If you have any questions, please cal the Section of Urology at 603-650-5091 
 
Thank You 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Appendix J: New Seigne Patient Letter 
 
 
 
Dear Patient: 
 
Dartmouth-Hitchcock Medical Center offers comprehensive care for individuals 
who have been diagnosed with prostate cancer. The Genitourinary Oncology 
Group (Urology/Oncology) and the Center for Shared Decision Making are 
working together to give you information about prostate cancer treatments. An 
appointment has been made for you with Dr. John Seigne in the Norris Cotton 
Cancer Center. We are sending with this letter instruction on how to complete the 
electronic health questionnaire, a packet about prostate cancer and a video 
about prostate cancer for you to watch before your appointment. 
 
The Health Questionnaire (H-Quest): 
A health questionnaire (H-Quest) is required for your appointment. You may 
do your H-Quest online at least 2 days before your appointment or you may 
be able to do your H-Quest 1 hour prior to your appointment. If you have 
internet access, you can access H-Quest online at www.DHMC.org by 
clicking on “patient online”. Please call 603-650-5091 if the secretary has not 
given you information about “patient online”.  
To trouble shoot any issues with patient online please call 603-653-3800.  
 
This video: 
• gives general
• describes some treatments and side effects 
 information about early stage prostate cancer 
• is not
 
 meant to provide specific recommendations for you 
At your appointment, you will meet with Dr. John Seigne for 45 minutes. Dr. 
Seigne will review the health questionnaire, explain the treatment options that 
apply to you and go over your specific case. Because of the nature of the visit, 
there are many questions and concerns that arise. Often the appointments may 
last longer then expected as providers strive to address ALL the needs of their 
patients. We ask for your patience in the event the clinic is behind schedule.  
 
You may wish to watch the video again after you have met with your Urologist. 
When you are ready to return the video, you may drop it off at the Center for 
Shared Decision Making or send it back in the enclosed mailing envelope. 
Please return the enclosed questionnaire and consent with the video. 
 
If you do not have a DVD player, please call us at 603-650-5578 to request a 
VHS version. You can also set up a time to watch the video at the Center for 
Shared Decision Making.  
Thank You 
  
 
Appendix K: New Hartford/Zaki Patient Letter 
 
 
 
 
Dear Patient: 
 
Dartmouth-Hitchcock Medical Center offers comprehensive care for individuals 
who have been diagnosed with prostate cancer. The Radiation Oncology Group 
and the Center for Shared Decision Making are working together to give you 
information about prostate cancer treatments. An appointment has been made 
for you with Dr. Alan Hartford and/or Dr. Bassem Zaki in the Norris Cotton 
Cancer Center. We are sending with this letter a packet about prostate cancer 
and a video about prostate cancer for you to watch before your appointment. 
 
This video: 
• gives general
• describes some treatments and side effects 
 information about early stage prostate cancer 
• is not
 
 meant to provide specific recommendations for you 
At your appointment, you will meet with a nurse for 30 minutes and Dr. Alan 
Hartford and/or Dr. Bassem Zaki for 60 minutes. The providers will explain the 
treatment options that apply to you and go over your specific case. Because of 
the nature of the visit, there are many question and concerns that arise. Often the 
appointments may last longer then expected as providers strive to address ALL 
the needs of their patients. We ask for your patience in the event the clinic is 
behind schedule.  
 
You may wish to watch the video again after you have met with your Radiation 
Oncologist. When you are ready to return the video, you may drop it off at the 
Center for Shared Decision Making or send it back in the enclosed mailing 
envelope. Please return the enclosed questionnaire and consent with the video. 
 
If you do not have a DVD player, please call us at 603-650-5578 to request a 
VHS version. You can also set up a time to watch the video at the Center for 
Shared Decision Making.  
 
 
Thank You 
 
 
 
 
 
 
 
  
 
Dear Patient: 
 
Dartmouth-Hitchcock Medical Center offers comprehensive care for individuals 
who have been diagnosed with prostate cancer. The Genitourinary Oncology 
Group (Urology/Oncology) and the Center for Shared Decision Making are 
working together to give you information about prostate cancer treatments. An 
appointment has been made for you with Dr. Alan Hartford or Dr. Zaki in the 
Norris Cotton Cancer Center. We are sending with this letter instruction on how 
to complete the electronic health questionnaire, a packet about prostate cancer 
and a video about prostate cancer for you to watch before your appointment. 
 
The Health Questionnaire (H-Quest): 
A health questionnaire (H-Quest) is required for your appointment. You may 
do your H-Quest online at least 2 days before your appointment or you may 
be able to do your H-Quest 1 hour prior to your appointment. If you have 
internet access, you can access H-Quest online at www.DHMC.org by 
clicking on “patient online”. Please call 603-650-5091 if the secretary has not 
given you information about “patient online”.  
To trouble shoot any issues with patient online please call 603-653-3800.  
 
This video: 
• gives general
• describes some treatments and side effects 
 information about early stage prostate cancer 
• is not
 
 meant to provide specific recommendations for you 
At your appointment, you will meet with Dr. Hartford or Dr Zaki. The providers will 
review the health questionnaire, explain the treatment options that apply to you 
and go over your specific case. Because of the nature of the visit, there are many 
questions and concerns that arise. Often the appointments may last longer then 
expected as providers strive to address ALL the needs of their patients. We ask 
for your patience in the event the clinic is behind schedule.  
 
You may wish to watch the video again after you have met with your Urologist. 
When you are ready to return the video, you may drop it off at the Center for 
Shared Decision Making or send it back in the enclosed mailing envelope. 
Please return the enclosed questionnaire and consent with the video. 
 
If you do not have a DVD player, please call us at 603-650-5578 to request a 
VHS version. You can also set up a time to watch the video at the Center for 
Shared Decision Making.  
 
 
Thank You 
 
 
 
  
 
 
Appendix L: Collaboration 
 
 
 
 
Collaboration with DCS: 
Dynamic Clinical Systems  (DCS) is “A Patient-Centered Approach to 
clinical information management” (see PDF-ISS). DCS created an Informational 
Survey System (ISS) that is a web-based tool for collecting and capturing patient 
health information. The ISS system electronically integrates health surveys into 
the medical community. The system uses question branching logic, timing 
parameter, real time outcome reporting, and care summary reports. Validated 
surveys with clinical surveys create a Health Questionnaire (H-Quest) that is 
administered by the ISS system.  
 
 DCS was sponsored by Dartmouth College through a small business 
executive program. Through Dartmouth College, DCS contracted with Dartmouth 
Hitchcock Clinic to test and integrate the ISS system. DCS sponsors the 
development of the health questionnaires and production of ISS and provides 
free use of ISS at Dartmouth. DCS holds exclusive rights for testing and 
developing the ISS system in the Dartmouth Hitchcock Clinic free of charge. The 
developed H-Quest is provided free of charge to the Clinic and DCS uses the H-
Quest for a for-profit company. DCS’ initiative to create and develop an H-Quest 
for prostate cancer came from a contract to develop a prostate cancer H-Quest 
for University of California – San Francisco (UCSF) Clinic. DCS contacted 
  
 
Urology about a possible opportunity regarding the integration of H-Quest with 
newly diagnosed prostate cancer patients as UCSF’s prostate cancer health 
questionnaire was developed.  
 
As newly diagnosed prostate cancer patients are diagnosed in the section 
of Urology (Department of Medicine), the Section Chief of Urology  (Dr. John 
Heaney) authorized the development and integration of the prostate cancer H-
Quest into the Clinic. (Dr. Heaney offered me the opportunity to take full 
responsibility of developing and collaborating with the medical center for the 
successful integration of H-Quest, which I accepted.)   
 
Newly diagnosed prostate cancer patients have two access points within 
DHMC: DH-Clinic (Urology) and the NCCC (Radiation). Within each institution, 
the providers who’s patients include newly diagnosed prostate cancer patients, 
were contacted for collaboration on the H-Quest initiative. Once each section 
was on board, each department support staff and administrative personnel were 
also contacted for collaboration on the H-Quest initiative. As each department 
uses shared resources from Mary Hitchcock Hospital and Dartmouth College, 
both institutions were also contacted for support and continued utilization of 
resources.   
 
A year was spent on the development of the prostate cancer-specific 
health questionnaire. Because ISS was already integrated in other departments 
at DHMC/NCCC, guidelines were established from an ISS steering committee. 
The committee created a standard H-Quest that was to be used for all 
  
 
departments integrating H-Quest. The standard H-Quest (patient registration 
information - name, age, medical record number, date of birth, core review of 
symptoms, etc.) was universal for all departments, whilst each department made 
the remaining H-Quest specific to their needs.  
 
DCS used the framework from the DHMC standard H-Quest (120 
questions) and a prostate cancer H-Quest for university of California- San 
Francisco  (UCSF) (additional 350 questions) to create a draft of the DHMC 
prostate cancer H-Quest (500 questions). As UCSF prostate cancer H-Quest 
was geared towards prostate cancer survivorship − and not newly diagnosed 
prostate cancer patients, and the potential for answering 500 questions is an 
unrealistic patient burden; extensive review of each question and validating tools 
was performed. 
 
Weekly meetings were established to evaluate the need of each question 
from a clinical perspective. Dr. Heaney had sole propriety over which questions 
were on the prostate cancer H-Quest (consideration was given to the length of 
the health questionnaire vs. the need for information during the clinical encounter 
and research opportunities). Once a draft of the H-Quest was completed, testing 
of H-Quest began. Testers from DCS and my self spent many hours testing 
branching logic, timing parameters, and general length of time. Several drafts of 
the H-Quest were reviewed by DCS, John Heaney, and myself. Dr. John Heaney 
reviewed the final H-Quest before it was integrated into his prostate cancer clinic.  
 
  
 
In other attempts to integrate the health questionnaire in the Spine center, 
DCS collaborated with Administrative Services (see below). DCS created an 
interface with the scheduling system (IDX-see below which is supported by 
Administrative Services). DCS scans the scheduling system for specific ‘visit 
types’. Some visit types correspond to pre-identified appointments that require a 
health questionnaire (per the department and/or clinician). DCS system then 
generates a specific health questionnaire that corresponds to the visit type; the 
health questionnaire is accessed by the patient (see section 3.2.1.1).  
 
DCS also collaborated with the Clinical Information System (CIS). CIS is 
the electronic medical record system for Dartmouth Hitchcock Medical Center. 
CIS contains patient profile, billing information, clinical documents, lab and 
pathology results, diagnostic tests, order requisitions, patient entered data 
(where the H-Quest is stored), administrative documents and non-Dartmouth 
Hitchcock documents.  
 
DCS created an interface with CIS to electronically download the patient-
reported informational summary report directly into the patient’s records. 
Providers are able to access the patient summary report for their office notes and 
clinical encounter. CIS also provides other clinical services such as a ‘view of 
providers patient schedule’; the providers’ daily schedules are a direct reflection 
of the ‘IDX’ scheduling system. DCS successfully facilitated collaboration with 
CIS, IDX and DCS.  
 
 
  
 
Collaboration with Dartmouth Hitchcock Clinic 
 
Collaboration with Urology: 
Simultaneously, during the development and testing for the prostate H-
Quest, the initial steps were taken for the integration of H-Quest in the Urology 
Clinic (within DH-Clinic and the NCCC). From a section perspective, several 
events have to occur before the integration of the H-Quest: 1. Training, System 
change, Integration. 
 
Training:  
Firstly, the administrative staff in the Urology Department needed to be 
trained on how H-Quest was going to be integrated into the normal process of 
care. All administrative support personnel attended a two-hour training session 
regarding H-Quest. In the training, we reviewed: the health questions, what the 
patients actually complete, what was “behind” the scenes, how it was integrated 
into the medical record chart, how to access the information in the chart, and 
their role within the H-Quest process (all questions were answered).  
 
Providers were trained on the process of the health questionnaire, the new 
visit type identifying newly diagnosed prostate cancer patients, their patient’s 
process for accessing and conducting the health questionnaire. Providers were 
also trained on how to access the health questionnaire for the medical record 
chart  (location, copy and paste rules and billing privileges for the health 
questionnaire). Providers were also trained/educated on the pros/cons of the 
health questionnaire (i.e. The health questionnaire is patient-reported information 
  
 
and everything on the health questionnaire needs to be validated. It is also 
important that the information on the health questionnaire does not show 
negatives, thus if a patient did not ‘check” something in the health questionnaire 
it will not appear on the summary report.) 
  
System Change: 
 The DCS system uses a set of values to search the IDX scheduling 
system to create and issue health questions for each patient. The health 
questionnaire issues are determined individually by the patients visit type (Please 
see visit type changes below), provider, and clinic location (i.e. values used for 
searching IDX). A new visit type was created to identify the newly diagnosed 
prostate cancer patients (INS). Secretaries were using a visit type SPC (Special 
Prostate Clinic) to identify any cancer patient coming to the Urology Clinic. As the 
health questionnaires only focus on newly diagnosed prostate cancer (not 
bladder cancer, kidney cancer, testicular cancer or other cancer type), 
secretaries needed to differentiate the type of cancer patient coming to the clinic 
and schedule them with the new visit type5
  
. As Dr. John Heaney was scheduling 
two weeks ahead, secretaries in the Department of Urology started differentiating 
between cancer patients as soon as the new visit type was created and 
integrating them into the IDX system.  
Similarly, since some patients were scheduled weeks in advance, the 
sectaries were supervised in reviewing all visit type patients with an “SPC” and 
                                            
5 If the patient was identified incorrectly, a patient other than a newly diagnosed prostate cancer patient 
would be asked to fill out a newly diagnosis prostate cancer health questionnaires.  
  
 
rescheduling any ‘SPC’ patients that were newly diagnosed with prostate cancer 
to the new visit type of “INS”. Thus, all patients who had already had a clinic 
appointment, and new patients with prostate cancer, were all converted to a new 
visit type of “INS”.  
  
All providers’ schedules in IDX scheduling system needed to be altered. 
The “master” schedules all needed to include the new visit type. The “masters” 
for each provider were altered to include “INS” visit type. Because provider 
schedules were the only resource secretaries had to view; the health 
questionnaires were only issued for newly diagnosed prostate cancer patients. A 
new scheduling master was created, so that secretaries could just review/see 
health questionnaires scheduled for each patient, for a particular provider. The 
new resource allowed secretaries/clinic staff to identify patients who would be 
filling out a newly diagnosed prostate cancer health questionnaire prior to their 
appointment. This was done for two reasons:  
1. It gave the department another way to view who would be taking a health 
questionnaire other then just looking at a visit type  
2. It provided a quicker resource for staff to enter the patient’s medical record to 
see if the health questionnaire was completed since patients could complete the 
health questionnaire from home (or any internet access point) or one hour prior 
to their appointment.  
  
After two months of trouble-shooting, the new visit type was conducted. 
Secretaries were unsure about what “newly diagnosed prostate cancer patient” 
  
 
meant. Information about “newly diagnosed prostate cancer” was reviewed. 
Subsequent questions were added to the secretaries’ phone script to screen for 
newly diagnosed prostate cancer patients, if the secretary was unsure about 
where the patient was in the cancer trajectory.  
Question 1. Have you chosen a treatment option for your prostate cancer? 
Question 2. How long has it been since you were diagnosed with prostate 
cancer?  
These two questions helped filter patients that have chosen Watchful 
Waiting/Active Surveillance for their prostate cancer treatment, and patients that 
were unsure if they were newly diagnosed prostate cancer patients (since 
patients who have undergone treatment are no longer newly diagnosed).  
 
Integration: 
 Secretaries: Secretaries in Urology were trained in the new visit type. IDX 
training was conducted to train secretaries in utilizing the new ‘INS” visit type. 
The “INS” automatically selects an appointment one hour prior to the provider’s 
appointment, to allow enough time for the patient to complete the health 
questionnaires. The one hour prior appointment location is different for each 
provider, as the physicians see their patients in different locations. Secretaries 
were also informed of the disclaimer that if the patient finished the health 
questionnaire prior to the appointment (i.e. at home or another internet access 
point) the patient did not need to come to the clinic one hour prior to the 
appointment.  
  
  
 
A script was developed for the secretaries to reiterate the need for the 
health questionnaire prior to the appointment. They also reviewed the locations 
where a patient could complete the health questionnaire at DHMC/NCCC. 
Patients preferring to complete the health questionnaire on-line prior to coming to 
DHMC/NCCC were transferred  (via phone) to patient On-line Services 
Department at DHMC (see Administration Services).  
  
As secretaries scheduled for the H-Quest, along with the provider’s newly 
diagnosed prostate cancer appointment; reminder codes were entered into the 
scheduling system that were displayed to the patient via a reminder letter. The 
secretaries tested secretarial codes and training was conducted for the use of 
these codes (See Administrative Services). 
Clinic: 
 The nursing staff and other administrative staff were trained on the new 
health questionnaires. They received access into the DCS system which allowed 
them to be able to print a ‘hard copy” of the summary report and/or the 
completed health questionnaire for the provider (at the provider’s request).  
 
Collaboration with Administrative Services: 
 Simultaneously, during the integration of H-Quest in Urology, 
Administrative Services were contacted. Administrative Services (Admin 
Services) is a department sponsored by the Dartmouth Hitchcock Clinic and 
Mary Hitchcock hospital that provides secretarial and administrative support for 
Dartmouth Hitchcock Medical Center. Admin services are responsible for, and 
  
 
support, the scheduling system ‘IDX’ for Dartmouth Hitchcock Clinic, Mary 
Hitchcock Hospital and NCCC. The scheduling system ‘IDX’ (see section on mail 
notification) is linked to a mail notification system. Letters containing the patients’ 
appointment time, location and parking information are sent directly to the patient 
from the “mail room”.  
 
Visit types:  
 As DCS generates health questionnaires based on the scheduling system, 
the scheduling system needed to reflect the integration of the new health 
questionnaire. Each visit to the Urology Clinic is labeled by a visit time, a visit 
type (what the patient is being seen for; a pre-determined set of acronyms), a 
visit duration time, a pre-set location, specific reason of the visit and general 
comment for the provider and/or the secretary.  
 
Each visit type corresponds to a specific type of patient session with a pre 
determined duration (which can be edited by the secretaries). Prior to the H-
Quest integration in Urology, secretaries in Urology would schedule prostate 
cancer patient with a visit type of SPC (Special Prostate Clinic). ‘SPC’ visit type is 
specific to Urology, and lets the Urology staff know that the patient is coming to 
the clinic for general prostate cancer related issues. The ‘SPC’ visit type has: an 
automatic duration type of 45 minutes, a pre determined scheduling time and 
location for patients (Wednesday mornings for Dr. John Seigne 3K pediatric 
Oncology location (NCCN), Thursday mornings for Dr. John Heaney, 3K Clinic D 
Hematology Oncology location (NCCN)). Time, visit type, patient name, location 
  
 
of clinic, reason for visit and comments are all scheduled in IDX and access and 
displayed through CIS. 
 
As DCS uses the visit types to generate a corresponding health 
questionnaire, Urology created a new visit type to identify and schedule newly 
diagnosed prostate cancer patients. Admin services created an ‘INS’ (initial new 
survey) to use for all newly diagnosed prostate cancer patients who have not 
chosen treatment.  
 
‘INS’ Behind the Scenes: 
 The “INS” visit type is interfaced with DCS, Administrative Services, the 
mail notification, and Urology. The DCS interface scans the ‘IDX’ scheduling 
system for the ‘INS’ visit type. The ‘INS’ visit type is captured by DCS with its 
corresponding patient names, Medical Record Number (MRN), provider, location 
of appointment, and time of appointment. A health questionnaire is then 
generated for the patients and remains in a secured Wi-Fi server for the patient 
to access. Administrative Services in Urology uses ‘INS’ visit type to create 
master schedules for the providers. The secretaries in the Urology clinic use the 
master schedules for scheduling purposes. The INS visit type also generates a 
corresponding letter that is mailed to the patient (see below).  
 
The ‘INS’ visit type clinical significance: 
 From a clinical perspective, the INS visit type provides the support staff 
with general information about the patient, and a guide for the pre-encounter 
  
 
requirements. The INS visit type labels the patient as a newly diagnosed prostate 
cancer patient that needs a health questionnaire prior to the appointment along 
with the general work-up assessment (updated medication list, symptom 
assessment, health assessment  − height, weight, blood pressure, and urine 
sample).  
 
Patient On-Line (POL): 
Patient On-Line (POL) is an initiative by Administrative Services to grant 
patient more access to health care providers at DHMC/NCCC. POL allows 
patients to contact their subscribing providers about medical questions and 
medication renewals via the internet. POL also allows patients to access their 
medical records and view their appointment schedule. POL is accessed through 
the DHMC website. Patients are required to fill out their demographic information. 
A letter is mailed to the patient enclosing their login ID and their password. As 
this process can take over four weeks to be completed (due to patient verification 
and letter distribution), patients needing access to POL to complete their health 
questionnaires required instant access to POL.  
 
Patients calling Urology and scheduled for a newly diagnosed prostate 
cancer health questionnaire were given the option to take the health 
questionnaire online. Patients requesting to do the health questionnaire prior to 
their appointment (online) were transferred via the phone to a POL 
representative. Special negotiations were established to allow a POL 
representative to issue the login and password to the patient via the phone 
  
 
instantly. Patients were walked through the POL instructions over the phone. 
Patients were also given computer support to access POL along with POL 
navigation support to access the H-Quest. POL diverted all questions regarding 
the H-Quest specific questions to Telisa Stewart.  
  
Secretarial codes:  
 Administrative Services support all secretarial scheduling training and 
initiatives. Collaboration was developed with Administrative Services to create 
reminder codes for patients to view messages on their reminder appointment 
letter. The secretary enters reminder codes during the scheduling process in IDX. 
Manually entered codes by the secretaries produce pre established statements 
on the patient’s letter. Code 113 (Please remember that a health questionnaire is 
required prior to your appointment) and code 219 (If you would like to do the 
health questionnaire on line, Please call 603-653-3830 to gain access to the 
Patient Online) were created to remind patients about the health questionnaire 
and to direct calls to the appropriate location. Code 347 was also added to the 
patients letter that read, “You can complete the health questionnaire one hour 
prior to your appointment or online. If you complete the health questionnaire 
online you do NOT NEED to come one hour prior to your appointment.) The 
codes reduced the number of secretarial errors in providing information to 
patients and allow for constant, quick, and appointment-specific information to be 
added to the generic patient reminder letter. 
 
 
 
  
 
Mail notification:  
Administrative Services are also responsible for creating and adjusting 
reminder letters that are sent to the patients. Numerous hours were spent 
learning how to display non-provider appointments. Administrative Services 
created new programming to re-display the patient reminder letters to include 
health questionnaires. A typical letter would display the patient’s appointment to 
Urology and/or Radiation Oncology with a location and time. The programming 
would automatically include the health questionnaire appointment one hour prior 
to the first appointment (whether it was Urology and/or Radiation Oncology). 
Secretaries were required to manually edit all patient letters until programming 
from Administrative Services was complete.  
 
Collaboration with Billing and Coding:  
 The prostate H-Quest is a non-billable document that is not accepted by 
any health insurance. As H-Quest is patient-reported information, no 
fee/bills/reimbursements are applied either by the patient or by DHMC. However, 
providers can copy and paste the patients’ demographics and core review of 
symptoms from H-quest summary report into their office notes. After providers 
verbally verify the health information with the patients, the office note is a billable 
document for any health insurance. The Billing and Coding Departments were 
collaborated with in order for them to understand the H-Quest system, 
understand how providers utilize the summary report generated by the H-Quest, 
and created billable codes to account for the information collected by the provider 
through H-Quest. 
  
 
  
Collaboration with Radiation Oncology 
Simultaneously, during the development and testing for the prostate H-
Quest and the integration of H-Quest in Urology, the integration of H-Quest into 
Radiation (NCCC) began. Because Radiation is part of the NCCC, secretaries 
are not supported by Administrative Services (unlike Urology who is part of the 
DHMC).  
 
Training: 
 First, the administrative staff in the Radiation Oncology Department 
needed to be trained on how H-Quest was going to be integrated into the 
standard process of care. All administrative support personnel attended a two 
hour training session regarding H-Quest. In the training we reviewed: the health 
questions, what the patients actually completed, what was “behind” the scene, 
how it was integrated into the medical record chart, how to access the 
information in the chart, and their role within the H-Quest process (all questions 
were answered).  
 
Providers were trained on the process of the health questionnaire, the new 
visit type identifying newly diagnosed prostate cancer patients, their patient’s 
process for accessing and conducting the health questionnaire. Providers were 
also trained on how to access the health questionnaire for the medical records 
(location, copy and paste rules, and billing privileges for the health 
questionnaire). Providers were also trained/educated on the pro/cons of the 
  
 
health questionnaire (i.e. The health questionnaire is patient-reported information 
and everything on the health questionnaire needs to be validated. Furthermore, it 
was explained that the information on the health questionnaire does not show 
negatives, thus if a patient did not “check” something in the health questionnaire 
it will not appear on the summary report.) 
  
System Change: 
 The DCS system uses a set of values to search the IDX scheduling 
system to create and issue health questions for each patient. The health 
questionnaire issued for each patient is determined by the patient’s visit type 
(Please see visit type changes below), provider, and clinic location (i.e. values 
used for searching IDX). A new visit type was created to identify the newly 
diagnosed prostate cancer patients (IVT). Secretaries were using a visit type IVT 
to identify any cancer patient coming to the Radiation Oncology Clinic. As the 
health questionnaires only focused on newly diagnosed prostate cancer 
secretaries needed to differentiate the type of cancer patient coming to the clinic 
and schedule them with the new visit type6
  
. As Dr. Alan Hartford was scheduling 
six weeks ahead, secretaries in the Department of Radiation Oncology  
(Rad/Onc) started differentiating between cancer patients as soon as the new 
visit type was created and integrated into the IDX system.  
Since the time of the appointment scheduling and the actual day of the 
encounter had such a large window, secretaries were able to review their visit 
                                            
6 If the patient was identified incorrectly, a patient other than a newly diagnosed prostate cancer patient 
would be asked to fill out a newly diagnosis prostate cancer health questionnaires.  
  
 
type identification and scheduling about 7 weeks prior to the H-Quest start date. 
No effort was required to convert new patient work-up (NPW) to the new prostate 
cancer specific H-Quest.  
  
All providers’ schedules in IDX scheduling system needed to be altered. 
The “master” schedules all needed to include the new visit type. The “masters” 
for each provider were altered to include “IVT” visit type. Because, provider 
schedules were the only resource secretaries had; to view the health 
questionnaires issued for only newly diagnosed prostate cancer patients, a new 
scheduling master was created; so that secretaries could just review/see health 
questionnaires scheduled for each patient, for a particular provider. The new 
resource allowed secretaries/clinic staff to identify patients who would be filling 
out a newly diagnosed prostate cancer health questionnaire prior to their 
appointment. This was done for two reasons:  
1. It gave the department another way to view who would be taking a health 
questionnaire other then just looking at a visit type  
2. It provided a quicker resource for staff to enter the patient’s medical record to 
see if the health questionnaire was completed since patients could complete the 
health questionnaire from home (or any internet access point) or one hour prior 
to their appointment.  
  
After two weeks of trouble-shooting, the new visit type was conducted. 
Secretaries were unsure about what “newly diagnosed prostate cancer patient” 
meant. Information about “newly diagnosed prostate cancer” was reviewed. 
  
 
Subsequent questions were added to the secretaries’ phone script to screen for 
newly diagnosed prostate cancer patients if the secretary was unsure about 
where the patient was in the cancer trajectory.  
Question 1. Have you chosen a treatment option for your prostate cancer? 
Question 2. How long has it been since you were diagnosed with prostate 
cancer?  
These two questions helped filter patients that have chosen Watchful 
Waiting/Active Surveillance for their prostate cancer treatment, and patients that 
were unsure if they were newly diagnosed prostate cancer patients (since 
patients who have under gone treatment are no longer newly diagnosed).  
  
Integration: 
 Secretaries: Secretaries in Rad/Onc were trained in using the new visit 
type. IDX training was conducted to train secretaries in utilizing the new ‘IVT” visit 
type. The “IVT” automatically selects an appointment one hour prior to the 
provider’s appointment to allow enough time for the patient to complete the 
health questionnaires “in house”. Secretaries were also informed of the 
disclaimer that if the patient finished the health questionnaire prior to the 
appointment (i.e. at home or another internet access point) the patient did not 
need to come to the clinic one hour prior to the appointment.  
  
A script was developed for the secretaries to reiterate the need for the 
health questionnaire prior to the appointment. They also reviewed the locations 
where a patient could complete the health questionnaire at DHMC/NCCC. 
  
 
Patients wanting to complete the health questionnaire on-line prior to coming to 
DHMC/NCCC were mailed access  (log in name and password) by the Patient 
On-Line Services Department at DHMC (see Administration Services).  
  
As secretaries scheduled for the H-Quest along with the providers newly 
diagnosed prostate cancer appointment, reminder codes are entered to the 
scheduling system that are displayed to the patient via a reminder letter. 
Secretarial codes were tested by the Urology Department, thus providing training 
for secretaries on use of these codes (See Administrative Services). 
 
Clinic: 
 The nursing staff and other administrative staff were trained on the new 
health questionnaires. They received access into the DCS system which allowed 
them to be able to print a ‘hard copy” of the summary report and/or the complete 
health questionnaire for the provider (at the provider’s request).  
 
Collaboration with Shared Decision Making (SDM): 
Simultaneously, during the development and testing for the prostate H-
Quest, the integration of H-Quest in the Urology clinic, the integration of H-Quest 
into Radiation Oncology, the collaboration and integration with Shared Decision 
Making (SDM) took root.  
  
The goal of the SDM was to standardize the health information provided to 
newly diagnosed prostate cancer patients regardless of which clinic was 
accessed (Urology and/or Radiation Oncology). Two collaborative endeavors 
  
 
were undertaken: first, to integrate the SDM video (mailed to the patient) about 
prostate cancer; second, to create and establish a ‘neutral’ prostate cancer 
packet. Collaboration with SDM was established to not only integrate the video 
but also support and track educational information sent to the patient.  
 
 Integration of the video: 
 SDM was contacted to standardize the process so that all newly 
diagnosed prostate cancer patients received the SDM prostate cancer video 
(henceforth the word “video” will be used in place of “SDM prostate cancer 
video”). Dr. John Seigne in Urology was the only provider utilizing the SDM video 
with his newly diagnosed prostate cancer patients. Collaboration with SDM was 
established for the integration of the video in both Urology and Radiation  
 
Oncology Clinic.  
 Each provider (Dr. John Heaney, Dr. Alan Hartford, Dr. Bassem Zaki and 
Dr. John Seigne) was individually approached about the integration of the video; 
each provider was given the video to preview. A focus group of the four providers 
was conducted once after a weekly scheduled meeting. Providers discussed 
sending a generalized video to newly diagnosed prostate cancer patients. 
Reservations included: video is too general, patients may think they are eligible 
for all treatment options, may confuse patients who have already made a 
decision, Urology felt video lead patients more towards radiation, 
Radiation/Oncology felt that the video lead patients more toward Urology, how 
would patients receive the video, how do we remove the burden of the video from 
  
 
the provider. Positive reflections included: provides general information about 
prostate cancer (location, treatment choice, treatment side effects), standardized 
patient information, provides a baseline of knowledge for patients, alleviates the 
provider from conducting the “general prostate cancer informational dump” at the 
appointment, and provided unbiased information for patients. After careful 
debate, the unstructured informal focus group concluded that providing the video 
would be beneficial for patients.  
 
SDM office was then consulted about integrating the health questionnaire 
in both Urology and Rad/Onc Clinics. Several meetings were conducted to 
review strategy, patient flow, secretaries’ responsibilities and integration, and 
system management. In conclusion of the meetings, a flow chart was developed 
to integrate the SDM video (see Training below). For Dr. Seigne, newly 
diagnosed prostate cancer patients are generally diagnosed at DHMC. The 
established patient/provider relationship allows Dr. Seigne to customize an 
appointment letter that contains specific health information regarding their cancer 
stage, Gleason score, pathology information from positive biopsy, and PSA. This 
customized letter is emailed to Dr. Seignes’ secretary. When scheduling the new 
prostate cancer consultation with Dr. Seigne, the secretary prints out the 
customized letter. The secretary schedules the patient for a new prostate cancer 
consultation  (INS appointment) and requests the automatically generated 
appointment letter to come to her (instead of automatically mailing it the patient.) 
Dr. Seigne’s secretary receives the automatic letter; the sectary attaches the 
custom letter generated by Dr. Seigne. The secretary then takes the two letters 
  
 
and adds them to the front of the prostate cancer packet, the packet is then 
mailed internally to SDM (See below). Because Dr. Heaney, Dr. Hartford, and Dr. 
Zaki generally see patients that are diagnosed outside of DHMC, the providers 
are unable to generate a custom letter outlining the pathology and specific health 
information to the patient. Thus, the secretary schedules the new patient 
appointment  (see above), requests the automatically generated letter to come to 
the corresponding clinic. The secretary then adds the letter to the front of the new 
prostate cancer packet. The packets were sent via inter-office mail from the 
respective departments to SDM.  
 
Department of Shared Decision Making (SDM) 
Several meetings were conducted to review SDM role in the patient 
education process, and the integration of SDM into Urology and Radiation 
Oncology in a disease specific role. In order to comply with the philosophies of 
SDM, SDM had input into the prostate cancer packets of health information. They 
concurred that the information provided was displayed in a neutral and non-
treatment leaning way. 
 
SDM Process: 
Shared Decision Making (SDM) department reviews each packet and 
verifies that each packet is accompanied with a letter (either specific to the 
patient or generic) and has a complete prostate cancer packet. The secretary in 
SDM logs the patient into the SDM database (used only in SDM to track videos). 
The patient’s name, medical record number and address are added to the 
  
 
database; accompanying video tracking number is also added to the patient 
information. The SDM secretary places the prostate cancer video and a prostate 
cancer video booklet (text version of the video) in a pre paid self addressed 
envelope  (back to SDM). The pre-paid self address envelope (containing video 
and brochure) is then added to a large manila envelope where the prostate 
cancer packet (See below) and the appointment letter added. The SDM secretary 
then prints out a label for the large envelope and mails the entire packet to the 
patient. Any duplicate packets sent to SDM are sent back to the corresponding 
clinic (because of patient changing appointments, occasionally a duplicate 
patient packet will get generated. Departmental clinics are unable to track which 
patients received a packet and video, whilst SDM is able to track which patients 
receive a packet and video within their own database). 
 
A meeting with Urology, Radiation Oncology and SDM supervisors was 
conducted. The meeting reviewed the new procedure for integration of the video 
and the packet into the standard process of care. Concerns and questions were 
addressed in great detail. Subsequent meetings were conducted with each 
departments’ secretarial staff to review the new prostate cancer packet and SDM 
video that would be included with the appointment letter. After integration, trouble 
shooting was conducted for nearly three months.  
 
Integration of the Packets: 
A red packet of Urology-specific prostate cancer treatment was part of the 
normal process of care in Urology. Because the treatment information was 
  
 
biased towards Urology, a more neutral packet of prostate cancer information 
was developed. The neural packet was more mainstream with the mission of 
SDM to provide unbiased health information for the patients to participate in a 
shared decision about treatment. Thus the original “R Packet” was withdrawn 
from the standard process of care and was replaced by a new prostate cancer 
packet”.  
 
Since newly diagnosed prostate cancer patients (NDPCP) are entering 
DHMC/NCCC through Radiation Oncology and Urology/Oncology, patients from 
both departments will receive a prostate cancer packet of brochures prior to their 
initial visit. Providers responsible for seeing newly diagnosed prostate cancer 
patients were selected to participate in a focus group about what would be 
included in the new prostate cancer packet.  
 
Prostate cancer information/brochures were gathered from all patient 
education arias in a vast array of places throughout DHMC/NCCC. Since each 
department is responsible for ordering patient information, there was a plethora 
of educational material circulating throughout the facility (DHMC, NCCC). A 
collection of all known information materials regarding prostate cancer, prostate 
cancer treatment, prostate cancer side effects, prostate cancer support services, 
shared decision making, and general cancer information was gathered. Three 
folders were developed, prostate cancer packet folder”, “maybe folder”, and a 
“dump” folder was developed.  
 
  
 
A meeting with the Center for Shared Decision Making was held, in which 
two counselors helped to explore the brochures. Based on an informed choice 
and their philosophy of providing unbiased information and patient-friendly 
information, brochures were selected for the “prostate cancer packet folder”, 
“maybe” folder and the “dump” folder (corresponding to conceptually good, bad, 
maybe). The prostate cancer packet folder would be the standard of what would 
be mailed to newly diagnosed prostate cancer patients and hold all the 
brochures. The “maybe” folder would be discussed during a focus group with all 
providers present. The “dump” folder would not be included in the new packet of 
information. 
 
Providers responsible for seeing newly diagnosed prostate cancer patients 
were selected to review the prostate cancer packet. Scheduling constraints 
randomized the order of providers viewing the folders. Providers were asked to 
write agree/disagree next to their name on the outside of the folders to indicate 
how they felt about the content of the information; if they disagreed with a 
particular brochure then they were verbally asked to clarify. 
 
The three folders where first given to Dr. John Seigne for review. Dr. 
Seigne agreed with all the brochures in the “dump Folder”. He removed the 
brochures called “Sexuality and Cancer” from the “prostate cancer packet folder” 
and placed it in the “maybe Folder”.  
 
  
 
The (adjusted) folders were then given to Dr. John Heaney. Dr. John 
Heaney concurred with Dr. John Seignes about the “dump” folder; Dr. Heaney 
suggested that the brochure about “Sexuality and Cancer” be a part of the 
“prostate cancer packet”. The “Sexuality and Cancer” brochure was then moved 
from the “maybe” folder to the “prostate cancer packet folder”. Dr. John Heaney 
felt that his patients should have the resources available to them about “Sexuality 
and Cancer”. He felt that the brochure may be helpful to some of his patients. Dr. 
Alan Hartford was then given the three folders. He concurred with Dr. John 
Seigne and Dr. John Heaney about the “dump” folder. He agreed with Dr. 
Heaney about the “prostate cancer packet” folder (the “maybe” folder had no 
brochures at the time). The three folders were then given to Laura Stempkowski, 
Advanced Nurse Practitioner, who follows all cancer patients in Urology. Laura 
agreed with the “dump” folder but felt that her patients should not receive the 
“Sexuality and Cancer” brochure. She removed the brochure and placed it into 
the “maybe” folder.  
 
A focus group was arranged with the four providers. After an already 
scheduled weekly meeting, the providers remained for an additional ten minutes 
to discuss the “Sexuality and Cancer” brochure and the “prostate cancer packet” 
of information. 
 
Dr. Hartford stated, “that sexuality problems may be present prior to 
cancer diagnosis”. He felt that the brochure could help some of his patients 
understand their own bodies, address issues that they may not feel comfortable 
  
 
discussing with a provider. He felt that explaining treatment side effects did not 
assume any decision. Laura felt that the brochure did not focus on prostate 
cancer and treatment side effects. She states that “The brochure is not 
appropriate for my patients”, as she felt that they needed to hear about the 
treatment options from a provider before they read general information about 
sexuality that may or may not pertain to them. Dr. Seigne stated, “I don’t feel this 
brochure is appropriate for newly diagnosed prostate cancer patients because it 
does not focus on prostate cancer and sexuality but on a wide array of 
treatments. I don’t feel this would be appropriate for a patient to read until after I 
have spoken with him. Plus, we want to give patients information about 
treatments, “Sexuality and Cancer” presumes that they do not pick Watchful 
Waiting/Active Surveillance.” Collectively they agreed to not include the 
“Sexuality and Cancer” brochure in the packet of prostate cancer information.  
 
All providers responded positively to the new packet of prostate cancer 
information. All the providers felt that a selection of suitable internet sites should 
be provided for patients, some support group information should also be 
provided, accompanied by a suggested book list – to be provided on a piece of 
paper inserted into the prostate cancer packet. Similarly, providers wanted to see 
some caution statements about the packet’s general information; e.g. a 
statement that general information may or may not be appropriate for ALL 
patients.  
 
  
 
A letter was created to address provider’s concerns about general 
information given to patients (see Appendix B). The letter labeled, “Keep in mind” 
was emailed to all four providers and they were asked to make comments. All 
providers agreed with the three key points regarding the prostate cancer packet 
and the Video that would be included from the Center for Shared Decision 
Making, and the use of internet sites and books. All providers unanimously 
concurred that the letter did not need any alteration and should be added to the 
“prostate cancer packet”. 
 
Laura Stempkowski, Advanced Nurse Practitioner, and I had two meetings 
regarding the group’s recommendations on suggested internet sites, prostate 
cancer support groups and suggested books on prostate cancer. Four internet 
sites where chosen that were: regularly updated, were based on 
scientific/validated information and were patient friendly. The sites were from the: 
American Cancer Society, American Foundation for Urologic Disease, National 
Cancer Institute and the Prostate Cancer Foundation. Two support group’s 
names were added to the list. One support group that is sponsored and available 
at DHMC (Man to Man) was added, along with “Us Too” which is a nationally 
recognized support group for prostate cancer patients. The Urology Department 
had already pre-selected books on prostate cancer along with a suggested book 
list from the Center for Shared Decision Making. Suggested internet sites, 
support groups and prostate cancer books were compiled and added to a sheet 
that would be inserted into the packet (see Appendix C). The recommendations 
were e-mailed to all four providers and requested feedback. All four providers 
  
 
agreed with the recommendation letter and agreed for them to be added to the 
“prostate cancer packet”.  
 
The “prostate cancer packet” was brought back to the Center for Shared 
Decision Making for review. The center agreed with the overall the content, 
except for the ‘New patient letter’ (see Appendix I and Appendix J) from the 
providers (which was previously not discussed). The center stated that the 
information was “not patient friendly, was confusing, and did not highlight the 
recourses provided with the letter (prostate cancer packet of information, and 
video from the Center for Shared Decision Making (see Appendix G). We 
concluded the new patient letter needed to be re-written.  
 
The Center for Shared Decision Making provided a new patient letter from 
the comprehensive breast program. The letter was only slightly altered from 
breast patients to reflect prostate patients. Provider names were added to make 
the letter provider “specific”. “Before you arrive check list” (see Appendix H) 
paper was created, base on  the old patient letter. Each provider was then e-
mailed the “Before you arrive check list” and the individual provider letter (See 
Appendix I, J and K) and asked to provide feedback about the letters. All 
providers agreed that the letters were correct (see Appendix G).  
 
Rad/Urology administrator supervisors were asked to review the new 
patient letter, verify the content and provide feedback. Both administrative 
supervisors agreed that the letters were complete and error free. The letters were 
then added to the packet. All members agreed that the new packet of prostate 
  
 
cancer information now the “prostate cancer packet” would be sent to all newly 
diagnosed prostate cancer patients that are seeing either Dr. John Heaney or Dr. 
Alan Hartford prior to their new patient appointment. 
The “prostate cancer packet” was again circulated in it entirety:  
Brochures: 
 
-Where to Turn: Support through your cancer journey 
Prostate cancer support group (Green heading) 
-Rest Easy (Red Heading) 
-Man to Man: Prostate Cancer Education and Support Program 
-Shared Decision making: Helping with Making Your healthcare decision 
-Treatment choices for men with early stage prostate cancer (NCI-Blue 
book) 
-Cancer Resource Guide (Purple) 
-Prostate Cancer: Treatment Guidelines for Patients (green and white) 
DHMC Letters: 
-Provider letter: Dear Patient: -Suggested internet sites, Prostate cancer 
support,  
Recommended book list, suggested support groups, and internet sites.  
-Keep in Mind 
  -Before you arrive check list 
 
Color paper was picked for the four letters. Paper was selected by 
preference and visual appeal. It was determined that the “Before you arrive 
check list” should be on stalk paper, so it would stand out in a pile of paper along 
with making it more patient friendly to carry as a reminder and check list. The 
“Provider letter”, Suggested internet sites and “Keep in Mind” document, would 
be on regular color paper. Paper color was then identified in supplies ordering 
catalog, “Office Max” which is used by all DHMC departments. Ordering codes 
were added to the secretary protocol sheet. Color paper (yellow, green and blue) 
and stalk paper (yellow) was ordered for both Radiation and Urology and 
delivered to each department two days later.  
 
  
 
Brochures were ordered for the packets. A protocol sheet was developed 
(See Appendix G) for secretaries in each department. The protocol sheet outlines 
the procedures for ordering brochures from various vendors and/or departments 
that need to place the order. Both administrative supervisors reviewed the 
protocol. Both supervisors agreed with ordering procedures and “prostate cancer 
packet procedures”. Secretaries were then met with individually to review and 
complete the “prostate cancer packet” based on procedures. Administrative 
supervisors agreed upon implementation process and procedure of the “prostate 
cancer packets”. Radiation and Urology supervisors both held meetings with 
secretaries to confirm the process and procedure. 
 
Nursing support assumes all responsibilities for patient printed materials 
distributed directly by DHMC. Amity Johnson in Nursing Support was contacted 
to review directives about printed materials and ordering procedures were 
reviewed. Comparisons were made between the “prostate cancer packet” 
protocol and her job requirements along with printed material requirements. A 
partnership was established for secretaries to contact Amity and request patient 
brochures as identified in the protocol.  
 
Brochures coming from the National Cancer were organized through 
Patient Education. Patient Education is funded through DHMC and orders 
brochures that support patient’s educational needs. A flexible fund allows the 
department to order brochures that require payment (for DHMC departments). A 
  
 
meeting was conducted with the Director of Patient Education. During the 
meeting the prostate cancer packets were explored.  
There were several additional meetings were conducted that will not be 
reviewed.  Meetings included topics such as: 
A. How to order additional brochures from DHMC 
B. Do the directors in each department agree with materials?  
C. Conversations with the American Cancer society on how to order 
brochures for each clinic. 
D. Who will be responsible for ordering packet materials and how. 
E. Introducing the new prostate cancer patients with the center for shared 
decision making at DHMC 
F. Focus group during tumor board for final product review 
 
Dr. John Heaney and Dr. John Seigne are the only two providers in the 
Section of Urology that diagnose and treat prostate cancer patients. Dr. John 
Seigne was later approached for collaboration with their project. Stempkowski an 
Advanced Nurse Practitioner, who follows all prostate cancer patients in Urology 
was also contacted to participate. The Practice Manager and Administrator 
Supervisor for the section of Urology were involved later in the process. 
 
Currently, there are few hospitals that have integrated shared decision 
making into their medical practices. Dartmouth Hitchcock Medical Center 
(DHMC) in Lebanon New Hampshire has become a gold standard for the 
integration of shared decision making in medical practice. The Center for Shared 
  
 
Decision Making (CSDM) at DHMC is currently assisting patients in making an 
“informed medical decision.” The center provides educational videos, 
brochures/pamphlets, support, and counseling by a Registered Nurse/Counselor.  
 
Newly diagnosed prostate cancer patients (Urology cancer patients), for 
example, must seek out the CSDM for medical decision support. Providers and 
staff may suggest that patients utilize CSDM services; however, the Urology 
Clinic at DHMC rarely refers patients. The center is patient-focused and provides 
services upon patient requests. Patients may receive free counseling about 
treatment options if a they have met with their provider. The center is currently 
conducting research on breast cancer patients decision making methods to 
assist patients (predominantly female) in making breast cancer treatment 
choices; however, no formal shared decision making research from DHMC has 
been completed for men. 
 
 
  
 
 
Appendix M: Implementation Process for the Pilot Study: 
 
The pilot study was conducted in three phasesi7
 
 as each phase was 
conducted with a different provider. The first phase of the pilot was conducted 
with Dr. John Heaney in the Prostate Cancer Clinic. Patients were identified 
using the provider’s scheduling system. They were contacted by phone and 
provided information about the health questionnaire as part of their standard 
process of care. Patients were instructed to arrive at the clinic one hour prior to 
their appointment with their provider. Upon arrival, patients were greeted by Dr. 
Heaney’s nurse and the standard intake routine was conducted (updated 
medication list, height, weight, etc.). After the standard routine, the nurse 
introduced the electronic pad, educated the patient on how to use the stylus, 
reviewed the electronic consent with the patient, and instructed the patient to 
complete the health questionnaire. After each health questionnaire was 
completed, the health questionnaire summary report was printed out. Dr. John 
Heaney and his staff reviewed the summary report. The providers then reviewed 
the summary report with each patient (reviewing specific responses if he felt they 
were concerning). 
The second phase of the pilot was conducted with Dr. John Seigne in the 
Prostate Cancer Clinic. Patients were identified using the provider’s scheduling 
                                            
7 It was essential to conduct the pilot as a three phase process. Each provider provides health services with 
different secretaries and support staff. Similarly, patient flow was altered from the normal mainstream 
process.  
  
 
system. Patients were contacted by phone and provided information about the 
health questionnaire as part of their standard process of care. Patients were 
instructed to arrive at the clinic one hour prior to their appointment with their 
provider. Upon arrival, patients were greeted by the registration secretary and 
were instructed to wait for the nurse. Dr. Seigne’s nurse collected the patient and 
the standard intake routine was conducted (updated medication list, height, 
weight, etc.). After the standard routine, the nurse introduced the electronic pad, 
educated the patient on how to use the stylus, reviewed the electronic consent 
with the patient, and instructed the patient to complete the health questionnaire. 
After each health questionnaire was completed, the health questionnaire 
summary report was printed out. Dr. John Seigne reviewed the summary report. 
He then reviewed the summary report with each patient (reviewing specific 
responses if he felt they were concerning). 
 
The third phase of the pilot was conducted with Dr. Alan Hartford and Dr. 
Bassem Zaki in Radiation Oncology. Dr. Hartfords and Dr. Zaki’s radiation 
patients were identified using the provider’s scheduling system. Patients were 
contacted by phone and provided information about the health questionnaire as 
part of their standard process of care. Patients were instructed to arrive at the 
clinic one hour prior to their appointment with their provider. Upon arrival, 
patients were greeted by the Radiation Oncology nurse and the standard intake 
routine was conducted (updated medication list, height, weight, etc.). After the 
standard routine, the nurse introduced the electronic pad, educated the patient 
on how to use the stylus, reviewed the electronic consent with the patient, and 
  
 
instructed the patient to complete the health questionnaire. After each health 
questionnaire was completed, the health questionnaire summary report was 
printed out. Dr. Hartford and Dr. Zaki’s staff reviewed the summary report. The 
providers then reviewed the summary report with each patient (reviewing specific 
responses if they felt they were concerning).  
 
 
  
 
 
 
Appendix N: Eligibility and Enrollment 
 
 
 
Phase 1: All newly diagnosed prostate cancer patients seen by Dr. John 
Heaney during the Thursday morning Prostate Cancer Clinic (located in the 
NCCC-Hematology Oncology, 3F) completed the health questionnaires as their 
standard process of care. There was no differentiation between patients that 
consented to the study and patients that did not. Patients were excluded if they 
did not speak English.  
 
Phase 2: All newly diagnosed prostate cancer patients seen by Dr. John 
Seigne during the Wednesday morning Prostate Cancer Clinic (located in the 
NCCC-Hematology Oncology, 3B) completed the health questionnaires as their 
standard process of care. There was no differentiation between patients that 
consented to the study and patients that did not. Patients were excluded if they 
did not speak English.  
 
Phase 3: All newly diagnosed prostate cancer patients seen by Dr. Alan 
Hartford and Dr. Bassem Zaki during the Friday morning Prostate Cancer Clinic 
(located in the NCCC-Radiation-Oncology, 2D) completed the health 
questionnaires as their standard process of care. There was no differentiation 
between patients that consented to the study and patients that did not. Patients 
were excluded if they did not speak English.  
  
 
Appendix O: Monitoring and Management 
 
 
 
 
 Careful consideration was given to the psychiatric and distress needs of 
each patient. The summary report graphically portrays the SF-12 allowing 
providers to quickly glance at physical, mental and social functioning. If any of 
the validated tools (GAD 7, PTSD, PHQ, MSAS and SF-12) revealed a need for 
further support, outside help from providers with a Certified Masters of Social 
Work (MSW) was sought. They were consulted, and meet with patients after the 
appointment with the Oncologist.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Appendix P: Trouble-Shooting 
 
 
 
 
Provider: From the providers prospective the disruption of patient flow 
became slightly problematic. Providers in the clinic were used to moving at their 
own pace and seeing patients consecutively. However, patients still finishing up 
the health questionnaire forced the provider to wait until the patient had 
completed the H-Quest, creating a domino effect, causing the provider not 
starting the Oncology encounter at its scheduled time. This problem was 
eventually rectified, as nursing staff made an effort to quickly launch the H-Quest 
and providers’ personal routines were changed as a result. 
 
The summary report was carefully reviewed after each patient by 
providers. Although training was given to the providers before the implementation 
of the H-Quest, they were still not confident in their ability to understand the 
validated screening tools; providers were extra cautious in the patient reported 
information before making any assumptions about the patients’ needs. 
 
The providers enjoyed the quick accessibility of health information, the 
ability to copy and paste the review of symptoms into the office note as a 
framework to review with the patient as part of their standard clinical encounter, 
and screening of mental and social aspects of the patient that were not always 
covered by the provider due to time constraints. Providers felt that they were 
providing a better health service to the patients by screening for psychological 
issues and distress.  
  
 
Counselor: Three patients were consulted by the MSW on request of the 
providers. The health questionnaire was reviewed by the MSW and the provider. 
If warranted, the provider introduced the counselor to the patient and asked 
permission before requesting the consult with the MSW (all three patients 
accepted). The summary report provided the counselor with a quick validated 
assessment of the patient’s mental, social and physical issues. The MSW all 
enjoyed the quick accessibility of information along with a baseline for them to 
launch a discussion about the needs of the patient. Dr. John Seigne had one 
patient referred to an MSW. The MSW was unable to see the patient following 
Dr. Seigne’s appointment; however, the patient was seen two hours later in the 
MSW counseling space in the Mary Hitchcock hospital. Dr. Hartford had no 
referral quests to the MSW. 
 
As all three providers see patients in different locations in the NCCC, 
different clinic days and times, the counselor found it problematic to have random 
requests for referrals through out the cancer center. To make this more 
streamlined, a part-time MSW was requested and was expected to be shared 
between prostate cancer Oncology providers. Until funding becomes available, 
the MSW has agreed to continue with immediate referral consultations. 
 
Patient: The majority of the patients seen in the clinic had positive 
experience filling out the H-Quest. The vast majority did not find the process too 
long and felt the information they provided would help their provider. Prostate 
cancer patients in general seemed extremely vested in their care and wanted to 
  
 
provide the provider with as much information as needed for the encounter. 
Some patients felt that the health questionnaire was a little too long and had 
some repetitive questions. After careful review, we were unable to change the 
questions because they are part of a validated tool. Most negative feelings arose 
because patients were afraid that their efforts with the H-Quest were not going to 
be acknowledged. Patients were delighted when the providers reviewed the 
summary report with the patients. Patients had no trouble following the 
instructions for H-Quest.  
 
As we were unable to identify patients with low literacy, some patients 
took twice as long to fill out the H-Quest. Similarly, some patients took an 
extending amount of time to fill out the H-Quest because of over-analyzing the 
questions.  
 Electronic pads: 
 The electronic pads use internet to launch the health questionnaire. 
Some locations within each clinic have lower connection speed then others. 
Providers had to be mindful about where patients sat to fill out the health 
questionnaire as their connection speed would hinder the time for completion.  
  
 
Appendix Q: Pilot Graphically Displayed 
No Cancer, Patient 
Follows up in Urology 6 
months later
Seigne
Hartford
And/
Or
Patient 
screened for 
prostate cancer
Heaney
Patient seen 
in 
3K/Med/Onc
Referral/ 
patient 
direct
Referrals
Pam (secretary), schedules 
appointment, requests pt 
information, generic 
appointment letter sent.
Patient seen 
in 3K
Robin (secretary), schedules 
appointment, requests pt 
information, urology packet, 
generic appointment letter 
sent. 
Dr. Seigne 
calls patients 
with 
diagnosis 
Email to Robin (Sec.) 
Custom letter because of 
established care, 
urology packet sent out 
Sees patient or Referral 
to Heaney/Hartford
Prostate 
cancer risk 
clinic
Positive for 
Prostate 
Cancer at 
DHMC
Patient seen 
in 2K
 
 
 
 
 
 
 
 
No Cancer, Patient 
Follows up in Urology 6 
months later
Seigne
Hartford
And/
Or
SDM sends 
out video, 
packet, letter
Patient 
screened for 
prostate cancer
Heaney
Patient seen 
in 
3K/Med/Onc
Patient does 
h-quest on 
line or 1 hr 
prior to appt. 
Referral/ 
patient 
direct
Referrals
Pam (secretary), schedules 
appointment, requests pt 
information,  notifies pt of H-
quest (documents pt to do 
online or 1hr prior). Packet, 
generic appointment letter 
get sent to SDM. 
SDM 
sends out 
video, 
packet, 
letter
Patient 
does h-
quest on 
line or 1 hr 
prior to 
appt. 
Patient seen 
in 
2K/Rad/Onc
Multi-
disciplinary 
clinic
Robin (secretary), schedules 
appointment, requests pt 
information,  notifies pt of H-
quest (documents pt to do 
online or 1hr prior). Packet, 
generic appointment letter 
get sent to SDM. 
Dr. Seigne 
calls patients 
with 
diagnosis 
Email to Robin (Sec.) 
Custom letter because of 
established care, packet 
sent to SDM, pt notified 
of h-quest (documents pt 
to do online or 1hr prior). 
Sees patient or Referral 
to Heaney/Hartford
Prostate 
cancer risk 
clinic
Positive for 
Prostate 
Cancer at 
DHMC
Patient 
reminded 
about H-
quest 
requirement
  
 
 
Appendix R: SF-12v2 Pre-coded items 
 
Pre-coded items:  Pre-code  Final Item Value 
 
Question 2a and 2b 
Yes, limited a lot  1    1 
Yes, limited a little  2    2  
No, not limited at all  3    3 
 
Question 5 
Not at all   1    5 
A little bit   2    4 
Moderately   3    3 
Quite a bit   4    2 
Extremely   5    1 
 
Question 1 
Excellent   1    5.0 
Very good   2    4.4 
Good    3    3.4 
Fair    4    2.0 
Poor    5    1.0 
 
Question 6a, and 6b 
All of the time  1    5 
Most of the time  2    4 
Some of the time  3    3 
A little of the time  4    2 
None of the time  5    1 
 
Question 3a, 3b, 4a, 4b, 6c and 7 
All of the Time  1    1 
Most of the time  2    2 
Some of the time  3    3 
 A little of the time  4    4  
None of the time  5    5 
 (Chart taken from(J. Ware, Kosinski M., Turner Bowker, Diane, Gandek, 
Barbara, 2005) 
 
 (See appendix T) SF-12v2 transforming score formula 
The formula below is used in transforming the scores: 
 
  
 
 
Transformed scale =  (Actual raw score – Lowest possible raw score)  
      Possible raw score range 
   * 100 
 
SF12-V2 Scale Sum final item value after recode 
Lowest and 
highest possible 
raw score 
Possible raw 
score range 
PF Items 2a + 2b 2, 6 4 
RP Items 3a + 3b 2, 10 8 
BP Item 5 1, 5 4 
GH Item 1 1, 5 4 
VT Item 6b 1, 5 4 
SF Item 7 1, 5 4 
RE Item 4a + 4b 2, 10 8 
MH Item 6a + 6b 2, 10 8 
 
Taken from page 36, Chapter 6. How to Score SF-12 Items (J. Ware, Kosinski 
M., Turner Bowker, Diane, Gandek, Barbara, 2005) 
 
 
 
  
 
 
Appendix S: SF-V2 Scores to Norm Based Scores 
 
To transform the SF-V2 scores to the NBS. 
 First a z-score for each scaled item is calculated. The z-core 
standardization subtracts the 1998 General U.S. population means by the score 
on each scale and then divides by the 1998 General U.S. population standard 
deviation for each score. 
 
SF12v2 Scale Mean SD 
PF 81.18122 29.10558 
RP 80.52856 27.13526 
BP 81.74015 24.53019 
GH 72.19795 23.19041 
VT 55.59090 24.84380 
SF 83.73793 24.75775 
RE 86.41051 22.35543 
MH 70.18217 20.50597 
Taken from page 47, Chapter 8 How to Score Standard Forms(J. Ware, Kosinski 
M., Turner Bowker, Diane, Gandek, Barbara, 2005) 
 
PF_Z= (PF - 81.18122) / 29.10558 
RP_Z= (RP - 80.52856) / 27.13526 
BP_Z= (BP - 81.74015) / 24.53019 
GH_Z= (GH - 72.19795) / 23.19041 
VT_Z= (VT - 55.59090) / 24.84380 
SF_Z= (SF - 83.73793) / 24.75775 
RE_Z= (RE - 86.41051) / 22.35543 
MH_Z= (MH - 70.18217) / 20.50597 
Taken from page 46, Chapter 8 how to Score Standard Forms(J. Ware, Kosinski 
M., Turner Bowker, Diane, Gandek, Barbara, 2005) 
 
 
  
 
 
Appendix T: “Z-Score Standardization 
 
NBS PF:  PF= 50+ (PF_Z * 10) 
NBS RP: RP= 50+ (RP_Z* 10) 
NBS BP: BP= 50 (BP_Z* 10) 
NBS GH: GH= 50+ (GH_Z* 10) 
NBS VT: VT= 50+ (VT_Z* 10) 
NBS SF:  SF= 50+ (SF_Z* 10) 
NBS RE: RE= 50+ (RE_Z* 10) 
NBS MH: MH= 50+ (MH_Z* 10) 
Taken from page 47, Chapter 8 how to Score Standard Forms(J. Ware, Kosinski 
M., Turner Bowker, Diane, Gandek, Barbara, 2005) 
 
 
 
 
 
  
 
 
Appendix U: Factor Score PCS and MCS 
 
SF12v2 Scale Factor Score Coefficients PCS Factor Score Coefficients MCS 
PF 0.42402 -0.22999 
RP 0.35119 -0.12329 
BP 0.31754 -0.09731 
GH 0.24954 -0.01571 
VT 0.02877 -0.23534 
SF -0.00753 0.26876 
RE -.019206 0.43407 
MH -0.22069 0.48581 
Taken from page 49, Chapter 8 how to Score Standard Forms(J. Ware, Kosinski 
M., Turner Bowker, Diane, Gandek, Barbara, 2005) 
 
The formula for the PCS and MCS are below: 
 
AGG_PCS= (PF_Z*0.42402)+ (RP_Z*0.35119)+ (BP_Z*0.31754)+ 
(GH_Z*0.24954)+ (VT_Z*0.02877)+ (SF_Z*-0.00753)+ (RE_Z*-.019206)+ 
(MH_Z*-0.22069) 
 
AGG_MCS= (PF_Z*-0.22999)+ (RP_Z*-0.12329)+ (BP_Z*-0.09731)+ (GH_Z*-
0.01571)+ (VT_Z*-0.23534)+ (SF_Z*0.26876)+ (RE_Z*-0.43407)+ (MH_Z*-
0.48581) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Appendix V: Results 
 
Descriptive statistics were analyzed for all variables. Bivariate analysis and a 
logistic regression were conducted on the independent and dependant 
variables. SPSS 18.0 statistical software was used for all statistical analysis.  
 
 
 
  
 
 
  
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
Dependant Variable 
The “Treatment leading toward” variable was first analyzed with 5 
categories. The categories were recoded as binary outcome. The variable 
represents participants who were sure about their choice for treatment or who 
were unsure which treatment choice they were leaning toward. The “treatment 
leaning toward variable” had 68% (335) of participants who were sure about the 
treatment choice they were leaning toward, and 29% of participants who were 
unsure which treatment choice they were leaning toward.  
  
 
 
 
 
 
 
 
Independent Variable 
Continuous Variables: 
The SF12-mental health component score and the distress thermometers 
were analyzed. The mental health component score had 464 patients that fully 
completed all question (22 patients did not completed the SF12-mental health 
component section). The mental health component score was normally 
distributed (see graph x) with a skewness of -1.358 and a kurtosis of 2.983. The 
mean is 52.976 with a standard deviation of 8.13. The distress thermometer had 
  
 
449 patients who answered the question (37 did not answer). The mean was 
2.15 with a standard deviation of 2.11. The distress thermometer was skewed to 
the left and the kurtosis was 1.565 and platykurtic (see appendix V). The Log 
function was performed on the data, normalizing the histogram and the frequency 
was re-run. The logged distress variable was more normally distributed (see 
graph x) with a skewness of -.932 (slightly skewed to the right) and a kurtosis of 
.236. 
  
 
  
 
 
  
 
 
 
Categorical Variables: 
 
The categorical independent variables were summarized according to the 
recommended algorithms and interpretations. The variables were recoded as 
binary outcomes that represented participants who met or did not meet the 
recommended threshold for having the disorder.  
 
The anxiety variable (GAD 7) had 474 participants who answered the 
GAD 7 questionnaire (12 participants did not answer GAD 7 or did not fully 
complete the questionnaire). Of the participants, 405 (83.3%) did not meet the 
threshold for anxiety, leaving 69 (14.2%) patients who had at least minimal 
  
 
anxiety. PHQ9 depression scale had 477 participants who fully completed the 
questionnaire (nine participants did not answer or had incomplete 
questionnaires). Of the participants who fully completed the PHQ9 questionnaire, 
320 participants (65.8%) did not meet the threshold for depression, leaving 157 
participants (32.3%) with at least mild symptoms. The PTSD variable had 465 
patients who completed the PTSD health questionnaire. A total of 98% (455) 
participants did not demonstrate PTSD symptoms and 2.2% (10) of participants 
had clinically meaningful posttraumatic stress levels.  
 
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
Logistic Regression 
 
 
 
Case Processing Summary 
Unweighted Casesa N Percent 
Selected Cases Included in 
Analysis 
390 80.6 
Missing 
Cases 
94 19.4 
Total 484 100.0 
Unselected Cases 0 .0 
Total 484 100.0 
a. If weight is in effect, see classification table for the total number of cases. 
  
 
 
 
Dependent Variable Encoding 
Original Value Internal Value 
Not sure 0 
Sure about choice 1 
 
 
 
 
 
 
 
 
Categorical Variables Codings 
 Frequ
ency 
Parameter coding 
(1) (2) (3) (4) (5) 
recodestage T1a 1 1.000 .000 .000 .000 .000 
T1b 1 .000 1.000 .000 .000 .000 
T1c 206 .000 .000 1.000 .000 .000 
T2a 125 .000 .000 .000 1.000 .000 
T2b 39 .000 .000 .000 .000 1.000 
T2c 18 .000 .000 .000 .000 .000 
recodeschool Less than 
high 
school 
18 1.000 .000 .000 
  
High 
school 
graduate 
74 .000 1.000 .000 
  
Some 
college 
90 .000 .000 1.000   
Graduate 
from 
college 
208 .000 .000 .000 
  
recodePHQ No 
depression 
255 1.000     
Depressio
n 
135 .000     
recodePTSDbi
nary 
No PTSD 381 1.000     
PTSD 9 .000     
recodeGAD No Anxiety 331 1.000     
Anxiety 59 .000     
  
 
Block 0: Beginning Block 
 
 
 
Classification Tablea,b 
 Observed Predicted 
 recodetreatmentleaning 
Percentage 
Correct 
 
Not sure 
Sure about 
choice 
Step 0 recodetreatmen
tleaning 
Not sure 0 115 .0 
Sure about 
choice 
0 275 100.0 
Overall Percentage   70.5 
a. Constant is included in the model. 
b. The cut value is .500 
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 0 Constant .872 .111 61.637 1 .000 2.391 
 
 
Variables not in the Equation 
 Score df Sig. 
Step 0 Variables recodeGADbinary(1) 1.857 1 .173 
Overall Statistics 1.857 1 .173 
 
 
Block 1: Method = Enter 
 
 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 1.947 1 .163 
Block 1.947 1 .163 
  
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 1.947 1 .163 
Block 1.947 1 .163 
Model 1.947 1 .163 
 
 
Model Summary 
Step 
-2 Log likelihood 
Cox & Snell R 
Square 
Nagelkerke R 
Square 
1 471.089a .005 .007 
a. Estimation terminated at iteration number 4 because 
parameter estimates changed by less than .001. 
 
 
Classification Tablea 
 Observed Predicted 
 recodetreatmentleaning 
Percentage 
Correct 
 
Not sure 
Sure about 
choice 
Step 1 recodetreatme
ntleaning 
Not sure 0 115 .0 
Sure about 
choice 
0 275 100.0 
Overall Percentage   70.5 
a. The cut value is .500 
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 1a recodeGA
Dbinary(1) 
-.455 .336 1.834 1 .176 .634 
Constant 1.264 .314 16.186 1 .000 3.538 
a. Variable(s) entered on step 1: recodeGADbinary. 
 
 
 
  
 
Block 2: Method = Enter 
 
 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 3.522 1 .061 
Block 3.522 1 .061 
Model 5.469 2 .065 
 
 
Model Summary 
Step -2 Log 
likelihood 
Cox & Snell R 
Square 
Nagelkerke R 
Square 
1 467.567a .014 .020 
a. Estimation terminated at iteration number 4 because 
parameter estimates changed by less than .001. 
 
 
Classification Tablea 
 Observed Predicted 
 recodetreatmentleaning 
Percentage 
Correct 
 
Not sure 
Sure about 
choice 
Step 1 recodetreatment
leaning 
Not 
sure 
0 115 .0 
Sure 
about 
choice 
0 275 100.0 
Overall Percentage   70.5 
a. The cut value is .500 
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 1a recodeGADbinary(1) -.238 .356 .446 1 .504 .788 
  
 
recodelogdistress .388 .206 3.545 1 .060 1.474 
Constant 1.050 .334 9.890 1 .002 2.856 
a. Variable(s) entered on step 1: recodelogdistress. 
 
 
 
Block 3: Method = Enter 
 
 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step .000 1 .984 
Block .000 1 .984 
Model 5.469 3 .140 
 
 
Model Summary 
Step -2 Log 
likelihood 
Cox & Snell R 
Square 
Nagelkerke R 
Square 
1 467.566a .014 .020 
a. Estimation terminated at iteration number 4 because 
parameter estimates changed by less than .001. 
 
 
Classification Tablea 
 Observed Predicted 
 recodetreatmentleaning 
Percentage 
Correct 
 
Not sure 
Sure about 
choice 
Step 1 recodetreatme
ntleaning 
Not sure 0 115 .0 
Sure 
about 
choice 
0 275 100.0 
Overall Percentage   70.5 
a. The cut value is .500 
  
 
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 1a recodeGADbinary(1) -.236 .370 .407 1 .524 .790 
recodelogdistress .387 .219 3.115 1 .078 1.472 
recodePHQbinary(1) -.006 .274 .000 1 .984 .994 
Constant 1.052 .349 9.087 1 .003 2.862 
a. Variable(s) entered on step 1: recodePHQbinary. 
 
 
 
Block 4: Method = Enter 
 
 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step .437 1 .509 
Block .437 1 .509 
Model 5.906 4 .206 
 
 
Model Summary 
Step -2 Log 
likelihood 
Cox & Snell R 
Square 
Nagelkerke R 
Square 
1 467.130a .015 .021 
a. Estimation terminated at iteration number 4 because 
parameter estimates changed by less than .001. 
 
 
Classification Tablea 
 Observed Predicted 
 recodetreatmentlea
ning Percentage Correct 
  
 
 Not 
sure 
Sure about 
choice 
Step 1 recodetreatme
ntleaning 
Not sure 0 115 .0 
Sure 
about 
choice 
0 275 100.0 
Overall Percentage   70.5 
a. The cut value is .500 
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 1a recodeGADbinar
y(1) 
-.245 .371 .437 1 .509 .782 
recodelogdistress .394 .219 3.231 1 .072 1.484 
recodePHQbinar
y(1) 
-.035 .278 .015 1 .901 .966 
recodePTSDbina
ry(1) 
.503 .743 .460 1 .498 1.654 
Constant .587 .764 .591 1 .442 1.799 
a. Variable(s) entered on step 1: recodePTSDbinary. 
 
 
 
 
 
 
 
 
 
 
Block 5: Method = Enter 
 
 
 
Omnibus Tests of Model Coefficients 
  
 
 Chi-square df Sig. 
Step 1 Step 3.787 1 .052 
Block 3.787 1 .052 
Model 9.693 5 .084 
 
 
Model Summary 
Step -2 Log 
likelihood 
Cox & Snell R 
Square 
Nagelkerke R 
Square 
1 463.343a .025 .035 
a. Estimation terminated at iteration number 4 because 
parameter estimates changed by less than .001. 
 
 
Classification Tablea 
 Observed Predicted 
 recodetreatmentlea
ning 
Percentage Correct 
 
Not 
sure 
Sure 
about 
choice 
Step 1 recodetr
eatmentl
eaning 
Not sure 0 115 .0 
Sure 
about 
choice 
0 275 100.0 
Overall Percentage   70.5 
a. The cut value is .500 
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 1a recodeGADbin
ary(1) 
-.040 .386 .011 1 .918 .961 
recodelogdistre
ss 
.313 .224 1.950 1 .163 1.367 
  
 
recodePHQbin
ary(1) 
.181 .299 .366 1 .545 1.199 
recodePTSDbin
ary(1) 
.629 .760 .684 1 .408 1.876 
@117MentalCo
mponentSumm
aryMCS 
-.038 .020 3.618 1 .057 .963 
Constant 2.171 1.153 3.543 1 .060 8.766 
a. Variable(s) entered on step 1: @117MentalComponentSummaryMCS. 
 
 
 
Block 6: Method = Enter 
 
 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 8.396 3 .039 
Block 8.396 3 .039 
Model 18.088 8 .021 
 
 
Model Summary 
Step -2 Log 
likelihood 
Cox & Snell R 
Square 
Nagelkerke R 
Square 
1 454.947a .045 .064 
a. Estimation terminated at iteration number 4 because 
parameter estimates changed by less than .001. 
 
 
Classification Tablea 
 Observed Predicted 
 recodetreatmentle
aning 
Perce
e Correct 
  
 
 
Not sure 
Sure 
about 
choice 
Step 1 recodetreatme
ntleaning 
Not sure 8 107 7.0 
Sure about choice 4 271 98.5 
Overall Percentage   71.5 
a. The cut value is .500 
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 1a recodeGADbin
ary(1) 
-.068 .389 .030 1 .862 .935 
recodelogdistr
ess 
.331 .226 2.148 1 .143 1.392 
recodePHQbin
ary(1) 
.113 .305 .138 1 .710 1.120 
recodePTSDbi
nary(1) 
.503 .779 .417 1 .519 1.654 
@117MentalC
omponentSum
maryMCS 
-.032 .020 2.515 1 .113 .968 
recodeschool   8.330 3 .040  
recodeschool(
1) 
.322 .663 .236 1 .627 1.380 
recodeschool(
2) 
-.462 .300 2.381 1 .123 .630 
recodeschool(
3) 
-.721 .274 6.915 1 .009 .486 
Constant 2.316 1.191 3.782 1 .052 10.131 
a. Variable(s) entered on step 1: recodeschool. 
 
 
 
Block 7: Method = Enter 
 
 
  
 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 4.708 5 .453 
Block 4.708 5 .453 
Model 22.796 13 .044 
 
 
Model Summary 
Step -2 Log 
likelihood 
Cox & Snell R 
Square 
Nagelkerke R 
Square 
1 450.240a .057 .081 
a. Estimation terminated at iteration number 20 because 
maximum iterations has been reached. Final solution 
cannot be found. 
 
 
Classification Tablea 
 Observed Predicted 
 
recodetreatmentleaning 
Percent
age 
Correct 
 
Not sure 
Sure about 
choice  
Step 1 recodetreat
mentleanin
g 
Not sure 10 105 8.7 
Sure 
about 
choice 
4 271 98.5 
Overall Percentage   72.
1 
a. The cut value is .500 
 
 
 
 
 
  
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 1a recodeGADb
inary(1) 
-.032 .392 .007 1 .934 .968 
recodelogdist
ress 
.346 .227 2.316 1 .128 1.414 
recodePHQb
inary(1) 
.112 .309 .131 1 .717 1.119 
recodePTSD
binary(1) 
.484 .781 .384 1 .535 1.623 
@117Mental
ComponentS
ummaryMCS 
-.030 .020 2.219 1 .136 .970 
recodeschool   8.554 3 .036  
recodeschool
(1) 
.324 .664 .239 1 .625 1.383 
recodeschool
(2) 
-.466 .302 2.378 1 .123 .628 
recodeschool
(3) 
-.738 .276 7.167 1 .007 .478 
recodestage   1.326 5 .932  
recodestage(
1) 
19.2
09 
40192
.969 
.000 1 1.00
0 
2.199
E8 
recodestage(
2) 
-
22.9
69 
40192
.970 
.000 1 1.00
0 
.000 
recodestage(
3) 
-.593 .672 .780 1 .377 .552 
recodestage(
4) 
-.712 .684 1.085 1 .298 .491 
recodestage(
5) 
-.775 .738 1.101 1 .294 .461 
Constant 2.84
6 
1.350 4.445 1 .035 17.227 
a. Variable(s) entered on step 1: recodestage. 
 
Final Model: 
  
 
 
1.  Model: GAD, PTSD, PHQ, Distress, MCS, Education 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 1a recodeGADbinary(
1) 
-.068 .389 .030 1 .862 .935 
recodePTSDbinary
(1) 
.503 .779 .417 1 .519 1.654 
recodePHQbinary(
1) 
.113 .305 .138 1 .710 1.120 
recodelogdistress .331 .226 2.148 1 .143 1.392 
@117MentalComp
onentSummaryMC
S 
-.032 .020 2.515 1 .113 .968 
recodeschool   8.330 3 .040  
recodeschool(1) .322 .663 .236 1 .627 1.380 
recodeschool(2) -.462 .300 2.381 1 .123 .630 
recodeschool(3) -.721 .274 6.915 1 .009 .486 
Constant 2.316 1.191 3.782 1 .052 10.131 
a. Variable(s) entered on step 1: recodeschool. 
 
2.  Model: GAD, PTSD, PHQ, Distress, MCS, Education 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 1a recodePTSDbinary(
1) 
.515 .779 .437 1 .509 1.673 
recodePHQbinary(1
) 
.065 .301 .047 1 .829 1.067 
recodelogdistress .311 .223 1.945 1 .163 1.365 
@117MentalCompo
nentSummaryMCS 
-.034 .020 2.930 1 .087 .967 
recodeschool   8.797 3 .032  
recodeschool(1) .305 .662 .212 1 .645 1.356 
recodeschool(2) -.504 .296 2.903 1 .088 .604 
recodeschool(3) -.733 .274 7.161 1 .007 .481 
  
 
Constant 2.36
2 
1.190 3.938 1 .047 10.614 
a. Variable(s) entered on step 1: recodeschool. 
 
3.  Model: GAD, PTSD, PHQ, Distress, MCS, Education 
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 1a recodePTSDbinary(1) .505 .767 .433 1 .510 1.657 
recodelogdistress .288 .216 1.782 1 .182 1.334 
@117MentalComponentS
ummaryMCS 
-.029 .018 2.774 1 .096 .971 
recodeschool   8.856 3 .031  
recodeschool(1) .320 .661 .235 1 .628 1.378 
recodeschool(2) -.498 .293 2.881 1 .090 .608 
recodeschool(3) -.728 .272 7.173 1 .007 .483 
Constant 2.178 1.131 3.705 1 .054 8.827 
a. Variable(s) entered on step 1: recodeschool. 
 
 
4.  Model: GAD, PTSD, PHQ, Distress, MCS, Education 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 1a recodelogdistress .320 .211 2.290 1 .130 1.377 
@117MentalComponentS
ummaryMCS 
-.026 .017 2.223 1 .136 .974 
recodeschool   10.021 3 .018  
recodeschool(1) .331 .660 .252 1 .616 1.393 
recodeschool(2) -.491 .292 2.832 1 .092 .612 
recodeschool(3) -.780 .269 8.401 1 .004 .458 
Constant 2.49
9 
.946 6.974 1 .008 12.175 
a. Variable(s) entered on step 1: recodeschool. 
 
5.  Model: GAD, PTSD, PHQ, Distress, MCS, Education 
  
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 1a recodelogdistress .451 .187 5.793 1 .016 1.570 
recodeschool   11.145 3 .011  
recodeschool(1) .228 .583 .153 1 .696 1.256 
recodeschool(2) -.464 .282 2.707 1 .100 .629 
recodeschool(3) -.832 .266 9.777 1 .002 .435 
Constant 1.123 .157 50.953 1 .000 3.073 
a. Variable(s) entered on step 1: recodeschool. 
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